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ABSTRACT 
Asthma is a chronic disease characterised by variable airflow obstruction, 
bronchial hyperresponsiveness and airways inflammation. At an immunological 
level Th2 inflammation and the presence of activated eosinophils and mast cells 
are key features of asthma. ST2, the receptor for the novel cytokine IL-33, is 
expressed upon Th2 lymphocytes and mast cells but its role in clinical and 
experimental asthma remains unclear. IL-33 has been shown to induce local and 
systemic eosinophilia when administered to the peritoneum of mice. In this 
thesis I have set out to test the hypothesis that the activation of mast cells by 
IL-33 acting on cell surface ST2 plays a critical role in allergic airways 
inflammation. 
I began by studying the function of ST2 on mast cells in vitro. I found that ST2 
was expressed at an early stage of development, and correlated closely with the 
expression of the stem cell factor receptor (c-kit), a marker present on mast 
cells from a progenitor stage. Despite this mast cells generated form ST2 gene 
deleted mice proliferated and matured normally. When mast cells were 
activated by IL-33, acting in an ST2-dependent manner, pro-inflammatory 
cytokines and chemokines were released that have potential roles in asthma, 
specifically IL-6, IL-13, MIP-1α and MCP-1. 
To extend these findings I looked at the role of ST2 in allergic airways 
inflammation. I first optimised and validated an ovalbumin and adjuvant based 
„short‟ twelve day model of murine asthma and demonstrated that ST2 gene 
deletion results in attenuated eosinophilic inflammation. In addition to being 
ST2 dependent it is possible that this adjuvant based short model is mast cell 
dependent, unlike longer adjuvant based models which are mast cell and ST2 
independent. Therefore I went on to study an adjuvant-free model of asthma 
which has been demonstrated to be mast cell dependent. In this adjuvant-free 
model of asthma the airway inflammation was attenuated in ST2 gene deficient 
mice compared with wild type mice, while AHR was unaffected. There was an 
associated reduction in IgE production and thoracic lymph node recall Th2 
cytokine responses. 
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I then examined the effect of ST2 activation in the lungs. When IL-33 was 
administered directly to the airways of naïve mice it induced the features of 
experimental asthma. There was extensive eosinophilic inflammation within the 
lung tissue and airspaces. The Th2 cytokines IL-5 and IL-13, and the eosinophil 
chemoattractant chemokines eotaxin-1 and eotaxin-2 were detected at 
increased concentrations. Significant airways hyperresponsiveness was also 
generated. Using ST2 gene deleted mice I demonstrated that these effects were 
ST2 specific. Although I have shown that mast cells are activated by IL-33 in 
vitro, I used mast cell deficient mice to demonstrate that the eosinophilic 
inflammation generated by IL-33 is unaffected by the absence of mast cells. 
These data show that IL-33 can induce in the lungs the cardinal pathological 
characteristics of asthma, and that it appears to act upstream of other 
important mediators such as IL-13 and the eotaxins. Furthermore the IL-33 
receptor ST2 is required in an adjuvant free model of asthma, which is more akin 
to human disease. Placing these findings in the context of recent evidence that 
IL-33 is released by structural cells in response to damage or injury suggests that 
IL-33 may play a key role in initiating the immunological features of clinical 
asthma. As a consequence of this position in the hierarchy of inflammation IL-33 
offers a promising direct target for novel biological therapies in asthma. 
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1.1 Asthma 
1.1.1 Clinical asthma 
Asthma is a cause of significant morbidity and mortality and is estimated to 
affect 300 million people worldwide, with increasing prevalence(1). Asthma is 
defined clinically by the presence of variable airflow obstruction and symptoms, 
namely wheeze, breathlessness, chest tightness or cough. Physiologically airways 
hyperresponsiveness (AHR) and airway inflammation are cardinal features(2,3). 
The nature of the immune response in asthma will be discussed in more detail 
later, but is generally characterised by eosinophilic inflammation. The mainstay 
of treatment is with bronchodilators plus inhaled, and in more refractory 
asthma, oral corticosteroids. 
While some patients have chronic stable disease of varying severity, 
exacerbations can also be a feature. Clinically exacerbations present as an acute 
worsening of symptoms and airflow obstruction for a period of hours or days and 
represent the commonest reason for hospital admission in asthmatic patients. 
This airflow obstruction is a result of smooth muscle contraction, airway oedema 
and mucus plugging(4). While exacerbations can be triggered by a number of 
factors including allergens, irritants and stress, the commonest cause is viral 
infection(5). Despite this association, studies have shown that in those with 
eosinophilic inflammation targeting asthma treatment based on the extent of 
eosinophilia rather than symptoms reduces exacerbation rates(6). 
Asthma can be associated with structural airway changes including smooth 
muscle hypertrophy and thickening of the epithelial basement membrane(7) and 
some patients with asthma develop gradually worsening lung function over 
time(8,9). While it is assumed that the latter is a consequence of the former this 
is not yet conclusively proven, as disease severity does not always correlate with 
measures of remodelling(10-14). 
Although defined clinically by the presence of variable airflow obstruction and 
appropriate symptoms, asthma is a heterogeneous disease and there is 
increasing interest in characterising different phenotypes. There is a wide range 
of overlapping descriptions, many of which are based on the clinical course and 
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response to treatment. They include the most widely used severity 
classifications(2,3) and other subgroups such as difficult asthma, severe asthma, 
refractory asthma, brittle asthma and steroid-resistant asthma(2,15,16). Another 
way of classifying asthma is according to pathophysiology, one of the oldest such 
distinctions being that of atopic (extrinsic) or non-atopic (intrinsic) asthma first 
described in the 19th century(17). Atopic asthma is characterised by positive skin 
testing or elevated serum IgE antibody for common allergens. The age of onset is 
usually earlier than in non-atopic asthma and there is often a positive family 
history as well as other co-existing atopic disease such as hay fever or eczema. It 
is thought that 70-90% of asthmatic patients have atopic asthma(18,19). While 
originally considered as two distinct entities the nature of the airway 
inflammation in both atopic and non-atopic asthma is almost identical and there 
is evidence of elevated total serum IgE or local IgE production in non-atopic 
asthma. This has led to the hypothesis that there may be no fundamental 
immunopathological distinction between the two subsets(18,19). At present 
there is considerable clinical interest in the distinction between eosinophilic and 
non-eosinophilic asthma, the later being characterised by a high proportion of 
neutrophils in the airways, histological differences and a relative resistance to 
steroid therapy(20). 
1.1.2 Animal models of asthma 
In parallel with human studies animal models provide an important tool in the 
study of mechanisms of asthma(21-23). It is necessary to recognise the 
limitations of such models and to use them for hypothesis-generating and testing 
with the clear intention of translational purposes. 
Mice [Mus musculus] are the species used most frequently to model asthma for a 
number of reasons including the extensive knowledge of the murine immune 
system, the availability of reagents and genetically manipulated animals as well 
as the practical advantages of working with small mammals. 
1.1.2.1 Features of animal models 
It is generally accepted that the cardinal features required of a model of asthma 
are eosinophilic inflammation and AHR(21).  
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The simplest method of measuring eosinophilic inflammation is to quantify the 
number of eosinophils within the airway lumen, which can be sampled by 
performing a bronchoalveolar lavage (BAL). Although investigators have used 
flow cytometry to quantify eosinophils(24), using standard microscopy to identify 
and count Romanovsky stained cells remains the gold standard. It can also be 
useful to measure the changes that occur within the lung parenchyma. Most 
commonly histological lung sections are stained and examined by microscopy. 
This allows inflammation to be assessed and can demonstrate other 
abnormalities, such as early perivascular changes and one of the other major 
features of asthma, mucus productions and associated goblet cell hyperplasia. 
The study of lung sections remains subjective and can be misleading when the 
changes are not homogenously distributed throughout the lungs. Scoring systems 
reduce the subjectivity but can be very labour intensive(25). One alternative is 
to quantify the eosinophils within the lung tissue by performing digests and 
counting individual stained cells counted by microscopy(26), however this results 
in the loss of the other information available on histology and is therefore rarely 
undertaken. 
More problematic than the assessment of inflammation is the measurement of 
AHR, which relies on assessing bronchoconstriction in response to a provoking 
agent. The currently accepted best parameter in humans is FEV1 which is a 
measure of airflow during a forced expiratory manoeuvre. This is effort 
dependent and requires patient co-operation and the use of a tight fitting 
mouthpiece, neither of which are possible in mice. The classical solution, 
developed in 1988, has been to intubate anaesthetised mice via tracheostomy, 
artificially ventilate them and then measure pulmonary resistance (RL) to airflow 
and dynamic compliance (Cdyn), a measure of lung stiffness(27). This method is 
accepted as the gold standard and gives very reproducible results, but requires 
considerable time and technical expertise(28). Alternatively lung function can be 
measured non-invasively using whole body plethysmography(29). Although there 
have been some reservations regarding this technique(28,30) it remains widely 
used by those working with asthma models and correlates well with the more 
technically demanding invasive measurements(29,31-34). 
Airway remodelling is a feature of asthma models that becomes evident with 
increasing duration of antigen challenge. In models of chronic asthma, using 
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more sustained challenge protocols, it is possible to induce features of airway 
remodelling, specifically extra-cellular matrix deposition and an increase in 
airway smooth muscle mass(35-38). 
1.1.2.2 Protocols 
The most common way of inducing experimental asthma is to employ a method 
of antigen sensitisation followed by local antigen challenge, although protocols 
which utilise cell transfer, gene manipulation or viral infection do exist. 
The antigen used can range from complex microorganisms, such as 
Aspergillus(39) and Schistosoma(40), to simple proteins. However, due to the 
problems with consistency of dosing, handling and preparation of complex 
micro-organisms most investigators choose to use soluble purified proteins or 
extracts. 
The majority of antigen based models use chicken egg ovalbumin (OVA), which is 
a useful experimental antigen available in a highly purified form, with a known 
epitope structure and available antibody and T cell receptor transgenic mice. 
Sensitising mice using OVA and alum adjuvant can induce IgE and Th2 responses 
and has been demonstrated to induce pulmonary eosinophilia and AHR upon 
subsequent airways challenge with OVA. While less well studied there is also 
interest in antigens with direct relevance to clinical asthma, such as cockroach 
antigen(41) and house dust mite extract(38,42). House dust mite antigens have 
specific properties which may be important in their pathophysiology, including 
intrinsic protease activity(43) and possibly an ability to modulate TLR 
signalling(44). 
Even among the models that utilise OVA there is considerable variation in the 
exact protocol used, with differences in dose, timing, route of administration 
and use of adjuvants(21). While subcutaneous, transcutaneous, intrapulmonary 
and intravenous sensitisations have been used, generally an intraperitoneal (IP) 
administration is employed. This is felt to deliver a systemic dose of antigen in a 
convenient and reproducible manner. The most popular methods of challenge 
are via direct intratracheal or intranasal administration or via nebulisation. 
While there are likely to be differences in the actual dose delivered they will all 
result in the delivery of soluble antigen to the respiratory tract. There is no 
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evidence that any method is superior and consequently the choice often falls to 
investigator experience and preference. 
Human vaccines generally employ adjuvants to boost the immune response to 
administered antigens, and the same technique is often used in a wide variety of 
animal models of allergic and autoimmune disease. Aluminium salts (alum) have 
been used in human vaccines since 1926(45), and remain by far the most widely 
used(46). Alum is also the most commonly used adjuvant in murine models of 
asthma, in part due to the fact that it is a strong inducer of Th2 
responses(47,48). 
The number of challenges employed and the duration of the model can also have 
an impact on the pathological changes seen. Models as short as 12 days(49) or 
models utilising only a single airways challenge(42) have been shown to induce 
IgE production, pulmonary eosinophilia and AHR. Models designed to 
demonstrate the features of airway remodelling tend to require multiple 
repeated challenges over a period of around two months(35-37). 
While the various different models used all generate the required features of 
experimental asthma, these protocol differences can affect the apparent 
contribution of different cells, cytokines and pathways, as will become clear 
later in this introduction. It is generally accepted that the best protocols for 
achieving a robust Th2 dependent model in which pulmonary eosinophilia, 
antigen-specific IgE and AHR are generated are those using BALB/c mice 
sensitised with antigen in adjuvant followed by multiple airways challenges over 
a total period of around four weeks(21). 
1.1.2.3 Genetic background 
While the majority of investigators use BALB/c mice in the study of asthma 
others strains are also used, most frequently C57Bl/6 mice which are often the 
background on which gene knock-out and transgenic animals are generated. It is 
well established that while experimental asthma can be induced in BALB/c and 
C57Bl/6 mice there are differences between the strains. While the extent of 
pulmonary eosinophilia generated does not vary greatly, the magnitude of the 
IgE is response is reduced in C57Bl/6 mice(50-52). AHR also varies between 
different strains of mice, with airways responsiveness in naïve BALB/c mice 
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greater than in C57Bl/6 mice(50,53). There is a similar trend in models of 
asthma, with some protocols unable to generate AHR in C57Bl/6 mice(21,50,54). 
It has been suggested that these two strains may rely on different pathways for 
the generation of AHR, possibly due to functional differences in mast cells(55), 
including a deficiency in mast cell protease 7 in C57Bl/6 mice(56). 
1.1.3 Cellular components of asthma 
As early as 1864 Henry Salter recognised the importance of inflammation in 
asthma; “The inflammation or congestion of the mucous surface appears to be 
the stimulus that, through the nerves of the air tubes, excites the muscular wall 
to contract”, as well as ascribing a role to extrinsic “irritants”(17). Since then a 
great deal has been learnt about immunology and asthma, but the role of 
different inflammatory cells and mediators in the pathogenesis of asthma 
remains hotly debated. 
1.1.3.1 Eosinophils and IL-5 
The eosinophil was one of the first cells to be implicated in the pathophysiology 
of asthma. Early post-mortem reports identified eosinophils and Charcot-Leyden 
crystals, later discovered to be eosinophil granule crystals, in the airway lumen 
of asthmatic patients and in some cases elevated sputum or peripheral blood 
eosinophil counts were reported(57). A century later the eosinophil remains a 
focus of interest in the study of asthma, but just how central a role it plays is 
still unresolved. 
The primary evidence implicating eosinophils in the pathogenesis of asthma is 
the association between increased eosinophil numbers and asthma. Eosinophils 
in peripheral blood are readily measured and the level of eosinophilia correlates 
with AHR in response to methacholine(58,59) and in some cases with 
measurements of airflow resistance(59,60). Sputum eosinophilia is also easily 
assessed and correlates with asthma severity to the extent that it can be used to 
direct treatment with corticosteroids(6,61). As initial fears over the safety of 
bronchoscopy in asthmatics were allayed(62) reports were published showing 
elevated BAL eosinophils in asthmatic patients(63,64) that correlated with 
AHR(65-67), lung function(67) and severity(68). Using bronchoscopy it was also 
possible to take airway wall biopsies for histological studies(69). These 
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demonstrated increased eosinophil numbers within the airways(70,71) which 
correlated with AHR in some asthmatics(72) and showed evidence of 
degranulation and a unique distribution in asthmatics, with intraepithelial 
eosinophils only found in asthma(68). Despite this close association between 
airway eosinophilia and asthma it is important to note that this finding is not 
unique to asthma. Most notably sputum eosinophilia also occurs in eosinophilic 
bronchitis, a condition which shares the symptom of cough with asthma but 
without bronchoconstriction or AHR(73). 
Not only are eosinophils present in the airways of asthmatics, but they have the 
potential to contribute to the pathophysiology. Eosinophil granules contain the 
cytotoxic granule proteins major basic protein (MBP), eosinophil cationic protein 
(ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN)(74). 
MBP is the most studied of the granule products in asthma and there is increased 
MBP in the sputum(75) and lungs(76) of asthmatics. Not only is MBP directly 
cytotoxic to respiratory epithelial cells(77), but it can also induce 
bronchoconstriction in vitro(78). Eosinophil granule products can stimulate mast 
cells and basophils to release histamine(79-82). Although when the role of MBP-1 
was studied in vivo using MBP-1 gene knock-out mice there was no difference in 
eosinophilic inflammation or AHR(83). In addition to granule products eosinophils 
are also a potential source of Th2 cytokines(84-86) and may be able to drive Th2 
responses by other means(87,88). 
Despite the circumstantial evidence implicating eosinophils in the pathology of 
asthma the definitive proof is lacking. In an attempt to answer the question 
investigators have tried to study asthma in the absence of eosinophils. Since the 
discovery of IL-5 in 1985, initially named eosinophil differentiation factor(89), it 
has been closely linked with eosinophil function, driving differentiation, 
proliferation, activation and recruitment(90,91). Transgenic mice over-
expressing IL-5 display a profound blood eosinophilia with evidence of 
accumulation in the lungs(92). When IL-5 over-expression is induced in the lungs 
there is marked eosinophilic inflammation with associated goblet cell 
hyperplasia and collagen deposition in addition to a degree of spontaneous 
AHR(93). Consequently IL-5 had been targeted in models of asthma, either by 
using antibodies against IL-5 or by selective gene deletion (IL-5-/-). The results of 
these experiments are summarised in Table 1.1. 
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Mice Model Method EØ AHR Ref 
C57Bl/6 OVA + Alum IL-5-/-   (94) 
C57Bl/6 Aspergillus α-IL-51  NC (95) 
C57Bl/6 Aspergillus IL-5-/-  NC (95) 
C57Bl/6 S.mansoni α-IL-5  NC (96) 
C57Bl/6 OVA + Alum α-IL-5   (97) 
C57Bl/6 OVA + Alum IL-5-/-  
2 (97) 
BALB/c OVA + Alum α-IL-5  NC (54) 
BALB/c OVA + Alum α-IL-5   (98) 
BALB/c airways OVA3 α-IL-5   (99) 
BALB/c OVA + Alum α-IL-54  NC (100) 
BALB/c OVA + Alum IL-5-/-  NC (100) 
BALB/c OVA + Alum α-IL-5   (101) 
BALB/c OVA α-IL-5  NC (102) 
BALB/c OVA + Alum IL-5-/-  NC (103) 
B10.BR OVA + Alum α-IL-5   (104) 
Table 1.1 - Studies on the requirement for IL-5 in experimental asthma 
Key –  EØ: effect on lung eosinophil numbers. AHR: effect on airways hyperresponsiveness. α-IL-
5: anti-IL-5. : reduced. NC: no change. 
Notes - (1) Mice were also B cell deficient. (2) Eosinophil transfer restored AHR. (3) Protocol 
utilising repeated antigen challenge of naïve mice. (4) Mice were also IL-4-/- 
 
While blocking the function of IL-5 by either method consistently resulted in a 
significant reduction in lung eosinophils, although notably often not complete 
loss, the effect on AHR was more variable. All models which utilised systemic 
sensitisation with OVA alone, or an alternative antigen failed to demonstrate any 
reduction in AHR. In C57Bl/6 mice blocking IL-5 function in models utilising 
sensitisation with both OVA and alum invariably resulted in a reduction in AHR. 
The use of OVA and alum models of asthma in BALB/c mice gave more variable 
results with AHR unchanged in some and completely abrogated in others, 
although when IL-5 was targeted in BALB/c mice by gene deletion rather than 
antibody, AHR was consistently preserved. In the few studies which assessed 
other changes in lung such as mucus production(97) and subepithelial 
fibrosis(102), these were shown to be attenuated by blocking IL-5. 
In human asthma IL-5 was among the first cytokines to be specifically targeted. 
The value of this as an immuno-therapeutic target was due not only to the 
relationship between IL-5, eosinophils and asthma already discussed, but also 
the finding that IL-5 inhalation induced sputum eosinophilia and AHR in 
asthmatic patients(105). 
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In 2000 a randomised double-blind placebo controlled trial of anti-IL-5 involving 
24 atopic asthmatics was published(106). Patients were given a single dose of 
anti-IL-5 antibody and were challenged with antigen one and four weeks later. 
Treatment resulted in a significant and sustained reduction in blood and sputum 
eosinophils but failed to demonstrate a difference in pre-challenge AHR or late 
asthmatic response, as measured by delayed bronchoconstriction in response to 
allergen challenge. On face value this suggests a dissociation between 
eosinophilia and AHR. However there have been criticisms of the study, including 
concerns over the interpretation of the late asthmatic response data and the 
small number of patients studied(107). Although a subsequent similarly powered 
study confirmed the reduction of blood eosinophils with no change in 
measurements of AHR and lung function, it raised questions by demonstrating 
that anti-IL-5 treatment only reduced eosinophil numbers in the airway wall and 
bone marrow by around 50%(108). In this study there was a reduction in 
deposition of extra-cellular matrix proteins and BAL TGFβ(109), both features 
associated with airways remodelling. 
It was not until 2007 that a larger study was conducted in which 362 patients 
with moderate asthma received 3 monthly doses of anti-IL-5(110). Treatment 
failed to produce any clinically relevant improvement in measures of airflow 
obstruction or symptom scores but did show a trend towards a reduction in 
exacerbations. In light of this trend combined with an increasing understanding 
of the relationship between eosinophil levels and asthma control two further 
studies were carried out, the results of which have just been 
published(111,112). Both recruited subjects with very severe asthma, the 
majority of whom were on regular oral steroids, and both demonstrated a 
significant reduction in the primary end-point of exacerbations. Not only do 
these studies suggest a role for anti-IL-5 therapy in a select group of patients, 
but they also support a pathophysiological role for IL-5 and eosinophils in asthma 
exacerbations. 
One of the caveats when drawing conclusions regarding the role of eosinophils 
from any study is the failure to completely eliminate eosinophils from the lung. 
As discussed above this has been a criticism of the interpretation of clinical 
studies of anti-IL-5 therapy, but is also a problem in the murine studies with a 
population of eosinophils persisting in all of them. 
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In an attempt to address the role of eosinophils more directly eosinophil 
deficient mice were generated by two different groups using different 
approaches. The first group genetically engineered C57Bl/6 mice with diphtheria 
toxin linked to the promoter for the eosinophil granule protein EPO (PHIL mice) 
which resulted in mice in which eosinophils were almost completely absent(113). 
When allergic airways inflammation was generated using OVA/Alum in these 
mice less than 0.5% of BAL cells were eosinophils and no eosinophils were seen in 
lung sections. Other histological changes, including goblet cell hyperplasia, were 
attenuated but not lost. AHR however was completely absent in PHIL mice. 
The second group, in a paper published simultaneously, used the previously 
described(114) ΔdblGATA mice on a BALB/c background in OVA/alum driven 
acute and chronic models of asthma(115). These mice have a deletion in the 
high affinity GATA-binding site of the GATA-1 transcription factor which results 
in slightly impaired red cell production and a complete absence of circulating 
eosinophils, even if an IL-5 transgene is introduced(114). In both the acute and 
chronic models of asthma there was a complete absence of eosinophils in BAL 
and lung tissue with goblet cell hyperplasia unaffected(115). Using these 
ΔdblGATA mice for the chronic asthma model resulted in a reduction in both 
collagen deposition and airway smooth muscle hypertrophy. In contrast to the 
findings in PHIL mice, AHR was preserved in ΔdblGATA mice. 
These two papers reached contradictory conclusions regarding the role of 
eosinophils in AHR. In order to reconcile this discrepancy it is necessary to look 
at the different mice used. As AHR was preserved in the mice that appeared to 
have the most complete ablation of eosinophils such a difference seems unlikely 
to be responsible. One possible explanation is the genetic background, the PHIL 
mice were on a C57Bl/6 background, which appears to be more dependent on 
eosinophils for AHR in IL-5-/- experiments as discussed above, whereas the 
ΔdblGATA mice were on a BALB/c background where the effect of eosinophil 
depletion on AHR is more variable. This is supported by a recent paper in which 
BALB/c and C57Bl/6 ΔdblGATA mice were compared(116). The BALB/c ΔdblGATA 
mice had preserved AHR and histological changes as previously reported, 
whereas the C57Bl/6 ΔdblGATA mice failed to develop AHR or show any 
histological changes. 
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Ultimately the role of eosinophils in asthma remains unclear. In mice it appears 
that, depending on the strain and protocol, AHR can be induced in an eosinophil 
dependent or independent manner. In humans it appears that eosinophils play a 
key role in exacerbations of asthma. In addition both murine and human data 
also suggest a role for eosinophils in airway remodelling. 
1.1.3.2 B lymphocytes and IgE 
The role of external agents in provoking asthma was identified as far back as the 
nineteenth century when “extrinsic” asthma was first described (17) and many 
years later associations were made between asthma and allergy or 
anaphylaxis(117). Extrinsic asthma came to be viewed as a form of Type I 
hypersensitivity reaction, which were later found to be mediated by a serum 
component (118) ultimately identified as a novel immunoglobulin isotype; 
IgE(119). Mast cells express the high affinity IgE receptor (FcεRI) and Type I 
hypersensitivity reactions are recognised as being mediated by the degranulation 
of mast cells due to the cross-linking of surface bound IgE by allergen(120). 
Following the association between IgE and hypersensitivity elevated levels of 
serum IgE were detected in some asthmatic patients(121), and atopic asthma is 
now defined as being associated with elevated serum IgE antibody to common 
inhaled allergens. Consequently questions have been asked regarding the 
potential role of IgE in the pathogenesis of asthma. 
Initial animal studies showed that the administration of anti-IgE antibodies, 
which mimicked allergens by cross-linking surface bound IgE, resulted in 
AHR(122). Similarly the transfer of OVA-specific IgE followed by intranasal OVA 
challenge also resulted in AHR, in addition to a modest airways 
eosinophilia(123). When blocking anti-IgE antibodies were used in a house dust 
mite antigen model of asthma eosinophil accumulation was attenuated, although 
AHR was not measured(42). More recent studies using mice with a selective IgE 
deficiency have reached differing conclusions. In an OVA/Alum based model of 
asthma AHR and inflammation were preserved in IgE deficient mice(124), while 
in a model where naïve mice were repeatedly challenged with OVA alone IgE 
deficiency resulted in the loss of AHR and reduced inflammation(125). Taken 
together these observations fail to provide a clear picture regarding the role of 
IgE in experimental asthma. 
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In clinical asthma the use of the anti-IgE monoclonal antibody omalizumab has 
provided good evidence for the importance of IgE. Initial studies in asthmatics 
showed that as well as reducing serum IgE concentrations, omalizumab inhibited 
bronchoconstriction in response to allergen challenge(126,127). Subsequent 
clinical trials demonstrated that in patients with moderate to severe allergic 
asthma, treatment resulted in reduced exacerbations and symptoms and allowed 
inhaled steroid doses to be reduced(128-130). The greatest benefit appeared to 
be in patients with the most severe and poorly controlled asthma(131,132). 
Consequently omalizumab is now recommended for use in patients with 
uncontrolled atopic asthma both in the UK(133) and elsewhere. 
While the need for B cells in asthma is generally considered to be as a source of 
IgE, their role could potentially include the production of other 
immunoglobulins, antigen presentation and cytokine production. By using B cell 
deficient mice it has been possible to study the contribution of these cells to 
asthma. As expected these mice consistently fail to generate any 
immunoglobulins, but no study has shown any difference in the development of 
typical inflammation and eosinophil accumulation within the lungs(104,134-136). 
As in IgE deficient mice, the requirement for B cells in the generation of AHR 
depends on the model used. AHR in response to OVA challenge was unaffected in 
B cell deficient mice immunised with OVA and alum(104,136). However, when 
allergic airways inflammation was generated by the repeated challenge of naïve 
mice with OVA, AHR was B cell dependent and restored by the transfer of OVA-
sepcific IgE, although it is important to note that in this report AHR was 
measured by studying tracheal segments ex vivo(134). 
1.1.3.3 Mast cells 
While mast cells were first identified by Ehrlich in his doctoral thesis in 
1878(137) their function remained unclear for many years, although they were 
described as sentinel cells because of their location in mucosal surfaces of the 
gut, lung and skin. Since histamine was already associated with anaphylaxis(138) 
and AHR(139), the mast cell began to attract attention in the study of allergy 
and asthma with the discovery in 1952 that mast cells could release 
histamine(140,141). By the early 1970s this had led to the hypothesis that 
asthma was a form of Type I hypersensitivity reaction, with inflammation a 
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result of allergen triggered release of mast cell mediators via surface IgE. While 
the importance of IgE in atopic asthma discussed earlier lends support to this 
theory, IgE can interact with a number of other cells, for example to mediate 
antigen presentation by dendritic cells and B cells, or to activate 
eosinophils(120). Therefore more direct evidence is required for a pathogenic 
role of mast cells in asthma. 
Bronchoscopic lavage has consistently found elevated mast cell numbers from 
the airway lumen of asthmatic patients(66,70,142-144), with some evidence of 
correlation with airflow obstruction(64). Biopsy studies of mast cell numbers 
within the wall of the airways themselves have sometimes yielded conflicting 
data. Within the epithelium there are reports of increased(145-147) or 
unaltered(143,148) mast cells numbers, while within the submucosa mast cell 
numbers have been found to be unchanged(72,148,149) or reduced(150). Within 
the airway smooth muscle mast cell numbers are consistently elevated(151,152). 
The number of mast cells within the smooth muscle layer correlates with AHR in 
both asthmatic(151) and allergic non-asthmatic patients(153). Further evidence 
for the importance of mast cells in smooth muscle bundles in asthma is the 
comparison with eosinophilic bronchitis. In this disease there is eosinophilic 
inflammation and cough as in asthma but no AHR, and mast cells are not found 
within the smooth muscle bundles(151).  
Support for mast cell activation comes from the findings there is histological 
evidence of mast cell degranulation in the airways of asthmatic 
patients(70,145,148,150,152) and that BAL histamine levels are elevated in 
symptomatic asthmatics(154). 
These reports that mast cells, which are capable of releasing a wide array of 
pro-inflammatory mediators, are present in increased numbers within asthmatic 
airways and show evidence of degranulation suggests they may play a role in 
asthma. Using W/Wv or W-sh mast cell deficient mice investigators have tried to 
establish whether or not there is a requirement for mast cells in allergic airways 
inflammation. 
While there had been a previous experiment showing no change in Ascaris 
induced pulmonary eosinophilia in W/Wv mice(155), the earliest report on the 
requirement for mast cells in experimental asthma was published in 1994. Wild 
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type and W/Wv mice were immunised with OVA and alum on day 0 before being 
challenged with nebulised OVA on days 14 to 21. There was no change in 
histological inflammation but a small, non-significant reduction in BAL 
eosinophils(156). Three subsequent papers also failed to show any requirement 
for mast cells in the generation of airways eosinophilia. All three models utilised 
alum at sensitisation, with house dust mite(42) or OVA(157,158) as the antigen, 
and used protocols between 20 and 30 days long.  When AHR was assessed 
results were inconsistent with one study demonstrating no requirement for mast 
cells(157) and another mast cell dependence(158). 
Contrasting results were obtained utilising protocols which differed from these 
more traditional models of asthma. In a short model utilising OVA and alum with 
the final challenge on day 12, BAL and histological eosinophilia was significantly 
reduced in W/Wv mice and was restored when these mice were reconstituted 
with mast cells(159). When mice were immunised with OVA and alum on days 0 
and 14 before receiving a single nebulised OVA challenge on day 28, lung 
eosinophil accumulation was significantly reduced in W/Wv mice 48 hours later, 
although not at any of the four other time points studied(160). In another 
variant of the model mice were immunised with OVA and alum on day 0 followed 
by OVA alone on day 10 after which they were challenge with nebulised OVA on 
days 17 and 24, resulting in a significant reduction in eosinophilia in W/Wv 
mice(161). Once again the effect on AHR was variable with some showin 
depence on mast cells(161) and others independence(160). 
In 2000 Williams and Galli made a significant contribution to our understanding 
of the role of mast cells in experimental asthma when they compared the 
requirement for mast cells of two different models(162). As with most previous 
studies they found that when mice immunised with OVA and alum were 
challenged lung eosinophilia was generated equally well in wild type and W/Wv 
mice. However when immunised with OVA without adjuvant eosinophilic 
inflammation was significantly reduced in W/Wv mice. The same was also true of 
AHR, which was attenuated in mast cell deficient mice only when immunised 
with OVA alone. Subsequent studies have confirmed the requirement for mast 
cells in alum-free models of asthma using W-sh as well as in W/Wv 
mice(33,37,163). Interestingly in mast cell reconstitution experiments one of the 
essential roles of mast cells in these models is as a source of TNFα (33,163). The 
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data regarding experimental asthma in mast cell deficient mice is summarised in 
Table 1.2. 
Mice Model Length EØ AHR Ref 
W/Wv OVA + Alum 21 days NC - (156) 
W/Wv OVA + Alum 12 days  - (159) 
W/Wv HDM + Alum 21 days NC - (42) 
W/Wv OVA + Alum 30 days NC NC (157) 
W/Wv OVA + Alum 20 days NC  (158) 
W/Wv OVA + Alum 30 days NC NC (162) 
W/Wv OVA 46 days   (162) 
W/Wv OVA + Alum 28 days 1 NC (160) 
W/Wv + W-sh OVA 75 days   (37) 
W/Wv OVA + Alum2 24 days   (161) 
W-sh OVA 46 days   (33) 
W/Wv + W-sh OVA 30 days   (163) 
Table 1.2 – The effect of mast cell deficiency on the outcomes of experimental asthma. 
Key –  Length: duration of model used. EØ: effect on lung eosinophil numbers. AHR: effect on 
airways hyperresponsiveness. : reduced. NC: no change. HDM: house dust mite antigen 
Notes - (1) Of five timepoints studied eosinophils only reduced at 48 hours. (2) Alum was used 
with first sensitisation only. 
 
The clinical data certainly suggest a role for mast cells in asthma, perhaps 
related to smooth muscle function. The data from asthma models is more 
difficult to interpret, with a clear requirement for mast cells when alum is 
omitted, although the exact role they play is not clear. 
1.1.3.4 T lymphocytes 
Initial histological studies in asthma focused on the eosinophils and mast 
cells(57,150) and T cells were not much studied until their central role in the 
immune response became understood. In particular their capacity to recruit cells 
of the innate immune system, including eosinophils, and their ability to provide 
help to B cells in antibody production and isotype switching(164). It was also at 
this time that T cell biology was revolutionised by the discovery of the Th1 and 
Th2 subsets of helper T cells(165). 
In humans there are reports of increased T cell numbers within the airway 
wall(166) and lumen(67,167), but not peripheral blood(167,168) of asthmatics. 
Regardless of the location sampled, the proportion of activated T cells is 
consistently elevated(71,168-171) and this rise correlates with eosinophil 
Chapter 1:  35 
numbers(67,166,172) and AHR(67). A study using anti-CD4 to target helper T 
cells in severe asthma demonstrated an improvement in peak expiratory flow 
but no significant change in FEV1 or symptoms(173). While this raised the 
possibility that T cells could be targeted in asthma there has been no further 
progress in this area. 
Antibodies against CD4 have also been used in murine studies of allergic airways 
inflammation, showing that helper T cell depletion before or after sensitisation 
results in markedly reduced eosinophilia, AHR and remodelling(100,174-176), but 
has no effect on AHR or remodelling when given after challenge in a chronic 
model(177,178). Similarly B and T cell deficient SCID or RAG-/- mice fail to 
develop airways eosinophilia and AHR(54,95,179,180). In RAG-/- mice both could 
be restored by reconstitution with CD4 cells(95). The corollary of this is that 
eosinophilic inflammation and AHR can be induced in naïve mice by the transfer 
of antigen-specific helper T cells(180,181). The requirement for CD8 cells is less 
clearly defined; two adjuvant free models have found conflicting results with 
one showing that CD8 cells were required for eosinophilic inflammation and 
AHR(182) and another that eosinophilic inflammation was unaffected in CD8 
deficient mice(179). 
Th2 inflammation 
Shortly after the identification of Th1 and Th2 lymphocyte subsets investigators 
began to look for a link between Th2 cells and atopy due to the established role 
of the Th2 cytokine IL-4 in IgE synthesis(183). BAL obtained from asthmatic 
patients contains elevated levels of Th2 cytokines(170,171) and cells expressing 
Th2 cytokines(184,185). Similar results have been obtained from bronchial 
biopsies (184,186-188), sputum(189,190) and peripheral blood(170). In one study 
there was a direct correlation between the number of IL-5+ cells within the BAL 
and clinical measures of bronchoconstriction(191), and while expression of IL-5 is 
not necessarily restricted to T cells, other have shown that in asthma the 
majority of IL-4 and IL-5 positive cells are T cells(184). 
Further support for Th2 inflammation in asthma comes from studies looking at 
the Th2 associated transcription factors STAT6(192) and GATA-3(193) which are 
expressed at elevated levels in BAL and biopsy samples from 
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asthmatics(194,195). Conversely the Th1 associated transcription factor T-
bet(196) is expressed at significantly reduced levels(197). 
Data from murine models concur with those from humans. Transfer of polarised 
antigen-specific Th1 cells followed by airways challenge results in neutrophilic 
rather than eosinophilic inflammation and fails to induce AHR(180,198,199). 
However when antigen-specific Th2 cells are transferred into naïve wild type or 
SCID mice then airways challenge induces eosinophilic inflammation, mucus 
hyper-secretion and AHR(180,198,199). 
Th2 cytokines 
The defining cytokines of the Th2 subset are IL-4, IL-5, IL-13 and variably IL-
9(165,200,201). The contribution of IL-5 has already been discussed when 
considering the role of eosinophils in asthma.  
In 1986 the name IL-4 was proposed for what had previously been variously 
known as B-cell stimulating factor 1, B-cell growth factor 1, B-cell IgG 
differentiation factor and IgG1 induction factor(202). As the names imply, IL-4 
was already recognised for being able to induce B cell growth and isotype 
switching to the Th2 associated isotypes IgG1(203) and IgE(204). Two months 
later IL-4 was associated with the Th2 subset of T cells(165) and was 
subsequently shown to be a crucial factor in driving Th2 development(205). 
When IL-13 was discovered in 1993 it was found to be closely linked to the IL-4 
gene on chromosome 5 and expressed by Th2 but not Th1 cells(206,207). The 
association with Th2 inflammation and atopy was strengthened by the finding 
that IL-13 could induce IgE production, independently of IL-4. The functional 
overlap between IL-4 and IL-13 is due to the fact that they share a common 
receptor subunit. The Type I IL-4R consists of the IL-4Rα and γc subunits and the 
Type II IL-4R consists of the same IL-4Rα subunit plus an IL-13Rα1 subunit. IL-4 
signals through both receptors whereas IL-13 signals only through the Type II 
receptor(208). 
The finding that IL-4 can induce the features of asthma in mice, including 
eosinophilia, AHR and goblet cell hyperplasia(209,210), is perhaps not surprising 
given the ability of IL-4 to induce Th2 cytokine production and inflammation. In 
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order to assess whether or not experimental asthma is IL-4 dependent IL-4 
deficient mice have been used, which have impaired Th2 responses(211) and are 
unable to produce IgG1 or IgE(212). As summarised in Table 1.3 these have 
consistently shown a requirement for IL-4 in the development of airways 
eosinophilia, regardless of strain, model or adjuvant use. The only exception was 
the finding that epicutaneous sensitisation with OVA results in IL-4 independent 
BAL eosinophilia in response to OVA challenge(213). Also shown in Table 1.3 are 
the effects of using anti-IL-4 antibodies on airways eosinophilia, which are less 
consistent, perhaps due to an inability to completely block IL-4 signalling. AHR is 
also variable with the suggestion of a strain effect, being preserved in IL-4-/- 
BALB/c mice but reduced in C57Bl/6 IL-4-/- mice, similar to the strain difference 
seen in IL-5-/- mice. 
 
Mice Model Method EØ AHR Ref 
C57Bl/6 OVA + Alum IL-4-/-  - (156) 
C57Bl/6 OVA + Alum IL-4-/-  - (214) 
C57Bl/6 OVA + Alum α-IL-4  - (214) 
C57Bl/6 OVA + Alum IL-4-/-   (215) 
C57Bl/6 OVA + Alum IL-4-/-   (216) 
BALB/c OVA + Alum α-IL-4 NC  (54) 
C57Bl/6 OVA + Alum IL-4-/-  NC (217) 
BALB/c OVA + Alum IL-4-/-  NC (100) 
BALB/c TF-OVA IL-4-/-  NC (198,199) 
C57Bl/6 airways OVA1 IL-4-/-   (213) 
C57Bl/6 epicutaneous OVA2 IL-4-/- NC  (213) 
BALB/c GM-CSF + OVA3 IL-4-/-   (218) 
Table 1.3 – Studies on the requirement for IL-4 in experimental asthma 
Key –  EØ: effect on lung eosinophil numbers. AHR: effect on airways hyperresponsiveness. α-IL-
4: anti-IL-4. : reduced. NC: no change. TF-OVA: model employing adoptive transfer of 
OVA-specific T cells followed by antigen challenge. 
Notes (1) Protocol utilising repeated antigen challenge of naïve mice. (2) Protocol utilising 
epicutaneous sensitisation followed by airways challenge. (3) Protocol utilising airways 
GM-CSF over-expression and OVA challenge. 
 
A number of studies have also been carried out in mice deficient in STAT-6, an 
essential element in both IL-4 and IL-13 signalling. These have shown loss of AHR 
and mucus production with reduced or absent airways eosinophilia(219-221). 
Studies in mice deficient in the common IL-4Rα chain used for both IL-4 and IL-
13 signalling have shown that eosinophilic inflammation and mucus production 
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are attenuated while AHR is preserved(209,221), perhaps due to the existence of 
an IL-4Rα independent signalling pathway for IL-13(222). 
A number of approaches have been applied to address the specific role of IL-13, 
independently of IL-4. When IL-13 is administered to, or expressed in, the lungs 
IgE production, AHR and local eosinophilia and goblet cell hyperplasia are 
induced(209,221,223-225). Blocking the function of IL-13 has been achieved with 
soluble anti-IL-13 and IL-13Rα2 (IL-13Rα2-Fc) or by generating mice lacking IL-13 
or IL-13Rα1. Results of these experiments are summarised in Table 1.4 and show 
a fairly consistent failure to generate AHR or goblet cell hyperplasia with 
preserved airways eosinophilia. 
 
Mice Model Method EØ AHR Goblet Ref 
A/J OVA IL-13Rα2-Fc NC   (223) 
BALB/c OVA + Alum IL-13Rα2-Fc    (209) 
BALB/c OVA + Alum IL-13-/- NC NC  (226) 
BALB/c OVA + Alum IL-13-/- NC   (225) 
BALB/c TF-OVA IL-13-/- NC   (225) 
BALB/c OVA + Alum α-IL-13 NC  - (227) 
BALB/c S. mansoni IL-13Rα1-/- NC   (228) 
NS OVA + Alum IL-13Rα1-/-    (229) 
Table 1.4 - Studies on the requirement for IL-13 in experimental asthma 
KEY –  EØ: effect on lung eosinophil numbers. AHR: effect on airways hyperresponsiveness. 
Goblet: goblet cell hyperplasia. : reduced. : absent. NC: no change. NS: Not stated. 
 
Overall it would appear that IL-4 is crucial in the generation of IgE and the 
development of Th2 inflammation and consequent eosinophil accumulation, IL-5 
plays a key role in eosinophilic inflammation and IL-13 is responsible for AHR and 
goblet cell hyperplasia. 
Other cytokines in asthma 
While evidence of Th2 inflammation is consistently found in clinical asthma 
there are reports of increased IFNγ producing cells within the airways(230-232), 
particularly in those with more severe disease(233,234). As discussed above the 
transfer of Th1 cells alone fails to generate experimental asthma in mice, but 
when co-transferred with Th2 cells results have been conflicting. Two 
independent groups found that when polarised antigen-specific Th1 and Th2 cells 
were co-transferred before airways challenge the extent of BAL eosinophilia was 
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attenuated as compared with the transfer of Th2 cells alone(180,235), although 
histological inflammation and AHR were unaffected(180). However another 
group utilising a similar model, but with only a single antigen challenge, found 
that BAL eosinophilia was not generated following the transfer of Th1 or Th2 
cells alone, but only with the co-transfer of both populations(236). While it is 
hard to draw firm conclusions it would certainly seem that asthma is not simply 
due to changes in the Th1-Th2 balance. 
Drugs targeting TNFα are now widely used in Crohn‟s disease and rheumatoid 
arthritis, and are the only anti-cytokine therapies in regular clinical use for 
inflammatory disease. TNFα is found at elevated levels in the airways of 
asthmatics, particularly in mast cells(237,238). Murine models also support a 
role for mast cell derived TNFα(33,163). Following on from the apparent efficacy 
of anti-TNFα for severe asthma in a small uncontrolled study(239) there have 
been a number of studies addressing the use of anti-TNFα therapy in asthma. An 
initial randomised controlled study of 10 patients with severe asthma also looked 
promising with improvements in AHR, lung function and quality of life(240). 
Unfortunately subsequent small trials in both patients with severe(241) and more 
mild(242,243) asthma failed to show any convincing benefit. A much larger trial 
of 309 patients with severe asthma also failed to demonstrate any benefit(244). 
In light of these results and concerns over safety it seems unlikely that anti-
TNFα therapies will become widely used in asthma, although the possibility 
remains that a specific subset of patients may be identified who will benefit. 
There has recently been considerable interest in the novel Th17 subset of helper 
T cells. They are characterised by the production of IL-17 and play a key role in 
certain autoimmune diseases(245,246). While IL-17 has been detected at 
elevated levels in the sputum and BAL of asthmatic patients(247,248), the role it 
plays in disease is unclear. In rodent models IL-17 expression or administration 
to the lungs results in non-eosinophilic inflammation(249-251). However in 
murine models of asthma IL-17 deficiency attenuates eosinophil accumulation in 
some studies(251,252) but not others(253), and IL-17 administered at challenge 
blocks AHR and eosinophil recruitment(252). Antibody studies with anti-IL-17 
have yielded similarly conflicting results(254,255) 
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The subset of chemotactic cytokines, or chemokines, play an important role in 
asthma due to their function as inducers of leucocyte migration and activation. 
In asthma there has been particular interest in the chemokines which act on Th2 
cells and eosinophils. Th2 cells preferentially express the chemokine receptors 
CCR3 and CCR4(256,257), the ligands for which include eotaxin-1 (CCL11), 
eotaxin-2 (CCL24), RANTES (CCL5) and TARC (CCL17). While RANTES and TARC 
are both elevated in asthma (258,259), the eotaxin chemokines have attracted 
particular interest due their potent and relatively selective effect on eosinophil 
migration(260), mediated via CCR3. In clinical asthma CCR3 and eotaxin-1 are 
detected at increased levels within the lungs and serum(261-264), and increased 
pulmonary or serum eotaxin-1 correlates increased AHR and airflow 
obstruction(263,264). Epithelial cells, fibroblasts and macrophages appear to be 
the source of eotaxin-1 in asthma(261,262,265). Murine models have shown that 
blocking eotaxin-1 or eotaxin-2 alone by antibodies or gene deletion partially 
reduces eosinophil recruitment(179,260,266-268), whereas elimination of all 
eotaxin signalling by CCR3 knock-out or eotaxin-1/eotaxin-2 double knock-out, 
has a much more dramatic effect on lung eosinophilia(268-270). Effects on AHR 
have been much more variable(266,269,270), in keeping with the dissociation 
between eosinophilic inflammation and AHR discussed earlier. CCR3 antagonists 
have yielded promising results in animal studies(271,272) and there is currently 
interest from pharmaceutical companies in developing such molecules for 
therapeutic use in asthma. 
Regulatory T lymphocytes 
There are at least three major types of regulatory T (TReg) cells: CD4+CD25+, Tr1 
and Th3 cells with overlapping functions(273-275). CD25+ T cells are arguably the 
best characterized so far. This subset of CD4+ T cells constitutively express the 
IL-2R α-chain (CD25) and a role in immune regulation was postulated following 
the observation that depletion of CD25+ T cells results in the development of 
organ-specific auto-immunity and the production of auto-antibodies (275,275). 
CD25+ T cells can suppress both Th1 and Th2 cell development and the effector 
functions of committed Th1/Th2 cells (276,276). In humans CD25+ TReg numbers 
are reduced in asthma(277), and may be functionally impaired (277,278). In 
experimental asthma there is evidence that CD25+(26,279-282) and Tr1(283) 
cells can suppress IgE production, pulmonary eosinophilia and AHR. 
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1.1.3.5 Macrophages and dendritic cells 
While there is some debate as to the relationship between them(284), 
macrophages and dendritic cells (DCs) are derived from circulating 
monocytes(285,286) and are both involved in the uptake of foreign material 
within the lung, although probably have distinct functions. 
Macrophages are the most abundant inflammatory cells within the lung, making 
up the majority of cells within the normal BAL(285). There are both interstitial 
macrophages within the lung parenchyma, and alveolar macrophages that line 
the alveoli and airways and are therefore directly exposed to the air. While 
traditionally considered as phagocytic effector cells, macrophages can also 
direct the immune response by antigen presentation and cytokine release. 
Despite the presence of high numbers of macrophages at the interface between 
the lung and the environment, little is known about the role they play in 
asthma. When macrophages are adoptively transferred into murine lungs they 
attenuate models of allergic airways disease(287,288). Initial studies using 
macrophage depletion demonstrated a worsening of experimental asthma, with 
the suggestion that the mechanism is the promotion of a protective Th1 
response(289,290). However more recent studies have been contradictory, with 
a subset of CD11b+ CD11cint macrophages capable of inducing allergic airways 
inflammation(291), and a macrophage depletion model showing abrogated 
eosinophilia and AHR(255). All these results must be interpreted with caution as 
adoptively transferred macrophages may not be representative of the normal 
lung macrophage population, and depletion techniques are incomplete and not 
necessarily clearly targeted. 
DCs are professional antigen presenting cells and play a key role in directing the 
adaptive immune response. Within the lungs immature mucosal DCs sitting 
beneath the epithelium, as well as alveolar DCs within the air-spaces, are 
constantly sampling inhaled antigens(292). In the context of inflammation, 
particularly associated with TLR ligands(293), DCs are activated and migrate to 
the draining lymph nodes to present their antigens, thereby activating helper T 
cells(292). Under other circumstances DCs can promote tolerance(294) and the 
generation of regulatory T cells(295). The development of Th cells into a Th1, 
Th2 or Th17 phenotype is probably determined at the time of antigen 
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presentation by DCs and is strongly influenced by co-stimulatory molecules and 
the cytokine milieu present(296). In addition to the role DCs play at sensitisation 
they are also found at increased numbers following antigen challenge in both 
mice and humans(297). Evidence for the importance of DCs in experimental 
asthma comes from the findings that challenge of mice which have received 
antigen pulsed DCs results in eosinophilic airways inflammation(298,299) and 
depletion of DCs attenuates the inflammation and AHR in models of 
asthma(300,301). 
1.1.3.6 Stromal cells 
The most important structural cells in the lung are epithelial cells, endothelial 
cells, fibroblasts and smooth muscle cells. While initially considered as target 
cells in asthma which were bystanders affected by the inflammatory process, it 
is now becoming clear that they are active participants in the immune response. 
Epithelial abnormalities, particularly shedding, have long been recognised as 
features of asthma (57,69) and were thought to be an end result of 
inflammation. It is now accepted that epithelial cells are far from inert and can 
release a number of mediators including TGFβ, eotaxin, IL-5 and IL-13 in 
response to pathogens, toxins or direct injury(302). There is also evidence that 
epithelial cells can drive myofibroblast proliferation, and collagen deposition, 
thereby contributing to airway remodelling. TGFβ appears to be central in this 
process(303) and can be induced in epithelial cells in response to IL-4 and IL-
13(304). 
While the function of smooth muscle in healthy lungs is debated(305), the role it 
plays in bronchoconstriction and AHR is well established. Smooth muscle cells 
also contribute to remodelling, both in terms of increased smooth muscle 
mass(306) and influences on the extracellular matrix(307,308). Some of these 
effects may be due to fundamental differences in smooth muscle cells of 
asthmatics, while others may be due to the response of smooth muscle cells to 
inflammatory mediators(308). In addition to these downstream effects, it is now 
becoming clear that smooth muscle cells play a role in the inflammatory 
response by releasing a number of pro-inflammatory mediators including IL-6, IL-
8, TGFβ and eotaxin(308,309).  
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1.1.3.7 Neutrophils 
In healthy controls the cellular content of sputum is comprised of around two 
thirds macrophages and one third neutrophils, with eosinophils makingup less 
than 1%(310-312). As discussed previously, clinical asthma is characterised by an 
increase in eosinophil numbers within the sputum, BAL and airway walls. 
However reports began to emerge in the 1990s suggesting that airways 
eosinophilia is not universal in asthmatic patients. Not only did a significant 
proportion of patients experiencing a mild exacerbation have a normal 
eosinophil count(313), but patients with sudden onset fatal asthma(314), severe 
exacerbations(315), and severe asthma on oral corticosteroids(316) often had 
significantly elevated numbers of neutrophils within the airways and lung tissue. 
Since then there has been considerable interest in trying to characterise this 
subgroup of patients. While around 70-80% of asthmatic patients have elevated 
sputum eosinophil numbers the remainder have “non-eosinophilic” asthma, with 
either normal or elevated neutrophils(20). Not only is a neutrophilic asthma 
associated with more severe asthma, but also with a failure to respond to 
corticosteroids(317). Interestingly mast cells are also present within the smooth 
muscle bundles in neutrophilic asthma(318), a characteristic finding in 
eosinophilic asthma(151). One of the histological features that appears to be 
unique to eosinophilic asthma is basement membrane thickening, suggesting that 
airway remodelling may not be a feature of neutrophilic asthma. 
The role of neutrophils in the pathophysiology of asthma remains unknown. In 
patients with neutrophilic asthma there is evidence of activation of the innate 
immune system, with elevated sputum IL-8, TLR mRNA and LPS as compared 
with eosinophilic asthma(319). The role of neutrophils in experimental asthma 
has not been addressed and almost all current animal models reproduce 
eosinophilic asthma. There is one report describing a model of non-eosinophilic 
asthma in which AHR was generated(320). However neutrophils were only 
modestly elevated within the BAL at 8% with eosinophils still detectable at 1%, 
and within the lung tissue eosinophils were more abundant than neutrophils.  
---oOo--- 
Despite significant advances in our understanding of asthma over the past one 
hundred years the exact role of different cells and cytokines remains unclear. 
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While eosinophils are perhaps not as central as once thought, particularly in 
AHR, they appear to be important in asthma exacerbations and airways 
remodelling. This implicates IL-5 and the eotaxins, which are key mediators in 
the activation and recruitment of eosinophils, in these processes. IL-4 and T 
cells are likely to be crucial in the development of Th2 inflammation which 
results in the production of IL-5 as well as IL-13, which appears to be important 
for AHR and mucus production. B and T lymphocytes as well as IL-4 are essential 
for the generation of IgE which is central in atopic asthma and may play a role in 
non-atopic asthma. The function of mast cells remains undefined, and while 
animal models suggest they are an essential source of TNFα, in clinical asthma 
TNFα does not appear to be an important therapeutic target. However the 
location of mast cells within the smooth muscle bundles in asthma but not 
eosinophilic bronchitis suggests they may play a role in AHR. Macrophages, DCs 
and neutrophils are also likely to have their roles to play. In addition to the cells 
of the immune system stromal cells are increasingly recognised as contributing 
to the inflammatory process. 
By studying novel cytokines which fit into this network of cells and mediators we 
can not only improve our understanding of the pathophysiology of asthma, but 
may also discover new therapeutic targets. IL-33 and the receptor ST2 represent 
one such cytokine. 
 
1.2 ST2 
1.2.1 ST2 gene and protein 
1.2.1.1 The discovery of ST2 
The gene for the protein referred to herein as ST2 was first described in 1989 by 
two independent groups. Initially referred to as T1, it was identified by 
screening of a cDNA library obtained from the murine 3T3 fibroblast cell line 
under mitogenic stimulation by over-expression of the ras oncogene(321). In 
these cells the T1 gene was also induced by dexamethasone and by re-feeding 
following serum starvation(321). At around the same time an identical gene, 
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referred to as ST2, was identified in 3T3 fibroblasts following serum re-feeding, 
which was absent in serum starved fibroblasts(322).  
Although ST2 would remain an orphan receptor until the discovery of the ligand 
IL-33 in 2005(323), a great deal was learnt about the biology of ST2 in the 
intervening sixteen years. 
1.2.1.2 The ST2 gene and its products 
The first described sequence for ST2 was 2.7kb long with two potential initiation 
sites encoding  a 337 amino acid protein with a predicted size of 37.7 or 38.5 
kDa(322,324). It has significant homology to the IL-1 receptor (IL-1R1) and is a 
member of the immunoglobulin superfamily, although it appears to lack 
transmembrane or cytoplasmic domains(322,324). Consequently it is referred to 
as soluble ST2 or sST2(325). The human cDNA for sST2 was then isolated from a 
granulocyte DNA library by screening with a probe from the murine sST2 
sequence before being sequenced from a helper T cell clone(326), the final 
protein having 68% homology to murine sST2(327). The murine St2 gene is 
located on chromosome 1 and is closely related to the IL-1r1 locus(328). The 
human St2 gene is also found closely related to Il-1r, in this case on chromosome 
2q12-13(329). Cells transfected with soluble ST2 produce an intracellular protein 
of 45-60 kDa and an extracellular protein of 60-70 kDa when glycosylation is 
permitted, the differences in size presumably representing different degrees of 
glycosylation (330,331). 
A third ST2 gene product has been described in human cells, referred to as ST2V, 
which was initially identified in a helper T-cell line(332). It resembles sST2, but 
due to alternative splicing, one of the three extracellular immunoglobulin 
domains is replaced by a hydrophobic tail. Although a homolog exists in chickens 
there is no evidence for the existence of ST2V in mice. In chickens there also 
exists a fourth product, ST2LV, which is identical to ST2L but due to alternative 
splicing lacks the exon encoding the transmembrane domain(333). No data exists 
regarding their function. Figure 1.1 shows the three transcription products from 
the human ST2 gene. 
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Figure 1.1 - Schematic representation of the human ST2 gene 
(A) The top line shows the location of ST2 in the human genome. The bottom line indicates the 
expanded region for the human ST2 gene. Exons are shown as boxes and numbered from 1a to 11 
with coding regions in red, and non-coding regions in white except for exon 5E in orange, which 
is specific to ST2V. (B) The exon usage starting from exon 5 for three spliced isoforms is shown. 
All the spliced isoforms thus far found commonly utilize from exon 2 to exon 5. The entire exon 8 
is integrated for ST2 or ST2V cDNA, while part of exon 8 is utilized for ST2L cDNA. Adapted from 
Li et al (334) 
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1.2.1.3 ST2 regulation and expression 
As previously discussed ST2 was initially identified in murine fibroblast lines and 
much of the understanding of ST2 gene regulation is from early studies in 
fibroblasts. Due to the fact that ST2 was induced by oncongene transfection or 
feeding following serum starvation(321,322), it was associated with the 
transition between the G0 and G1 state. 
Immediate early genes, many of which are transcription factors, are induced 
rapidly in resting cells without the need for synthesis of other proteins. Delayed 
early genes require the synthesis of other proteins, such as immediate early 
transcription factors, for activation and therefore such activation occurs later. 
The initial finding that ST2 induction peaked at 6-10 hours after serum 
stimulation of fibroblasts suggested that it might be a delayed early 
gene(321,322,335,336). 
Activator Protein-1 (AP-1) is a prototypical transcription factor and is a 
heterodimer made up of two variable immediate early gene products, often Jun 
and Fos proteins(337). Support for ST2 as a delayed early gene comes from the 
finding that the expression of AP-1 subunits can drive sST2, and to some extent 
ST2L, in both mouse and rat fibroblasts(335,338-340). Further evidence for ST2 
as a delayed early response gene is the finding that ST2 could not be induced by 
serum stimulation of fibroblasts in the presence of the protein synthesis inhibitor 
cycloheximide(335,336,339), although there is one report contradicting 
this(325). 
Ultimately it appears that ST2 can be induced via Fos/AP-1 as a protein synthesis 
dependent delayed early response gene (as is the case with serum stimulation), 
or via activation of p38 MAP kinase as a protein synthesis independent 
immediate early gene(341). 
Two potential promoter regions for ST2 have been identified in fibroblasts 
(342,343), one of which was found to be activated by AP-1 and contained a 
classical AP-1 site(343). Subsequently it has been shown that inflammatory 
stimuli can also upregulate ST2. In human fibroblasts sST2, and to a much lesser 
degree ST2L, are induced by PMA, TNF, IL-1α and IL-1β(344).  
Chapter 1:  48 
Since the initial identification of ST2 in fibroblasts ST2 expression has been 
detected in a number of other cells types under different conditions as shown in 
Table 1.5. These studies highlighted that sST2 is predominantly found in 
structural cells such as epithelial cells and fibroblasts while ST2L expression is 
more restricted to lympoid tissue and inflammatory cells, with particularly good 
evidence of expression by T cells and mast cells as discussed below. As in 
fibroblasts ST2 can be upregulated by inflammatory stimuli. TNFα similarly 
upregulates sST2 and ST2L in human vascular endothelial cells(341,344). In 
macrophages and monocytes ST2 expression is induced by LPS (345), and other 
TLR ligands can upregulate ST2 in spleen preparations(346). 
 
 murine human  
Tissues sST2 ST2L sST2 ST2L Ref 
Liver  R, P R R (339,344,347,348) 
Spleen  R   (334,339,344,347) 
Lung  R R R (334,339,344) 
Lymph node  R   (339) 
Bone marrow R R, P   (339,347,348)  
Bone R, P    (347,349,350) 
Skin R, P    (344,347) 
Bowel   R  (334) 
Placenta   R R (334,344) 
Kidney   R R (334,344) 
Cells      
Fibroblasts R, P R, P R1, P1  (324,327,331,344,348,351-354) 
Epithelial  R  R1, P R1 (339,353-356) 
Endothelial    R, P R (344,351,353) 
Smooth muscle   R R (353,357) 
Mast cell  R, P  R, P (347,348,350,352,358)  
T cells2  R, P R R, P (344,347,348,359-364) 
B cells  P   (348,360) 
PBMCs   R P (365,366) 
Mono/MO  R, P R1 R1 (339,348,353) 
Erythroid R R R  (339,344,347,350) 
 
Table 1.5 – Tissues and cells in which ST2 expression has been detected 
Whole tissues or cells, including cell lines, where sST2 or ST2L have been identified at the RNA 
(R) or protein (P) level. PBMCs = Peripheral blood mononuclear cells. Mono/MO = monocytes and 
macrophages. (1) Includes detection in cells specifically of lung origin (2) Preferentially detected 
in Th2 cells(359,360,362,364,365). 
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The expression of ST2 in different cells is controlled by the use of differing 
promoters. Mice and rat fibroblasts use a 4kb upstream promoter for both forms 
of ST2(339,343,350). While ST2 and ST2L from mast cells have an alternative 
exon 1 which is 10.5kb(367) upstream of the transcription start site in fibroblasts 
and has a separate promoter which is independent of serum growth factors(350) 
and contains several GATA elements, with GATA-1 over-expression enhancing 
ST2 expression (367,368). Like mast cells, Th2 cells utilise the distal promoter 
for sST2 and ST2L(368,369) and GATA-3 can bind to the distal promoter and 
activate ST2 in these cells(368). In humans the situation is less clear cut, 
although fibroblasts predominantly use the proximal promoter and leucocytes 
the distal promoter for both ST2 and ST2L(357,370). There is once again a GATA-
1 site in the distal promoter(370). However in human mast cells while ST2L is 
expressed utilising the distal promoter, sST2 appears to utilise both(357). 
T lymphocytes 
The report that ST2L RNA was expressed in T cell lines(347) was followed by the 
finding that this expression was limited to Th0 and Th2 lines and was enhanced 
under conditions favouring Th2 development(365). Subsequently two 
independent groups identified ST2L by differential display PCR as being 
expressed by murine Th2 and not Th1 cells(359,360), with similar findings from 
human Th2 cells(362,364).  
The frequency of ST2+ cells in naïve mice(360) and human peripheral 
blood(364,371) is low, at around 1-3% of CD4+ cells. However surface ST2L is 
upregulated under Th2 polarising conditions in vitro and in vivo. When naïve T 
cells are driven towards a Th2 phenotype in vitro 41-77% have been reported to 
express ST2(359,372,373). This upregulation of ST2 under Th2 polarising 
conditions is further enhanced by the addition of IL-6(373). Established Th2 cells 
also upregulate surface ST2L in response to TcR stimulation in the presence of 
co-stimulation(369). While IL-4 enhances ST2L expression IFNγ results in a net 
reduction in ST2L(369). In the context of disease ST2 can also be significantly 
upregulated, with expression on between 10% and 60% of murine CD4+ cells in 
Schistomsoma mansoni egg responses(374,375), Leishmania major 
infection(375,376) and experimental asthma(218,298,377,378). Although ST2L is 
restricted to Th2 T cells, IL-4 is not required for the expression of ST2L in 
vitro(360) or in vivo(376). Similarly IL-4 is not required for the production of IL-5 
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by ST2+ T cells, while the absence of IL-5 results in reduced ST2 expression 
(360). As would be expected ST2L+ T cells produce Th2 cytokines and are IL-4+ 
and IL-5+ on intra-cellular staining(359,360,373,374), and while under conditions 
favouring Th2 cells development CD4+ST2- cells expressed IL-4 and IL-10, albeit 
at lower levels than the CD4+ST2+ cells, none of them expressed IL-5(379). 
Mast cells 
The other main cell line of the haematopoetic lineage found to express ST2L are 
mast cells. Not only are they strong expressers of ST2L RNA(347,350,367), but 
they also express the protein on the cell surface(347,350). When compared with 
other leukocytes mast cells are all ST2L+ and have the highest concentration of 
surface ST2L(348). Following the finding that ST2L is expressed on foetal mast 
cell progenitors(348), a search for mast cell lineage cells in adults using an in 
vitro culture system found that ST2 appeared to be a marker of committed mast 
cell progenitors(380). Whereas the β7+CD27-ST2- fraction of bone marrow cells 
was able to generate mast cells, macrophages, erythrocytes and 
megakaryocytes, the β7+CD27-ST2+ fraction gave rise to mast cells alone. This 
fraction was the only one able to generate significant numbers of mast cells and 
also reconstituted irradiated W-sh mice with mast cells but not B cells, 
macrophages or granulocytes. 
Despite this, ST2 is not essential for mast cell production as ST2-/- mice have 
normal mast cell numbers in the skin and stomach and mast cells can be 
cultured from the bone marrow of these mice(381). These cultured ST2-/- mast 
cells degranulate normally in response to IgE cross-linking(381). 
1.2.2 ST2 function 
1.2.2.1 The function of ST2 in vitro 
The first studies investigating the role of ST2 in vitro used either antibodies 
against ST2 or recombinant sST2, often fused with the Fc portion of human IgG1 
(sST2-Fc) as experimental blocking agents. In the presence of ST2-Fc there is a 
reduction in IL-4 and IL-5 and an increase in IFNγ production by CD4+ T cells 
under both neutral and Th2 polarising conditions(372). When measuring Th2 cell 
proliferation and Th2 cytokine production not only is anti-ST2 antibody able to 
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enhance the effect of TcR signalling, but anti-ST2 alone can mediate these 
effects. This is dependent on the anti-ST2 being plate bound, presumably to 
mediate ST2 crosslinking, and is blocked by recombinant sST2(373). 
The development of ST2 gene knockout mice made it possible to study the effect 
of ST2 deficiency on T cells. ST2-/- and wild type T cells stimulated with anti-CD3 
produce identical levels of IL-4, IL-5 and IL-10 or IFNγ under Th2 or Th1 
polarising conditions respectively(381-383). However when ST2-/- OVA-specific T 
cells are activated by OVA peptide they produce significantly more IL-5 than wild 
type cells(383). 
When murine macrophages were studied it was shown that pre-treatment with 
sST2-Fc attenuates LPS mediated release of IL-6, IL-12 and TNFα(353,384-386). 
Similarly, sST2 was shown to inhibit LPS induced IL-1β, IL-6 and TNFα production 
by a human monocytic cell line and was associated with reduced IκB degradation 
and reduced binding of NFκB to the IL-6 promoter(387). In addition sST2-Fc 
induces macrophage NFκB(384,388) and down-regulates TLR-4 and TLR-1 
mRNA(384). Conversely ST2-/- macrophages produce increased quantities of IL-6 
and IL-12 in response to treatment with TLR ligands or IL-1(345).  
ST2 also appeared to be inhibitory in mast cells, with transfection reducing IL-1 
or LPS mediated NFκB activation and anti-ST2 antibody inhibiting IL-1 mediated 
NFκB activation in an ST2+ mast cell line(345). One possible mechanism for these 
inhibitory effects is the downregulation of NFκB by ST2 sequestration of MyD88 
and Mal(345).  
1.2.2.2 The function of ST2 in vivo 
The first studies investigating the role of ST2 in vivo used antibodies against ST2. 
One such polyclonal anti-ST2 antibody was shown to induce complement 
mediated lysis in vitro. When administered to Leishmania major susceptible Th2 
prone BALB/c mice they developed less severe disease with a reduced parasite 
load and evidence of switching to a protective Th1 response(359). However a 
later study using a different, non-lytic antibody or ST2-Fc found no difference in 
the course of L. major infection in BALB/c mice(385). In collagen induced 
arthritis the use of depleting anti-ST2 antibody exacerbated disease with 
evidence of enhanced Th1 responses(359). Conversely blocking ST2 function with 
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ST2-Fc at the time of disease onset reduces the severity of collagen-induced 
arthritis(389). 
sST2-Fc reduces mortality and cytokine production in LPS induced shock, 
whereas blocking anti-ST2 antibody has the opposite effect(384). While ST2-/- 
mice are as susceptible to LPS induced shock as wild type mice, pre-treatment 
with LPS protects wild type but not ST2-/- mice from subsequent challenge with a 
lethal dose of LPS(345). This effect may be mediated by LPS induced 
upregulation of ST2 on macrophages and subsequent MyD88 sequestration 
inhibiting TLR-4 signalling, phenomena which have been observed in vitro(345). 
Transfection with sST2-Fc results in reduced liver damage in a liver ischaemia-
reperfusion model. This was associated with a reduction in liver macrophage 
number and serum IL-6 and TNFα(386). Similar results were seen in an intestinal 
ischaemia-reperfusion model where treatment with sST2-Fc reduced neutrophil 
influx, histological damage and vascular permeability with an associated 
reduction in TNFα, CCL2(MCP-1) and CXCL1. Interestingly this effect was IL-10 
dependent, not only was there a rise in local IL-10, but the protective effect of 
sST2-Fc was lost in IL-10-/- mice(390). In a model of hepatic injury sST2-Fc 
treatment did not alter the extent of liver damage, but did enhance subsequent 
fibrosis with an associated increase in ex vivo Th2 cytokine production. This 
effect was abrogated by CD4 depletion and attenuated in IL-4-/- mice(388). 
Taken together these data suggest that ST2 can play a role the inflammatory 
response to tissue injury. 
The development of ST2 gene knockout mice(381,382,391) made it possible to 
ask further questions regarding the role of ST2. Initial phenotyping showed that 
naïve ST2-/- mice have normal serum immunoglobulin levels and a normal 
population of immune cells(382). 
In ST2-/- mice infected with Nippostrongylus brasiliensis serum immunoglobulin 
levels and ex vivo IL-4 and IFNγ production by CD4 T cells are unaffected(381). 
Although a later study suggested that T cell IL-5 was reduced in the lungs of ST2-
/- and ST2-Fc transgenic mice during N. brasiliensis infection, peripheral and 
lung eosinophilia, serum immunoglobulin induction and parasite clearance was 
unaffected(391). 
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A study of Schistosoma mansoni egg induced granuloma formation, a Th2 
dominated response(392), yielded intriguing results(382). When S. mansoni eggs 
were administered intravenously (IV) to naïve mice there was a dramatic 
impairment of eosinophil accumulation and pulmonary granuloma formation in 
ST2-/- mice. Conversely, when the eggs were administered IV to mice that were 
first immunised IP with eggs, granuloma formation and antibody production was 
unaffected in ST2-/- mice, although there was a reduction in ex vivo Th2 cytokine 
production(382). 
ST2-/- mice developed more severe pancreatic inflammation in a streptozotocin 
induced diabetes model(393). Observational studies have also reported elevated 
ST2 in models such as LPS induced acute lung injury, where BAL sST2 protein was 
elevated(353), an allergic model of contact dermatitis, where ST2 RNA was 
elevated in the skin(394) and bleomycin induced pulmonary fibrosis where ST2 
RNA was induced locally(354), 
ST2 in asthma 
Given the expression of ST2 on mast cells and Th2 cells it seemed reasonable 
that ST2 may be involved in the pathophysiology of asthma. A hypothesis that 
was later strengthened by the finding that lung ST2 RNA and serum sST2 protein 
were elevated during an OVA/Alum driven murine model of asthma(395). 
Initial studies into the role of ST2 in allergic airways inflammation relied on the 
administration of antibodies or exogenous sST2, and consistently favoured a role 
for ST2 in asthma models. The first of these studies used anti-ST2 or sST2-Fc, 
both at a dose of 20 to 100 µg per mouse. Allergic airways inflammation was 
induced by the adoptive transfer of OVA specific T cells which had been 
polarised to a Th2 phenotype, followed one day later by two challenges of 
nebulised OVA on two consecutive days. When anti-ST2 or sST2-Fc was 
administered one hour prior to antigen challenge there was a substantial 
reduction in BAL eosinophils and Th2 cytokines, histological inflammation in the 
lung and AHR(360,372). A similar effect was seen in a 21 day OVA sensitisation 
and challenge model where mice were sensitised with IP OVA/Alum on two 
occasions before being twice challenged with nebulised OVA. Administration of 
the same anti-ST2 antibody 1 hour before each sensitisation and challenge 
resulted in a significant reduction in BAL eosinophils and IL-5 as well as serum 
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OVA-specific IgE(372). In a model of asthma mediated by the adoptive transfer 
of OVA pulsed DCs followed by seven nebulised doses of OVA, treatment with 
anti-ST2 or ST2-Fc at the time of DC transfer reduced BAL eosinophilia and 
histological inflammation(298). In respiratory syncytial (RSV) virus induced Th2 
mediated eosinophilic lung disease in mice administration of anti-ST2 around the 
time of RSV challenge attenuated disease severity, as measured by BAL 
eosinophilia and weight loss, although viral clearance was delayed(396). Using 
the alternative technique of intravenous ST2 gene transfer resulted in reduced 
BAL eosinophils, IL-4 and IL-5 in a 14 day OVA/Alum model of asthma(395).  
Subsequent studies in ST2 gene knockout mice yielded results contrary to the 
data from anti-ST2 and sST2 experiments. In a 35 day model of asthma with 
OVA/Alum sensitisation followed by OVA challenge C57Bl/6 wild type and ST2-/- 
mice showed identical levels of BAL eosinophilia, histological inflammation and 
serum immunoglobulins(381). There were comparable results in BALB/c mice 
using a similar OVA/Alum model, this time over 30 days(383). Wild type and ST2-
/- mice had a similar of degree of AHR, histological inflammation and ex vivo 
cytokine production. However BAL eosinophils were elevated and macrophages 
were reduced in ST2-/- mice. An adoptive transfer model was then used to focus 
on the role of T cells. OVA specific wild type or ST2-/- Th2 cells were generated 
in vitro and transferred into wild type mice which had been primed with 
OVA/Alum, mice were challenged daily with nebulised OVA over the following 
five days. When compared with mice that received wild type Th2 cells those that 
received ST2-/- Th2 cells had elevated BAL and lung eosinophilia, increased 
inflammation and mucus production on lung histology and dramatically enhanced 
AHR, leading to increased mortality. The BAL, lungs and lymph nodes were 
enriched for antigen specific T cells, but total macrophage numbers in the BAL 
were reduced. BAL and lung cytokine and chemokine levels were all low and 
there was no difference between groups. There was no evidence of a mast cell 
or basophil contribution as serum mast cell protease-1 and lung mast cell 
numbers were unaffected.  Allergic inflammation was also independent of B-
cells or recipient T cells as lung and BAL inflammation was unaffected if RAG-/- 
mice were used as recipients(383). 
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1.2.2.3 ST2 in clinical disease 
Although sST2 and ST2L had been detected in human cells and samples at both 
the RNA and protein level, it was the development of an ELISA for sST2(397) 
which made it possible to identify and study the role of ST2 in clinical disease. 
The first of these studies suggested that serum sST2 was elevated in a small 
cohort of six asthmatics as compared with patients with lung cancer or healthy 
controls(397). A subsequent larger study of 56 patients also found that serum 
sST2 was slightly elevated in asthma, but was further elevated during 
exacerbations when levels correlated with severity of exacerbation, peak 
expiratory flow rate and PaCO2(398). 
While sample sizes were often very small, serum sST2 was also found to be 
elevated in a number of other conditions including eosinophilic pneumonia(399), 
autoimmune diseases such as rheumatoid arthritis, SLE, Wegener‟s 
granulomatosis and Bechet‟s disease (400), idiopathic pulmonary fibrosis (401), 
sepsis and trauma where ST2 correlated with mortality (402), in patients treated 
with H2 antagonists(403,404), and in the CSF of patients with subarachnoid 
haemorrhage(405). 
A large Japanese cohort study found a number of Single-nucleotide 
polymorphisms (SNPs) in the ST2 gene and went on to study seven of them in 
patients with atopic dermatitis and normal controls. One SNP, located in exon 
1a, showed a significant association with atopic dermatitis, and among patients 
with atopic dermatitis those with the associated genotype had higher levels of 
serum sST2 and IgE. Of the haplotypes incorporating all seven loci one was 
associated with atopic dermatitis and this haplotype was associated with 
stronger ST2 promoter activity in a reporter system(406). 
ST2 in heart disease 
The possibility that ST2 might be involved in heart disease was raised after the 
finding that sST2, and to a lesser extent ST2L, were up-regulated in cardiac 
myocytes and fibroblasts under mechanical strain(406,407). This observation was 
extended to the whole organism with data showing ST2 RNA was upregulated in 
the left ventricle and sST2 was elevated in the serum of mice following 
myocardial infarction (MI)(406). In a small cohort of patients serum ST2 was 
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elevated immediately post MI and levels correlated with creatinine kinase, a 
marker of cardiac damage, and with poor left ventricular function post MI(406). 
A later study of 810 patients with acute MI found that serum ST2 at presentation 
correlated with troponin, a marker of cardiac damage, and was a predictor of 
subsequent mortality or heart failure(408). However sST2 appeared to be a poor 
predictor of acute coronary syndrome in an emergency setting, although 
measurements were made very early and there was no comparison with gold 
standard biomarkers(409). Serum sST2 was also found to rise following coronary 
artery bypass grafting(410). A study of 161 patients with severe heart failure 
found that serum sST2 was elevated, correlated with other biomarkers of heart 
failure, BNP and proANP, and was a predictor of mortality (411). A study of 593 
breathless patients, of whom 208 had acute heart failure, found that serum sST2 
was elevated in those with heart failure and correlated with NT-proBNP, left 
ventricular systolic dysfunction and mortality. Interestingly, among patients with 
elevated sST2 without heart failure the commonest cause of death was lung 
disease, including obstructive lung disease, pneumonia and lung cancer(412). 
1.2.2.4 The search for a ligand for ST2 
Given the structure of ST2 and it‟s homology to the IL-1 receptor it was 
immediately ascribed the function of a receptor(347,351,365,413). IL-1 was 
quickly excluded as a ligand given that it did not bind to, or signal via, ST2 
(414). However the hypothesis that ST2 could function as a receptor was 
supported by the findings that IL-1 could induce reporter activation, NFΚB 
activation, kinase activity and IL-4 produvction from T cells via a fusion protein 
with the extracellular portion of IL-1R1 and the intracellular portion of 
ST2(351,415,416). While a number of candidate ligands were proposed, they 
failed to show any functional activity(351,415). 
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1.3 Interleukin-33 
1.3.1 IL-33 gene and protein 
In late 2005 the discovery of IL-33 was reported, a novel IL-1 family cytokine and 
a functional ligand for ST2(323). It was discovered using a computational 
database search for IL-1 family members. Human IL-33 is found on chromosome 
9p24.1 and murine IL-33 on 19qC1. They encode proteins of 270 and 266 amino 
acids respectively, both with a molecular weight of 30kDa. Human and murine 
IL-33 share 55% homology at the amino acid level. Within the IL-1 family IL-33 
most closely resembles IL-18. It later became clear that IL-33 is identical to the 
previously reported nuclear factor from high endothelial venules (NF-HEV) which 
was found by subtractive hybridization to be preferentially expressed in high 
endothelial venule (HEV) cells as compared with other endothelial cells(417). 
1.3.1.1 IL-33 expression 
In the mouse IL-33 RNA is detected at high levels in the stomach, lung, spinal 
cord, brain, and skin and at lower levels in lymph nodes, resting DCs, spleen, 
pancreas, kidney, and heart. In the human IL-33 RNA is detected in resting 
bronchial epithelial cells and smooth muscle cells, including those from bronchi, 
pulmonary arteries and coronary arteries, and in cytokine activated fibroblasts. 
Activated murine bone marrow macrophages, and to a much lesser extent 
activated human macrophages and DCs also express IL-33(323). Using in-situ 
hybridization and RT-PCR IL-33 RNA was detected in endothelial cells from 
human tonsils, rheumatoid arthritis synovium and Crohn‟s disease intestine(418). 
As mentioned previously, IL-33 protein is also detected in endothelial cells, 
specifically those of HEVs, and in a few scattered cells in the T- and B-cell 
zones, of human tonsils(417). 
In an adoptive transfer model of asthma OVA/Alum priming alone induced IL-33 
RNA in the lungs, and expression was further enhanced following challenge(383). 
Within the rat heart IL-33 RNA and protein has been detected from cardiac 
fibroblasts, and to a much lesser extent cardiac myocytes, and is upregulated by 
biomechanical strain(407). A similar result was seen in vivo where cardiac 
overload in mice led to increased IL-33 in cardiac fibroblasts(407). 
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1.3.1.2 IL-33 processing 
In keeping with the finding that within the first 65 amino acids of IL-33 there is a 
putative Helix-Turn-Helix (HTH) DNA-Binding Domain(417), IL-33 has been found 
to localise to the nucleus(417). In human tonsillar HEV endothelial cells an 
exclusively nuclear distribution of naturally occurring IL-33 was seen, and 
specifically in heterochromatin (tightly packed transcriptionally inactive DNA) 
rich areas(418). This association was demonstrated in other cell types using 
transfection with GFP tagged IL-33(418). Using truncated proteins it was 
confirmed that the 65 amino acids containing the HTH domain at the N-terminal 
end of IL-33 were responsible for this nuclear localisation(418). These data 
would be in keeping with the suggestion that IL-33 has a pro-domain(323), and 
the evidence that it can be cleaved from the 30kDa product to an 18kDa 
“mature” form by caspase-1(323). However IL-33 does not contain a classical 
caspase-1 cleavage site and there is no evidence of cleavage in vivo. Nuclear 
localisation was observed with endogenous IL-33 in HEV endothelial cells, or with 
transfected IL-33 in other cells, even when specific antibodies against the IL-1 
like C-terminal end of “mature” IL-33 were used(418). 
1.3.2 IL-33 function 
1.3.2.1 IL-33 signalling 
The binding of IL-33 to ST2 was demonstrated by the fact that ST2 co-
precipitates IL-33, and vice versa(323,407), and that binding of anti-ST2 to the 
surface of mast cells is blocked by IL-33(323). Cells transfected with ST2 showed 
NFκB activation using a GFP reporter system(323). ST2 transfected cells 
stimulated with IL-33 were also used to show that ST2 recruits MyD88, IRAK, 
IRAK4, and to a lesser extent TRAF6 and that IκB, Erk1/2, p38, and JNK are 
phosphorylated. This was confirmed using bone marrow derived mast cells 
(BMMCs), previously shown to express surface ST2L(347,350), where IL-33 
treatment resulted in NFΚB, Erk1/2, p38, and JNK phosphorylation, which could 
be blocked with anti-ST2 antibody(323).  
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1.3.2.2 IL-33 function 
At the time of undertaking this research there was very little data on the effect 
of IL-33, all of which was in the paper by Schmitz et al(323). 
The only functional in vitro data was of the effect of IL-33 on T cells. In keeping 
with earlier studies which had activated ST2 by antibody cross-linking(373), IL-33 
enhanced IL-5 and IL-13 production by Th2 cells stimulated via the TcR with 
CD28 co-stimulation, although IL-4 production was unaffected(323). While there 
was evidence of IL-33 induced signalling in mast cells there was no data on the 
functional effects of this(323). 
To study the effects in vivo, recombinant IL-33 was administered IP to C57Bl/6 
mice at a dose of 0.4 or 4 g each day for a total of seven days(323). This 
resulted in a marked increase in peripheral blood eosinophils, and to a lesser 
extent lymphocytes and neutrophils, with elevated serum IgE and IgA. There was 
splenomegaly with increased monocytes, eosinophils and plasma cells within the 
spleen. Histological studies revealed changes within the gastro-intestinal tract 
and lungs. There was epithelial hyperplasia and inflammatory infiltrates, 
including eosinophils, in the oesophagus and goblet cell hypertrophy with excess 
mucus in the intestines. In the lungs there was epithelial hypertrophy and mucus 
hypersecretion in addition to vascular changes, namely perivascular 
mononuclear and myeloid infiltrates round medium and small vessels with 
medial hypertrophy. There was evidence of Th2 activation with elevated serum 
IL-5 and IL-13 and increased IL-4, IL-5 and IL-13 RNA in the thymus, spleen, liver 
and lung. When IL-33 was administered to IL-13-/- mice the epithelial changes 
seen in the lungs of wild type mice were absent, but the vascular changes 
remained. 
 
1.4 Objectives 
In the preceding Introduction I have highlighted the current understanding of the 
immunological basis of asthma and some of the key questions that remain. While 
the importance of Th2 inflammation is well established the exact role of 
different cells and cytokines remains unclear. There is still uncertainty over 
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what mechanisms are involved in the initiation of airways inflammation, the 
place of different cytokines within the hierarchy and sequence of events that 
occurs and the relationship between structural cells and inflammatory cells. 
IL-33 is a novel cytokine about which very little is known, but which has the 
ability to induce Th2 inflammation and eosinophilia in vivo. The receptor for IL-
33, ST2 is expressed at very high levels on mast cells, and there is a body of 
evidence that suggests ST2 plays an important role in Th2 inflammation, 
although the importance of the IL-33 – ST2 axis in experimental asthma is 
unresolved. 
My hypothesis is that „The activation of ST2 on mast cells by IL-33 plays an 
important role in allergic airways inflammation‟. 
To address this question I have set out three objectives. 
2. To establish if mast cells can be activated by IL-33, acting via ST2 to 
produce pro-inflammatory cytokines and chemokines in vitro. 
3. To optimise a murine model of experimental asthma and establish 
whether there is a need for ST2 in this model. 
4. To assess whether or not IL-33 can activate mast cells within the airways 
to induce the features of experimental asthma in vivo. 
By achieving these aims I hope to show that IL-33 is a key cytokine in asthma and 
hence potentially a novel therapeutic target. 
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Materials and Methods 
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2.1 Reagents and buffers 
Reagents and chemicals were purchased from Sigma-Aldrich (Poole, UK) and 
culture media was purchased from Invitrogen Ltd (Paisley, UK) unless stated 
otherwise. Commonly used buffers and solutions are listed in Table 2.1. 
IL-33 used was from one of two sources. For all in vitro experiments commercial 
IL-33 (ALEXIS Corporation, Switzerland) was used. For in vivo experiments IL-33 
produced within the laboratory was used. The methods for the production of IL-
33 have been published elsewhere(419). Briefly, mouse IL-33 cDNA was cloned 
from IL-1-stimulated fibroblasts, and the cDNA sequence was transformed into 
host Escherichia coli. IL-33 protein was induced by IPTG and purified by Ni-NTA 
affinity chromatography followed by polymyxin B column to remove endotoxin. 
The purity of IL-33 was more than 95% and endotoxin levels were less than 0.01 
EU/µg of protein by the QCL-1000 pyrogen test (Bio-Whittaker). Bioactivity and 
specificity of recombinant IL-33 were confirmed by its ability to induce IL-5 
production from wild type but not ST2-/- Th2 cells. 
Phosphate buffered saline (PBS) 8g NaCl, 1.16g Na2HPO4, 0.2g KCl, 0.2g 
KH2PO4 in 1 litre distilled water, pH 7.4 
Avertin stock 1:1 w/v solution of 2,2,2-tribromoethanol 
in tert-amyl alcohol 
Complete medium 500 ml RPMI 1640, 50 ml inactivated FBS, 5 
ml pen / strep, 5 ml L-glutamine 
Complete IMDM 500 ml Iscove's Modified Dulbecco's 
Medium (IMDM), 50 ml inactivated FBS, 5 
ml pen / strep, 5 ml L-glutamine 
FACS buffer  2% FCS in PBS 
BD ELISA Coating buffer  0.1M NaHCO3 pH 8.4 
ELISA Wash buffer  0.05% Tween-20 in PBS pH 7.4 
BD ELISA assay buffer  10% FCS in PBS 
R&D ELISA assay buffer  1% BSA in PBS 
Biousource ELISA assay buffer  0.5% BSA and 0.1% Tween in PBS 
OptEIA Coating Buffer  8.4g NaHCO3, 3.56g Na2CO3 in 1 litre 
distilled water, pH 9.5 
0.05M Citrate buffer  24.8 ml 0.05M citric acid 
25.2 ml 0.05M trisodium citrate 
Sodium Carbonate Buffer 25 ml 0.2M Na2CO3 
25 ml 0.2M NaHCO3 
Table 2.1 – List of commonly used buffers and solutions 
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2.2 Animals 
Wild type (WT) BALB/c and C57Bl/6 mice were obtained from Harlan Olac 
(Bicester, Oxon, UK). ST2 gene knockout BALB/c mice have a deletion within the 
ST2 gene which involves the majority of exons 4 and 5 (382). These mice had 
previously been obtained from Professor Andrew Mackenzie, BBRC, University of 
Cambridge and were bred in in-house by Biological Services, University of 
Glasgow.  
W-sh mice are among the mice which have a mutation of the white spotting (W) 
locus. This locus was first described nearly a century ago when a mutation was 
found to result in abnormal haematopoiesis and pigmentation(420) and the gene 
responsible was subsequently identified as the Kit gene which encodes the stem 
cell factor receptor(421). KitW/KitW-v (W/Wv) mice are a heterozygous cross 
between the generally non-viable KitW/KitW mice and the modestly mast cell 
deficient KitW-v/KitW-v mice. These W/Wv mice are profoundly mast cell 
deficient, with mast cells only detected in the skin, and even there at <1% of the 
level found in normal mice(422). They are also profoundly anaemic, relatively 
neutropenic and sterile(423,424). W/Wv mice were the most utilised strain in the 
investigation of mast cell deficiency until the KitW-sh/KitW-sh (W-sh) mutation was 
identified, named after the white “sash” coat colouring which was observed on 
heterozygotes(425). W-sh mice have a markedly reduced expression of Kit upon 
mast cells and consequently a dramatic mast cell deficiency with no detectable 
mast cells in any organs including the lung(426,427), with the exception of the 
skin where mast cells have been reported as absent(426) or detected from birth, 
falling to around 1% of the level found in wild type mice by 12 weeks of 
age(427). In addition these mice are fertile and have no evidence of any other 
haematopoietic defect(427,428). For the purposes of this work W-sh mice, on a 
C57Bl/6 background (B6.Cg-KitW-sh/HNihrJaeBsmJ, stock number 005051) were 
ordered directly from The Jackson Laboratory (Bar Harbor, Maine, USA) and a 
colony established with the help of Biological Services, University of Glasgow. 
All animals were housed in pathogen-free conditions in facilities run by 
Biological Services, University of Glasgow in strict accordance with United 
Kingdom Home Office regulations under the Animals (Scientific Procedures) Act 
1986. Animals were given access ad libitum to standard feed and water. All 
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procedures were carried under Project Licence Number 60/3119, Procedure 9, or 
Project Licence Number 60/3791, Procedure 5.  
 
2.3 In vivo procedures 
2.3.1 Antigen dosing procedures 
2.3.1.1 Intranasal dosing 
Mice were anaesthetised by the intraperitoneal injection of 250 µl of avertin 
solution (1:40 dilution of avertin stock in PBS). Using a 200 µl pipette, 30 µl of 
reagent in sterile PBS was administered to the nostrils. Mice recovered from 
anaesthesia in a warmed box with supplemental oxygen. 
2.3.1.2 Intratracheal dosing 
Mice were anaesthetised by the intraperitoneal injection of 250 µl of avertin 
before being placed upon a custom made support which separated the upper and 
lower incisors. This allowed direct insertion of a blunt-tipped 25G needle 
(Becton Dickinson, Franklin Lakes, USA; blunted by the IBLS Workshop, University 
of Glasgow) into the trachea and instillation of 50 µl of reagent in sterile PBS. 
Mice were removed from the apparatus and recovered from anaesthesia in a 
warmed box with supplemental oxygen. 
2.3.2 Induction of allergic airways inflammation 
Initially a model of experimental asthma was employed that was already in use 
within the laboratory(429-431), and had been adapted from a previously 
published model(432). Female BALB/c mice aged 6-8 weeks were immunised by 
IP injection of 100 µg chicken ovalbumin (OVA, Grade V, Sigma-Aldrich) adsorbed 
to 2mg aluminium hydroxide (alum, Brenntag Biosector, Frederlkssund, 
Denmark) on days 0 and 14. On days 14, 25, 26 and 27 mice were challenged 
with 30 µg OVA by intranasal administration. Mice were culled on day 28 by IP 
injection of avertin 500 µl before exsanguination. Samples were collected as 
detailed below. In some experiments airway AHR to methacholine was measured 
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by Penh on day 28 prior to culling. As detailed in Chapter 4, modifications were 
made to this model during the course of this work. 
2.3.3 IL-33 administration 
As detailed in Chapter 5, a number of different dosing protocols were used in 
the study of the effect of IL-33 upon the lungs. Female wild type or ST2-/- 
BALB/c, or wild type or W-sh C57Bl/6 mice aged 6-8 weeks received 2 µg of 
murine IL-33 using the intranasal dosing technique. In the administration of 
multiple doses the interval was 24 hours between dosing. Mice were culled 24 or 
more hours after the final dose by the method detailed in Section 2.3.2. Samples 
were collected as detailed below. In some experiments AHR was measured by 
Penh prior to culling. 
2.3.4 Measure of airways hyperresponsiveness 
The gold standard for the assessment of AHR is to directly measure airflow 
resistance and lung compliance in anaesthetised mice via tracheostomy. 
However this technique is not only technically demanding and time consuming, 
but also requires considerable expertise and investment in equipment. Due to 
local experience the decision was made to use whole body plethysmograph, the 
equipment for which was available. This technique is used to measure Enhanced 
Pause (Penh) as an indicator of airways responsiveness to broncho-provocation 
with methacholine(29). Animals are placed in a sealed chamber with a 
transducer which measures the pressure changes within it. These changes are 
driven by the respiratory cycle of the mouse within the chamber, partly as a 
direct result of airflow and partly due to rapid warming and cooling of air 
entering and leaving the lungs. Penh is a dimensionless parameter which is 
derived from the relationship between inspiratory and expiratory pressure as 
well as the „pause‟ which occurs at the end of expiration. Penh correlates well 
with the more technically demanding invasive measurements and remains widely 
used in murine models of asthma(29,31-34). 
Penh was measured at doubling doses, from 12.5 to 50 mg/ml of methacholine, 
as previously described(29). Briefly, individual mice were placed in each 
chamber of a 4 chamber plethysmography unit (EMMS, England, UK), and left 
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undisturbed for a 30 minute acclimatisation period. Mice were then challenged 
for 2 minute periods with nebulised saline (control) or graded doses of 
methacholine chloride. Penh was continually measured and an average reading 
for the challenge period calculated using EMMS EDAQ® software. 
2.3.5 Sample collection and preparation 
2.3.5.1 Serum 
Mice were injected with a lethal dose (500 µg) of avertin and killed by 
exsanguinations following the onset of full anaesthesia. The heart was exposed 
and blood withdrawn using a 1 ml syringe and 23G needle. The blood was stored 
in 1.5 ml centrifuge tubes for 2-3 hours to allow clotting, before being 
centrifuged at 14,000 rpm at 4°C for 30 mins (Jouan BR4i centrifuge). Serum was 
then decanted and stored at -20°C until analysed. 
2.3.5.2 Bronchoalveolar lavage 
After termination by cardiac puncture, BAL was performed. The trachea was 
exposed and a small incision made at the proximal end to allow cannulation with 
a 1 ml syringe and 23G needle sheathed with polythene tubing (0.58mm ID, 
0.78mm OD; VWR International). The needle was held in place and a seal formed 
using forceps, before instilling 0.8 ml of PBS into the lungs. After 10 seconds the 
fluid was aspirated and the process repeated with a second 0.8 ml aliquot. All 
the aspirated fluid was pooled in a 1.5 ml centrifuge tube and stored on ice until 
further processing. Live cell counts were performed in a Neubauer 
haemocytometer (Weber Scientific International Ltd, Teddington, UK) using a 
1:2 dilution with 0.4% trypan blue solution. 1x105 cells were spun onto glass 
slides using a Shandon Cytospin3 (ThermoShandon, Runcorn, UK) at 350rpm for 6 
minutes. Slides were air dried before fixing in methanol at room temperature for 
10 minutes. Fixed slides were stained by the Romanovsky method using Rapi-Diff 
II (BIOS Europe Limited, Lancashire, UK) and coverslips secured in place with 
DPX (BDH Laboratory Supplies, Poole, UK). 
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2.3.5.3 Lung and lymph node collection 
Once BAL had been performed the lungs were carefully removed from the 
thorax, en bloc with the heart. In some experiments the lymph nodes draining 
the lungs were harvested to study the response of local T cells. For these 
purposes mediastinal lymph nodes were collected and placed in 1.5 ml 
centrifuge tubes containing complete medium, where they were stored on ice 
until further processing. In experiments where lung histology was required lungs 
were inflated with 10% neutral buffered formalin (NBF, Sigma) via the trachea 
using a 1 ml syringe and 23G needle sheathed with polythene tubing, as used for 
BAL. The trachea was then tied off with thread and the lungs immersed in 10% 
NBF for later analysis. 
2.3.5.4 Bone marrow collection 
Mice aged 6-8 weeks were killed by cervical dislocation and the femur and tibia 
aseptically removed from both legs and placed in complete medium on ice until 
further processing. Under sterile conditions the proximal and distal ends were 
removed and the shaft flushed with RPMI 1640 medium using a 0.5 ml syringe 
with a prefitted 29G needle (MONOJECT insulin syringe, Covidien, Ireland). The 
cells were then dispersed by passage through a 100 μm nylon monofilament  
gauze (Cadisch Precision Meshes, London) and washed twice in RPMI 1640 
medium by centrifugation at 1400 rpm for 5 minutes at 4°C (Jouan CR3i 
centrifuge). Cells were resuspended in complete medium before being counted 
in a haemocytometer. 
2.3.6 In vitro culture 
All cell culture work was carried out under sterile conditions and wash steps 
were performed using sterile RPMI 1640 medium followed by centrifuge at 1400 
rpm for 5 minutes at 4°C (Jouan CR3i centrifuge) unless otherwise stated. Live 
cell counts were performed in a haemocytometer using a between a 1:2 and 1:10 
dilution with 0.4% trypan blue solution. Cultures were incubated at 37°C in a 
humidified incubator supplemented with 5% CO2. 
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2.3.7 Cell lines 
The human HMC-1 mast cell line was kindly donated by Dr J.H. Butterfield (Mayo 
Clinic, USA) and maintained in tissue culture flasks in complete IMDM. The 
murine P815 mast cell line was obtained from American Type Culture Collection, 
USA and maintained in tissue culture flasks in standard complete medium. Cells 
were split approximately twice per week. 
2.3.8 Bone marrow mast cell culture 
Bone marrow cells were prepared at a concentration of 1x106 cells/ml in 
complete medium and cultured in tissue culture flasks. Medium was 
supplemented with stem cell factor (PeproTech, London, UK) at 50 ng/ml and IL-
3 (PeproTech, London, UK) at 1 ng/ml. Twice per week, one third of the culture 
medium was aspirated and centrifuged at 1400 rpm for 5 minutes at 4°C (Jouan 
CR3i centrifuge). The medium was discarded and the cells resuspened in the 
same volume of complete medium containing stem cell factor (SCF) at 50 ng/ml 
and IL-3 at 1 ng/ml. Once a week cell counts were performed and the volume in 
each flask adjusted to maintain a concentration of between 0.5x106 and 1.5x106 
cells/ml. 
2.3.9 IL-33 stimulation 
Mast cells were cultured at a concentration of 1x106 cells/ml in 24, 48 or 96 well 
culture plates. Recombinant murine IL-33 was added to give the final desired 
concentration, medium alone was used in control cultures. Each condition was 
replicated in duplicate or triplicate. After the desired culture period medium 
was aspirated. In some cases the entire plate was centrifuged at 1400 rpm for 5 
minutes at 4°C (Jouan CR3i centrifuge) before supernatants were aspirated, in 
other cases the medium was aspirated into separate 1.5 ml tubes which were 
then centrifuged prior to supernatants being aspirated. All samples were stored 
frozen until analysed.  
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2.3.10 Lymph node culture 
Lymph nodes were prepared by crushing under 100 μm nylon monofilament 
gauze (Cadisch) with a 5 ml syringe plunger in RPMI 1640 medium.  Single cell 
suspensions were made by passing through nylon gauze into 25 ml centrifuge 
tubes before being washed twice. Cells were resuspended in complete medium 
and counted. Cells were placed in 24 well culture plates at a final concentration 
of 1x106 cells/ml and stimulated with medium alone or sterile OVA at final 
concentration of 1 mg/ml. After 72 hours of incubation supernatants were 
aspirated frozen for later analysis. 
To asses proliferation, lymph nodes cells were prepared and stimulated as above 
in triplicate for 48 hrs in round-bottomed 96 well tissue culture plates (200 μl 
per well). 15kBq of Tritiated [3H]-thymidine (West of Scotland Radionuclide 
Dispensary, Glasgow, UK) in 10μl sterile wash medium was added for the last 8 
hours of culture. Cells were harvested onto glass fibre filter paper (PerkinElmer, 
Beaconsfield, UK) using a 295-0054 Betaplate 96 well harvester (PerkinElmer). 
[3H]-thymidine incorporation was measured using a MicroBeta TriLux scintillation 
counter (PerkinElmer). All procedures were performed according to local 
radiation safety guidelines. 
 
2.4 Assays and analysis 
2.4.1 Flow cytometry [FACS] 
Prior to analysis mast cell numbers were counted and 1x105 cells added to FACS 
tubes (BD Biosciences, Oxford, UK) and kept on ice. Cells were centrifuged at 
1400 rpm for 5 minutes at 4°C (Jouan CR3i centrifuge) and washed in 1 ml FACS 
buffer before being suspended in a final volume of 40 µl FACS buffer. 1 µl of Fc 
block (anti- CD16/CD32, BD Biosciences) was added to each tube and incubated 
for 5 minutes. Fluorochrome labelled anti-ST2, anti-FcεRIα and anti-c-kit 
antibodies were added as detailed in Table 2.2. Full compensation was carried 
out before any FACS analysis and therefore a number of tubes were prepared 
with isotype controls as shown in Table 2.3 using mature mast cells. Antibodies 
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were incubated for 30 minutes on ice in the dark, after which cells were washed 
in 1 ml of FACS buffer before being resuspended in 400 µl of FACS buffer. Prior 
to analysis 3 µl of 7-Amino-actinomycin D (7-AAD, Via-Probe, BD Biosciences) was 
added to each tube to enable exclusion of dead cells. 
Samples were analysed using a FACSCalibur flow cytometer (BD Biosciences) and 
data acquired using CellQuest software (BD Biosciences). Live cells were gated 
according to FSC and SSC using the sample “cells”. 7-AAD positive dead cells 
were then excluding by gating using samples “cells” and “via”. Four quadrant 
plots were then made with each combination of FL1 (FITC), FL2 (PE) and FL4 
(APC). Using sample “iso” gates were drawn so that less than 2% of total cells 
were falsely positive on any axis. Using the single stained samples “ST2”, “Fcε” 
and “c-kit” compensation was carried out for emission overlap. The sample “no 
ST2” was run as a final isotype control for detailed analysis of ST2 expression. 
All data analysis was carried out using the FlowJo package (Tree Star Inc., 
Oregon, USA). 
 
Specifcity Label Volume Supplier Cat No. Clone Isotype 
ST2 FITC 2 ul MDB  101001F DJ8 Rat IgG1 
isotype FITC 4 ul BD BD553924 R3-34 Rat IgG1 
FcRIα PE 1 ul EB 12-5898-81 MAR-1 Hamster IgG 
isotype PE 1 ul BD BD553972 A19-3 Hamster IgG1 
c-kit APC 1 ul BD BD553356 2B8 Rat IgG2b, κ 
isotype APC 1 ul BD BD556924 A95-1 Rat IgG2b 
Table 2.2 – FACS antibodies 
Key - MDB = MD Biosciences, Zürich, Switzerland. BD = BD Biosciences, Oxford, UK. 
EB = EBioscience, Hatfield, UK.  
 
 
Label FITC Antibody PE Antibody APC Antibody 7AAD 
cells - - - - 
via - - - 3 l 
iso isotype isotype  isotype  - 
ST2 anti-ST2 isotype  isotype  - 
Fc isotype anti-FcεRIα  isotype  - 
c-kit isotype isotype  anti-c-kit - 
no ST2 isotype anti-FcεRIα  anti-c-kit 3 l 
Table 2.3 – Samples used in FACS compensation 
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2.4.2 Cytokine immunoassay 
Enzyme linked immunosorbant assays (ELISAs) were performed using paired 
antibodies or kits. Protocols and reagents differed depending on manufacturer. 
Table 2.4 details antibodies used. Buffers used are as detailed in Table 2.1. 
 
Analyte 
 
Supplier 
 
Capture 
(ug/ml) 
Detection 
(ug/ml) 
Sensitivity 
(pg/ml) 
Murine     
IL-4 BD 2 2 20 - 20,000 
IL-5 BD 4 4 10 - 10,000 
IL-6 BD 1 1 10 - 10,000 
IL-13 R&D Kit Kit 5 - 5,000 
TNFα BD Kit Kit 4 - 4,000 
IFNγ BD 1 1 40 – 40,000 
MIP-1α R&D Kit Kit 5 - 5,000 
Eotaxin-1 R&D 0.8 0.4 5 - 500 
Eotaxin-2 R&D 2 0.075 4 - 4,000 
TARC R&D 2 0.2 5 - 1,000 
RANTES R&D 2 0.4 5 - 1,000 
OVA-IgE BD - 2  -  
OVA-IgG1 BD - 0.5  -  
OVA-IgG2a BD - 0.5  -  
Human     
TNFα Invitrogen Kit Kit 4 - 4,000 
IL-5 R&D Kit Kit 3 - 3,000 
MIP-1α R&D Kit Kit 5 - 2,000 
Eotaxin-1 R&D Kit Kit 5 - 5,000 
Table 2.4 – ELISA antibodies and concentrations 
 
The protocol that follows is for antibody pairs from BD Biosciences. Unless stated 
otherwise all reagents and samples were added at a final volume of 50 µl/well. 
Immulon 4 HBX plates (Thermo Labsystems, Franklin, USA) were coated with 
detection antibody in BD ELISA coating buffer and incubated overnight. Plates 
were washed three times with ELISA wash buffer then incubated with 200 
µl/well of assay buffer for 1 hour at 37°C. After washing three times samples 
and standards were added. An eleven point doubling dilution standard curve and 
a blank were employed, both in duplicate and using assay buffer. After 
incubation for 2 hours at room temperature plates were washed five times 
before biotin-conjugated detection antibody in assay buffer was added to each 
well. After 1 hour at room temperature plates were washed three times and 
Streptavidin-HRP conjugate (Extravidin, Sigma), diluted 1:1000 with assay 
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buffer, was added. After 30 mintes plates were washed three times and 100 
µl/well of TMB substrate (KPL, Gaithersburg, USA) added. Plates were incubated 
in the dark for up to 30 minutes or until sufficient blue colour had developed. 
Optical density was read on an MRX II microplate reader (Dynex Technologies, 
Worthing, UK) at 630 nm running Revelation (Dynex Technologies) software, and 
sample values calculated from the standard curves generated. 
The protocol for antibodies from R&D (Abingdon, UK) was as above but the R&D 
ELISA assay buffer (Table 2.1) and Streptavidin-HRP conjugate provided by R&D 
and diluted to 1:200 were used. In addition the detection antibody was 
incubated for 2 hours rather than 1. The Eotaxin-2 detection antibody was 
diluted in the R&D ELISA assay buffer with the addition of 2% heat-inactivated 
normal goat serum. 
The protocol for antibodies from Invitrogen was as for the BD ELISA but the 
following modifications. Invitrogen ELISA assay buffer was used. The sample and 
detection steps were combined, with 50 µl/well of sample or standard added to 
each well followed immediately by 25 µl/well of detection antibody in assay 
buffer and then a 2 hour incubation. Streptavidin-HRP conjugate (Invitrogen) was 
used at a dilution of 1:200 in assay buffer. 
2.4.3 Ovalbumin-specific immunoassay 
OVA-specific IgE ELISA was carried out using BD ELISA assay buffer and volumes 
of 50 µl/well. Immulon 4 HBX plates (Thermo) were coated with OVA 10 µg/ml in 
OptEIA buffer and incubated overnight. Plates were washed three times with 
ELISA wash buffer then incubated with 200 µl/well of assay buffer for 1 hour at 
37°C before being washed three times again. In the absence of any standard for 
OVA specific immunoglobulins, serial dilution curves were obtained for each 
sample using assay buffer as a diluent. An initial sample dilution of between 1:10 
and 1:40 was used with serial 1:2 or 1:3 dilutions thereafter. After incubating for 
2 hours at room temperature plates washed five times. Detection antibody and 
Streptavidin-HRP conjugate (Enzyme Concentrate Avidin-HRP, BD Biosciences) 
were both diluted 1:250 together in assay buffer and 50 µl added to each well. 
After 1 hour plates were washed three times and 100 µl/well of TMB substrate 
(KPL) added. Plates were incubated in the dark for up to 30 minutes or until 
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sufficient blue colour had developed. Optical density was read on an MRX II 
microplate reader (Dynex Technologies) at 630 nm running Revelation (Dynex 
Technologies) software. 
OVA-specific IgG1 and IgG2a ELISA were carried out with an identical protocol 
with the following modifications. Initial sample dilution for IgG1 was 1:500 with 
1:3 serial dilutions and for IgG2a between 1:20 and 1:50 with 1:2 dilutions. 
Detection antibody was added alone as a separate step with a one hour 
incubation, followed by washing and the addition of Streptavidin-HRP conjugate 
(Sigma) incubated for 30 minutes.  
2.4.4 Multiplexed immunoassay 
Multiplexed immunoassay is a method by which multiple cytokines or other 
mediators are measured simultaneously in a small volume of fluid. This is 
achieved by using latex microbeads that are stably labelled with a characteristic 
mix of two fluorochromes and have an antibody to one specific analyte 
covalently attached to the surface. When incubated in the test solution, the 
antibody will bind its target cytokine in proportion to its concentration, and 
bound cytokine after washing can be detected using a biotin-labelled specific 
antibody in a sandwich-style immunoassay. Each bead can then be identified by 
its intrinsic twin fluorescent characteristics by flow cytometry. A streptavidin-
labelled third fluorochrome is used to quantify the antibody bound to on each 
bead which will be propotional to the concentration of the analyte in the test 
solution. This system can be made to quantify multiple ligands by using 
microbeads with different intrinsic fluorescent characteristics that are bound to 
mediator specific antibodies. 
Biosource Multiplex kits LHC0009 (Cytokine Human 25-Plex), LMC0006 (Cytokine 
Mouse 20-Plex) and LMC1031 (RANTES Mouse Singleplex) were used according to 
the manufacturer‟s instructions. All reagents and buffers were sourced from the 
kits. Briefly, the supplied 96 well filter plate was pre-wetted with Wash solution 
before aspiration of well contents using vacuum apparatus. If more than one kit 
was being used, beads were premixed. Otherwise beads were resuspended and 
50 µl bead mixture added per well and washed twice by the addition and 
aspiration of Wash solution from the wells. 50 µl/well Incubation Buffer was 
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added followed by 100 µl/well standard or 50µl Assay Diluent plus 50µl sample. 
Plates were protected from the light by aluminium foil and incubated on shaking 
apparatus at room temperature for 2 hours. The wells were then washed twice 
and 100 µl/well biotinylated detection antibody added and incubated for 1 hour 
as above. Following two more washes, 100 µl/well Steptavidin-RPE was added 
and incubated for 30 minutes as above. The wells were washed three more times 
before resuspending the beads in 100 µl/well Wash solution and acquiring data 
on a Luminex 100TM analyser(Luminex Corp., Texas, USA). Data was analysed 
using Luminex software (Luminex Corp.). 
2.4.5 Mast cell degranulation assay 
Degranulation of BMMCs in response to the calcium ionophore ionomycin (Sigma) 
was assessed by the measurement of β-hexosaminidase release. Cells were 
added to 96 well plates at a concentration of 1x106 cells/ml. PBS or ionomycin 
at a final concentration of 1 µg/ml was added and the plates incubated at 37°C 
for 30 minutes. The plates were centrifuged at 1400 rpm for 5 minutes at 4°C 
(Jouan CR3i centrifuge) and the supernatants aspirated. The cell pellets were 
lysed by the addition of 1% Triton-X (Sigma) in PBS. 25 µl of supernatant or 
lysate was then placed in each well of an Immulon 4 HBX plate (Thermo 
Labsystems) and 50 µl of p-nitrophenyl-N-acetyl-β-d-glucosamine (NAG,Sigma) 
substrate solution 1mM in 0.05M citrate buffer was added. After incubation in 
the dark at 37°C for 1 hour the reaction was quenched by the addition of sodium 
carbonate buffer 150 µl/well. Optical density was read on an MRX II microplate 
reader (Dynex Technologies) at 405 nm running Revelation (Dynex Technologies) 
software. 
2.4.6 Lung lavage analysis 
Differential cell counts were performed on cytospin preparations from BAL 
samples stained and mounted as in Section 2.3.5. Slides were randomised and 
blinded before counting. Using a light microscope at least 400 cells per slide 
were identified by staining and morphological characteristics at x1000 
magnification (Figure 2.1). 
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Figure 2.1 – Cytospin preparation of murine bronchoalveolar lavage  
Allergic airways inflammation was induced in BALB/c mice as described in 2.3.2. BAL was 
collected and cytospins prepared and stained with Rapi-Diff II Romanowsky stain as described 
above. Shown are representative images of (A) a macrophage, (B) eosinophils and (C) 
neutrophils. 
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2.4.7 Lung histology 
The lungs and heart were removed en bloc as detailed in Section 2.3.5 and 
placed in 10% NBF for at least 48 hours. They were then mounted in paraffin 
blocks, and 6 μm sections stained with haematoxylin and eosin (H&E; kindly 
performed by Mr. Roderick Ferrier, Department of Pathology, Western Infirmary, 
Glasgow). Sections were examined by light microscopy and peribronchial and 
perivascular inflammation assessed. 
 
2.5 Statistics 
Data were obtained from in vitro experiments and samples from in vivo 
experiments. Cell numbers, relative cell percentages, mediator concentrations 
and Penh (a dimensionless measure of AHR) were subject to statistical analysis. 
These are all quantitative variables which are normally distributed with equal 
variance. Therefore mean values were calculated and expressed with standard 
errors of the mean (SEM), and tests of significance performed using with 95% 
confidence intervals and unpaired Student‟s two-sample T-test, one-way ANOVA 
or two-way ANOVA depending on the data. A p value of less than 0.05 was 
considered significant. Statistical analysis was performed using Excel (Microsoft, 
Redmond, USA) and Minitab (Minitab Inc, State College, USA) software packages. 
Prior to undertaking in vivo work power calculations were performed where 
possible to inform sample size. For example, in the model of allergic airways 
inflammation, experiments were designed to detect a difference of 20% in mean 
BAL eosinophil percentage with a significance of 0.05 and a power of 0.95. From 
preliminary experiments the standard deviation of the BAL eosinophil percentage 
is 10%. As shown in Figure 2.2 a sample size of 8 mice per group is required. 
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Power and Sample Size  
 
2-Sample t Test 
 
Testing mean 1 = mean 2 (versus not =) 
Calculating power for mean 1 = mean 2 + difference 
Alpha = 0.05  Assumed standard deviation = 10 
 
 
            Sample  Target 
Difference    Size   Power  Actual Power 
        20       8    0.95      0.960221 
 
The sample size is for each group. 
 
Figure 2.2 – Power calculation for the sample size required in experimental asthma 
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The role of mast cell ST2 and the effect of 
activation by IL-33 
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In this chapter I will investigate the effect of IL-33 on mast cell lines before 
examining the role of ST2 in mast cell development and the effect of IL-33 on 
wild type and ST2 gene knock-out bone marrow mast cells. 
3.1 Introduction 
Initial studies of ST2 focused on fibroblasts, where the transcripts were first 
identified(321). Following the discovery that ST2 is selectively expressed on Th2 
cells but not Th1 cells(359,360,365), T cells and Th2 inflammation became a 
major focus of ST2 research. Mast cells, however, received relatively little 
attention in studies of ST2. 
Not only do mast cells express ST2 from a very early stage of cell 
development(380) but expression on mature mast cells appears to be ubiquitous 
and at high levels(348,381). Despite this, it has been reported that ST2-/- mice 
have normal mast cell numbers and that histamine and IL-4 production is not 
impaired in mast cells generated from such mice(381). It seems likely that ST2 is 
a functional receptor on mast cells as treatment with IL-33 induces NFκB, 
Erk1/2, p38, and JNK phosphorylation(323). 
In an attempt to understand the role of ST2 on mast cells I set out to generate 
bone marrow derived mast cells (BMMCs) from wild type and ST2-/- mice and to 
study the effect of IL-33 on these cells. My hypothesis is „IL-33 stimulates BMMCs 
to release cytokines and chemokines‟. 
 
3.2 The role of ST2 on human and murine mast cell lines 
Before attempting to establish a bone marrow culture system I sought to obtain 
proof of concept utilising mast cell lines. The HMC-1 human mast cell line is 
immortalised due to a constitutively active form of c-kit(433), the stem cell 
factor (SCF) receptor. Although it does not express receptors for IgE(434) it has 
been widely used in studies of mast cells.  The P815 murine mast cell line was 
described over 50 years ago(435) and like the HMC-1 cell line has a constitutively 
active form of c-kit(436) and also lacks the high affinity IgE receptor, FcεRI(437). 
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3.2.1 IL-33 induces cytokine production by human HMC-1 cells 
First I attempted to establish if mast cells could be induced to release cytokines 
when stimulated with IL-33. HMC-1 cells were harvested when they reached 
confluence and stimulated with increasing concentrations of recombinant human 
IL-33 (hIL-33). In order to establish a time course, supernatants were harvested 
after 3, 24 and 48 hours of culture. Since activated mast cells are capable of 
releasing both pre-formed and newly synthesised TNFα(438) and mast cell 
derived TNFα appears to be important in asthma(33,163), I chose to measure 
TNFα release by ELISA. IL-33 induced a dose dependent rise in TNFα 
concentration which was significant at 24 hours but not 48 hours (Figure 3.1). 
TNFα was detected at higher concentrations the longer the incubation period, 
although this effect was also evident in the absence of IL-33, suggesting that 
there is a basal level of TNFα production which is enhanced by IL-33. In summary 
the optimum activation of mast cells with IL-33 was achieved after 24 hours. 
To examine the possibility that the IL-33 induced increase in TNFα concentration 
was due to a pro-proliferative effect, cell counts were performed at each time 
point for each concentration. IL-33 had no effect on cell numbers following 48 
hours of culture (Figure 3.1D) and consequently the effect of IL-33 on TNFα 
release was preserved even when calculated as pg/105 cells (Figure 3.1E). In 
addition there was no effect on cell viability (data not shown). 
Given that the administration of IL-33 in vivo results in the accumulation of 
eosinophils(323) I looked for IL-33 induced HMC-1 production of IL-5 and eotaxin, 
which have been shown to play a key role in eosinophil maturation, mobilization 
and chemotaxis(74). IL-33 did not induce the release of eotaxin or IL-5 at 
detectable levels after 48 hours of culture (Figure 3.2). IL-5 and eotaxin were 
also undetectable after 3 or 24 hours of culture with IL-33 (data not shown). 
To determine the optimum dose of IL-33 and duration of treatment for further 
study a more complete dose response was characterised using between 0.01 and 
100 ng/ml of hIL-33. As TNFα had been almost undetectable following 3 hours of 
culture samples were only collected at 24 and 48 hours. As shown in Figure 3.3 a 
dose response curve was obtained which was most robust at 24 hours, with 
evidence of a significant response from 10 ng/ml of IL-33. 
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Although there was evidence of a dose responsive release of TNFα by IL-33 
stimulated mast cells, levels are low, rising to just above 100 pg/ml following 48 
hours of stimulation with 100 ng/ml of IL-33. This may reflect the fact that HMC-
1 mast cells appear to be relatively poor producers of TNFα(439). Consequently I 
used multiplexed immunoassay as a screening tool to look for the production of 
other cytokines or chemokines by HMC-1 cells stimulated with IL-33. IL-33 
induced the production of the chemokines MIP-1α, MIP-1β and MCP-1 at ng/ml 
levels and TNFα, IL-6 and IL-8 at lower levels (Figure 3.4). IL-1β, IL-2, IL-4, IL-5, 
IL-7, IL-10, IL-12, IL-13, IL-15, IL-17, IFNα IFNγ, eotaxin, RANTES, IP-10, MIG and 
GM-CSF were not induced at appreciable levels (data not shown). 
Although MCP-1 was produced at the highest levels baseline production in the 
absence of IL-33 stimulation was also high, meaning that IL-33 induced just over 
a twofold rise in MCP-1 production. MIP-1α was also produced at high levels, but 
as baseline production was lower the rise represent a 9 fold increase in MIP-1α 
production. In order to characterise the IL-33 induced production of MIP-1α a full 
dose response curve was obtained (Figure 3.5). Although levels of IL-33 induced 
MIP-1α were highest following 48 hours of culture, baseline MIP-1α production 
was also higher and a significant response to IL-33 was only observed at 
concentrations of 10 ng/ml and above. Following 24 hours of culture a better 
dose response curve was obtained with significant MIP-1α induction over baseline 
observed with concentrations of IL-33 as low as 1 ng/ml. 
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Figure 3.1 – IL-33 induces TNFα production by HMC-1 cells 
HMC-1 cells were harvested and washed when they reached confluence before being plated into 
24 well plates in duplicate. hIL-33 was added at 0, 6.7 or 20 ng/ml and aliquots of the 
supernatant were harvested at (A) 3, (B) 24 and (C) 48 hours. TNFα was measured by ELISA. At 
48 hours cell numbers were counted and cell concentration (D) and TNFα production per cell (E) 
calculated. Results are shown as the mean of duplicate culture wells +/- SEM. One-way ANOVA 
p<0.05 for the effect of IL-33 on TNFα at 24 hours, not significant at 3 and 48 hours. 
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Figure 3.2 – IL-33 does not induce IL-5 or eotaxin production by HMC-1 cells 
HMC-1 cells were cultured with hIL-33 as in Figure 3.1 and supernatants were collected after 48 
hours. IL-5 (A) and eotaxin (B) were measured by ELISA. Results are shown as the mean of 
duplicate culture wells +/- SEM. 
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Figure 3.3 – IL-33 induced TNFα production by HMC-1 cells is dose dependent  
HMC-1 cells were harvested when they reached confluence and were washed before being plated 
into a 24 well plate in triplicate. hIL-33 was added at between 0.01 and 100 ng/ml and aliquots 
of the supernatant were harvested at 24 (A) and 48 (B) hours. TNFα was measured by ELISA. 
Results are shown as the mean of triplicate culture wells +/- SEM. * p<0.05, ** p<0.01 compared 
with PBS. 
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Figure 3.4 - IL-33 induces the production of cytokines and chemokines by HMC-1 cells 
HMC-1 cells were cultured with 0 or 100 ng/ml of hIL-33 as in Figure 3.3 and supernatants were 
collected after 48 hours. MIP-1α, MIP-1β, MCP-1, TNFα, IL-6 and IL-8 were measured by 
multiplexed immunoassay. Results are from single samples. 
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Figure 3.5 - IL-33 induced MIP-1α production by HMC-1 cells is dose dependent 
HMC-1 cells were cultured with between 0.01 and 100 ng/ml of hIL-33 as in Figure 3.3 and 
aliquots of the supernatant were harvested at 24 and 48 hours. MIP-1α was measured by ELISA. 
Results are shown as the mean of triplicate culture wells +/- SEM. * p<0.05, ** p<0.01 compared 
with PBS. 
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3.2.2 IL-33 induces cytokine production by murine P815 cells 
The data above demonstrate that IL-33 is able to induce dose dependent 
chemokine and cytokine production from a human mast cell line. I hypothesised 
that this effect was not species specific and that a similar effect would be 
observed in a murine cell line. I set out to test this hypothesis using cells of the 
P815 murine mast cell line, which has been shown to express ST2 on the 
surface(348). Before carrying out further in vitro studies I sought not only to 
confirm that P815 cells expressed ST2 on their surface in my hands, but also to 
validate my FACS reagents and technique for the measuring the expression of 
ST2. P815 cells were freshly isolated from culture and stained with ST2-FITC 
antibodies before being analysed by FACS. These unstimulated P815 cells grown 
under standard culture conditions were uniformly ST2 positive (Figure 3.6). 
Given that the response to IL-33 was most evident after 24 hours of stimulation 
in HMC-1 cells this time point was also chosen in the study of P815 cells. 
Although there was no evidence of cytokine production at 3 hours in HMC-1 cells, 
this time point was also studied to examine the possibility of early cytokine 
release from P815 cells. Our group have previously found that human IL-33 is 
bioactive on murine T cells in vitro and so in these preliminary experiments hIL-
33 was used. 
P815 cells cultured in the presence of hIL-33 showed a similar pattern of TNFα 
production to HMC-1 cells with evidence of a dose response but with only low 
levels detected (Figure 3.7A). In contrast to HMC-1 cells there was no detectable 
MIP-1α at 24 hours at even the highest concentration of IL-33 (Figure 3.7B). IL-6 
on the other hand was produced at high levels with a significant response to 
concentrations of IL-33 as low as 0.1 ng/ml (Figure 3.7C). Once again I looked 
for the production of cytokines associated with eosinophilia but found no 
evidence of IL-5, eotaxin-1 or eotaxin-2 production (Figure 3.7D,E,F). At 3 hours 
all tested cytokines and chemokines were undetectable (data not shown). 
These data demonstrate that a murine mast cell line responds to IL-33 in a dose 
dependent manner with the release of pro-inflammatory cytokines and 
chemokines. While there are differences between the responses in human and 
murine mast cells, most notably the failure of the murine mast cell line to 
Chapter 3:  86 
produce MIP-1α, it is unclear whether these differences represent a true species 
difference or are simply a reflection of the differences between the specific 
transformed cell lines. 
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Figure 3.6 – P815 cells are ST2 positive 
P815 cells were isolated from ongoing cell culture and stained with ST2-FITC (white) or isotype-
FITC antibodies (grey). 
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Figure 3.7 – IL-33 induces the release of TNFα and IL-6 from P815 cells 
P815 cells were harvested and washed before being plated into a 24 well plate in triplicate at a 
concentration of 1x106/ml. hIL-33 was added at between 0.01 and 100 ng/ml and aliquots of the 
supernatant harvested at 24. Cytokines and chemokines were measured by ELISA. Results are 
shown as the mean of triplicate culture wells +/- SEM. * p<0.05, ** p<0.01 compared with PBS. 
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3.3 Bone marrow derived mast cell culture 
There were a number of reasons to study the effect of IL-33 on murine BMMCs. 
Most importantly, I hoped to generate BMMCs from mice lacking the ST2 receptor 
and thereby demonstrate a specific ligand-receptor dependence of the observed 
effects. Secondly, the differences seen in the responses of P815 and HMC-1 cells 
raised questions over how representative each cell line is of the wider 
population of mast cells. In the case of HMC-1 and P815 cell lines not only are 
they immortalised due to a constitutively activated SCF receptor but the 
absence of the high affinity IgE receptor, FcεRI makes them unlike most 
naturally occurring mast cells. 
3.3.1 Bone marrow mast cell maturation 
While it is possible to directly obtain mature mast cells from mice, from the 
peritoneum for example, the relatively small numbers obtained limit the studies 
possible and most investigators culture mast cells from bone marrow 
progenitors. Mast cells can be obtained from unrefined adult bone marrow cells 
by prolonged culture with mast cell growth factors, most commonly IL-
3(162,348,381) with the addition of SCF in some cases (440-442). On the basis of 
the experience within the laboratory(A.J. Melendez, personal communication) I 
opted to culture murine bone marrow cells with SCF (50 ng/ml) for the first 
three weeks and IL-3 (1 ng/ml) throughout, a protocol which others have also 
used(443). Mast cell maturity was determined by expression of the α chain of the 
high affinity IgE receptor (FcεRIα) and the SCF receptor (c-kit). Figure 3.8 shows 
an example of the typical gating strategy employed. 
By utilising serial FACS analysis it was possible to monitor the development of 
mature mast cells from bone marrow progenitors and so determine the time at 
which the population was fully mature. As shown in Figure 3.9 after 3 weeks of 
culture the majority of cultured cells (81%) express neither FcεRIα nor c-kit, 
although 12% are already FcεRIα+c-kit+. With increasing culture time the 
expression of FcεRIα and c-kit rises. By 6 weeks 85% of cells are c-kit positive 
and 74% FcεRIα+c-kit+. Further culture results in 99% of cells c-kit+ and 89% 
FcεRIα+c-kit+ by 8 weeks. Consequently BMMCs were considered to be mature 
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after 8 weeks of culture, although maturation was always confirmed by the 
presence of at least 95% c-kit+ cells by FACS. 
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Figure 3.8 - Mature mast cells express FcεRIα and c-kit 
BMMCs were harvested after 8 weeks of culture and stained with anti-FcεRIα and anti-c-kit 
antibodies. Cells were identified as a population with high FSC and SSC (A). Live cells were then 
gated by excluding 7-AAD positive cells (B). The expression of c-kit and FcεRIα on these cells was 
then analysed (C). 
 
 
 
Figure 3.9 - The expression of FcεRIα and c-kit on mast cells increase with culture time 
BMMCs were harvested after between 3 and 8 weeks of culture and analysed as described in 
Figure 3.8. 
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3.3.2 Expression of ST2 on bone marrow mast cells 
Although other investigators have reported the presence of ST2 on the surface of 
BMMCs(348,380,381) I sought to confirm that ST2 was expressed on the BMMCs I 
had obtained using the culture protocol described. Mature, 8 week old, BMMCs 
are 99% ST2 positive with a high fluorescence intensity, suggesting that not only 
do the majority of mature BMMCs express ST2, but that they express it at a 
relatively high surface density (Figure 3.10). This is particularly striking when 
compared to other ST2 expressing cells such as T cells(359,360). It has been 
reported that mast cells express ST2 from a very early stage(380) and Figure 
3.10 also shows that a small proportion of cells within the BMMC culture express 
ST2 after as little as 3 weeks of culture. As the culture progresses the proportion 
of ST2+ cells rises. 
Given the dynamic changes in the expression of FcεRIα, c-kit and ST2 during the 
course of BMMC culture, and the expression of ST2 on a subset of cells from an 
early stage, I sought to study the relationship between the expression of ST2 and 
the established mast cell markers FcεRIα and c-kit. When cells were gated 
according to their expression of ST2 (Figure 3.11) there was a very strong 
correlation with c-kit. After 3 weeks of culture greater than 95% of ST2- cells 
were c-kit- and over 90% of these were FcεRIα-c-kit-. Greater than 95% of ST2+ 
cells were c-kit+ and over 85% of these were FcεRIα+c-kit+.  
The corollary of this was to study the expression of ST2 by different populations 
of BMMCs depending on their surface expression of FcεRIα and c-kit. Figure 3.12 
shows the expression of ST2 by FcεRIα-c-kit-, FcεRIα+c-kit-, FcεRIα-c-kit+ and 
FcεRIα+c-kit+ populations at different stages of BMMC culture. At no point is ST2 
convincingly expressed by FcεRIα-c-kit- or FcεRIα+c-kit- cells. FcεRIα-c-kit+ cells 
have a bimodal ST2 expression with ST2- and ST2+ subpopulations present from 
very early in the culture. FcεRIα+c-kit+ cells on the other hand are 100% ST2 
positive at all times. 
These data suggest a relationship between the expression of ST2 and of c-kit. By 
plotting the two surface markers against each other it possible to see the 
relationship more clearly (Figure 3.13). 
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Figure 3.10 – The expression of ST2 on mast cells increases with culture time 
BMMCs were harvested after between 3 and 8 weeks of culture and analysed by FACS as detailed 
in Figure 3.8. Cells were also labelled with anti-ST2 (unshaded) or isotype matched antibody as a 
control (shaded). 
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Figure 3.11 – The expression of c-kit and FcεRIα differs according to the expression of ST2 
BMMCs were harvested after 3 or 8 weeks of culture and analysed by FACS as detailed in Figure 
3.10. Cells were then gated according to the expression of ST2 and the expression of c-kit and 
FcεRIα by the ST2- and ST2+ populations analysed. 
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Figure 3.12 - The expression of ST2 differs according to the expression of c-kit and FcεRIα 
BMMCs were harvested after between 3 and 8 weeks of culture and analysed by FACS as detailed 
in Figure 3.10. Cells were then gated according to the expression of c-kit and FcεRIα and the 
expression of ST2 by these populations analysed. 
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Figure 3.13 – The expression of ST2 correlates with the expression of c-kit 
BMMCs were harvested after 3 or 8 weeks of culture and analysed by FACS as detailed in Figure 
3.10. 
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3.4 ST2 deficient bone marrow mast cells 
The expression of ST2 at high levels on all mast cells from an early stage in 
development raises the possibility that ST2 may play an important role in the 
development or function of mast cells. It is known that BMMCs can be generated 
from mice in the absence of ST2(381,382) and that such ST2-/- mast cells produce 
normal levels of IL-4 upon stimulation with PMA and ionomycin, and of histamine 
upon IgE crosslinking(381). However there are no data regarding the 
development and surface phenotype of such mast cells from ST2-/- mice. To 
investigate the possibility that the absence of ST2 would alter BMMC 
development, mast cells were cultured from wild type (WT) and ST2-/- BALB/c 
mice and their expansion and surface expression of FcεRIα and c-kit measured 
over time. 
3.4.1 Growth and maturation of mast cells lacking ST2 
FACS analysis of mature WT and ST2-/- BMMCs demonstrates that the surface 
expression of FcεRIα and c-kit is unaffected by the absence of ST2. WT BMMCs 
are 98% c-kit+ and 85% FcεRIα+c-kit+ and ST2-/- BMMCs are 99% c-kit+ and 88% 
FcεRIα+c-kit+ (Figure 3.14). Similarly, there was no appreciable difference in the 
expression of c-kit and FcεRIα on less mature BMMC populations (data not 
shown). These data also confirm that anti-ST2 antibody binding is specific as 
there is no staining of BMMCs from ST2-/- mice. 
Figure 3.15A shows the total number of cells grown from bone marrow cells 
cultured with IL-3 and SCF culture over successive weeks. There is no difference 
between the growth curves for WT or ST2-/- BMMCs, demonstrating that the 
absence of ST2 has no impact on the number of BMMCs obtained at any of the 
time points studied. Interestingly total cell numbers rise steadily to a peak at 3 
weeks of culture before falling rapidly at week 4. This decline correlates with 
the withdrawal of SCF suggesting that SCF is required to maintain the population 
of BMMCs. This was confirmed when BMMCs were cultured with SCF and IL-3 
throughout (Figure 3.15B). Although a peak in cell numbers was still seen, in this 
case at 2 weeks, the fall in numbers was more gradual when SCF was continued. 
Surface expression of FcεRIα, c-kit and ST2 were not affected by the sustained 
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use of SCF during culture (data not shown). For subsequent experiments both IL-
3 and SCF were added for the full duration of BMMC culture. 
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Figure 3.14 - FcεRIα and c-kit expression is unaffected by the absence of ST2 
The surface expression of c-kit, FcεRIα and ST2 on mature 8 week old WT and ST2-/- BMMCs was 
analysed by FACS. Results are representative of three separate experiments. 
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Figure 3.15 - ST2 gene knockout does not affect BMMC numbers 
Wild type and ST2-/- bone marrow cells were cultured with SCF for 3 weeks and IL-3 
throughout(A) or with both IL-3 and SCF throughout(B). Total cell counts were performed each 
week and this was calculated as a proportion of the number of cells originally seeded. Data in A 
are from 4 separate cultures per group and are shown as the mean +/- SEM. Data from all groups 
is not available at every time point. Data in B are from a single culture per group. 
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3.4.2 Function of mast cells lacking ST2 
Having generated WT and ST2-/- cells with the surface phenotype of mast cells I 
sought to confirm the finding that mast cell function is unaffected by the 
absence of ST2. One of the hallmarks of mast cell activation is degranulation. 
Mast cells can be stimulated to degranulate by the calcium ionophore ionomycin 
and the granule product β-hexosaminidase measured. There was no significant 
difference between the proportional β-hexosaminidase release by activated WT 
and ST2-/- mast cells (Figure 3.16). There was also no difference in the total β-
hexosaminidase activity within WT and ST2-/- mast cells (data not shown). 
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Figure 3.16 - ST2 gene knockout does not affect mast cell degranulation 
Mature BMMCs were plated into a 96 well plate at a concentration of 1x106 cells/ml before the 
addition of PBS or ionomycin at a final concentration of 1 µg/ml. After a 30 minute incubation 
the β-hexosaminidase activity within the supernatant and cell lysate was assayed and the 
proportion of total activity contained in the lysate calculated. Results are shown as the mean of 
duplicate culture wells +/- SEM and are representative of three separate experiments. 
 
Chapter 3:  103 
3.5 The effect of IL-33 on bone marrow mast cells 
Having established that human and murine mast cell lines produce pro-
inflammatory cytokines and chemokines in response to stimulation with IL-33, 
and having cultured BMMCs from WT and ST2-/- mice, which appear to be 
identical in terms of growth, phenotype and function, I set out to examine the 
effect of IL-33 on these cultured mast cells. 
3.5.1 The effect of IL-33 on wild type mast cells 
Preliminary experiments were carried out to establish an effect of IL-33 on WT 
BMMCs and to optimise the sampling times and IL-33 concentration. MIP-1α, 
TNFα and IL-6 were chosen as readouts based on the data from mast cell lines. 
At 10 ng/ml IL-33 induced the release of MIP-1α, TNFα and IL-6 as measured at 
24 hours (Figure 3.17).  
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Figure 3.17 - IL-33 induces cytokine and chemokine release from BMMCs 
Mature WT BMMCs at a concentration of 1x106/ml were cultured in duplicate with mIL-33 at 
between 0.01 and 100 ng/ml and aliquots of the supernatant were harvested at 24 hours. MIP-
1α, TNFα and IL-6 were measured by ELISA. Results are shown as the mean of duplicate culture 
wells +/- SEM. * p<0.05, ** p<0.01 compared with PBS. 
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3.5.2 The need for ST2 in the mast cell response to IL-33 
While the data above show that IL-33 can induce cytokine and chemokine 
release from a freshly derived population of murine mast cells they do not 
confirm the specificity of action of IL-33. One possible confounding factor would 
be the contamination of the protein preparation with other bioactive molecules, 
for example TLR ligands such as LPS. In addition IL-33 could potentially act via 
another receptor in addition to ST2. In order to address these question mast 
cells from mice lacking ST2 were used as controls. Based on the preliminary data 
WT and ST2-/- BMMCs were stimulated with IL-33 at concentrations of 10 or 100 
ng/ml for 24 hours. The supernatants were analysed by a combination of 
multiplexed immunoassay and ELISA. There was a significant and dose responsive 
release of the MIP-1α, MCP-1, GM-CSF, VEGF, IL-6 and IL-13(Figure 3.18) from 
WT but not ST2-/- BMMCs. The following were not detected; IL-1α, IL-1β, IL-2, IL-
4, IL-5, IL-10, IL-12, IL-17, TNFα, IFNγ, eotaxin-1, eotaxin-2, FGF, MIG, IP-10, KC 
(data not shown).  
MIP-1α was produced at high levels, often in the ng/ml range, a finding which 
was highly repeatable across multiple batches of bone marrow mast cells, with 
peak production ranging from 500 to 2000 pg/ml. While the levels of IL-6 
produced were much lower this finding was equally robust. Similar results were 
obtained with MCP-1, with peak concentrations varying between 66 and 310 
pg/ml. IL-13 was not detected in experiments where MIP-1α was produced at 
levels of less than 1000 ng/ml. VEGF and GM-CSF were also not detected in all 
experiments. 
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Figure 3.18 - IL-33 induced cytokine and chemokine production by BMMCs is ST2 dependent 
Mature WT (■) and ST2-/- (□) BMMCs at a concentration of 1x106/ml were cultured in duplicate 
with mIL-33 at between 0.01 and 100 ng/ml and aliquots of the supernatant were harvested at 
24 hours. Cytokines and chemokines were measured by multiplexed immunoassay or ELISA. 
Results are shown as the mean of duplicate culture wells +/- SEM. One-way ANOVA on WT BMMC 
for the effect of IL-33 on MIP-1α, MCP-1, VEGF and IL-13 p<0.005, GM-CSF and IL-6 p<0.01. 
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3.6 Conclusions 
The work presented in this chapter attempts to address the role of the 
expression of ST2 by mast cells. These experiments demonstrate that normal 
development from bone marrow precursors to fully mature cells as well as mast 
cell function measured by mediator release does not appear to be affected by 
the absence of ST2. In addition, exogenous IL-33, acting via ST2, stimulates mast 
cells to produce pro-inflammatory cytokines and chemokines. 
The possibility that ST2 may be involved in mast cell development is raised as a 
consequence of the detection of cell surface ST2 early in mast cell development, 
which appears to be unique among leucocytes. An early study reported that 
almost 8% of unsorted bone marrow cells expressed ST2, with this proportion 
falling to 2% after six days of IL-3 culture before climbing steadily to 99.5% after 
4 weeks(348). With the exception of unsorted bone marrow cells ST2 was only 
expressed on c-kit+ cells.  
I have described a similar phenomenon during mast cell culture. When ST2 is 
plotted against c-kit there is a strong correlation, with over 90% of cells 
expressing either both or neither surface markers. After 3 weeks of culture there 
was a small (<5%) population of cells which where ST2- but expressed c-kit, 
although at a lower level than on ST2+ cells. At all time points studied c-kit- cells 
are ST2- and c-kit+FcεRIα+ cells are ST2+, whereas the intermediate c-kit+FcεRIα- 
cells contain ST2- and ST2+ populations, with the proportion of the latter 
increasing with time. This suggests that during mast cell development ST2 is 
expressed on c-kit+ single positive cells before they express FcεRIα. The data are 
compatible with the possibility that mast cells develop from c-kit+ST2- 
progenitors or that the c-kit+ population contains subpopulations of c-kit+ST2+ 
mast cell progenitors and c-kit+ST2- cells which lack the potential to become 
mast cells. Although the previously published report did identify a proportion of 
c-kit- cells expressing ST2 at the beginning of culture, inspection of the data 
raises the possibility that this may be a gating artefact, and the authors 
themselves refer to these cells as ST2low(348). 
ST2 has also been used as a marker of mast cell precursors. The Lin-c-kit+Sca-1- 
population of bone marrow cells is known to contain mast cell progenitors(444). 
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When these cells were sorted by β7 integrin, the majority of the mast cell 
generating activity was within the β7+ population. Further sorting of this 
population by ST2 revealed that while the β7+ST2- population was multipotent 
and could generate mast cells as well as other haematopoietic cells, the β7+ST2+ 
population generated mast cells exclusively, suggesting that ST2 is a marker of 
commitment to the mast cell lineage (380). 
While these data raise the possibility that ST2 is involved in mast cell 
development, data from ST2-/- mice has thus far suggested otherwise. Two 
independent groups have generated ST2-/- mice, from which it was possible to 
culture normal mast cells, as assessed by FACS(381,382).  These mast cells were 
also functionally normal with regards to cytokine release following non-specific 
activation, and IgE mediated histamine release. There was, however, no 
comment on how the growth and development of these cells compared with 
those from wild type mice. Mast cells were also detected in the gut and skin of 
ST2-/- mice, although at reduced numbers in the latter(381). While these data 
demonstrate that ST2 is not essential for mast cell development the possibility 
that mast cell development is somehow impaired in the absence of ST2 has not 
been addressed. I have found no evidence of any difference in the number of 
mast cells generated, the time taken to reach maturity or the expression of c-kit 
and FcεRIα in mast cells generated from ST2 deficient mice. Consequently there 
is still no explanation for the expression of ST2 at high levels at an early stage of 
mast cell development, prior to the expression of the IgE receptor. 
It is important to note that these culture systems are likely to be devoid of IL-33 
and also contain an excess of other mast cell growth factors. It is possible that 
under the influence of IL-3 and SCF the role of ST2 is unimportant, but that IL-33 
could play a role in mast cell development and maturation in their absence. In 
keeping with this there is now evidence that IL-33 can enhance the survival of 
both murine BMMCs and human cord blood derived mast cells (CBMCs) when 
incubated in the absence of other mast cell growth factors(445,446). 
At the outset of these studies it seemed likely that IL-33 would have an effect on 
mast cells, given their high level of ST2 expression and the finding that IL-33 
induced NFκB and MAP kinase activation in mast cells(323). However the nature 
of this effect was unknown. I have shown that IL-33 induces the release of 
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inflammatory mediators from mast cells. Specifically the pro-inflammatory 
cytokine IL-6, the Th2 cytokine IL-13 and the chemokines MIP-1α and MCP-1, and 
at times the classical growth factors GM-CSF and VEGF. 
Since completing this work these findings have been confirmed by four other 
studies. All found that IL-33 is a potent inducer of cytokine release from murine 
bone marrow mast cells, although the exact cytokine profile varied (Table 3.1). 
This variation may well be due to differences in protocol, including BMMC 
culture, sampling time and, perhaps most significantly, mouse strain. The only 
other data from BALB/c mast cells published by Kondo et al(447) correlated 
closely with the results I obtained. Human CBMCs have been shown to release IL-
1β, IL-3, IL-5, IL-6, IL-8, IL-13, TNFα, eotaxin-2, MCP-1, MIP-1α, TCA3, RANTES 
and TARC in response to stimulation with IL-33(446,448,449). 
 IL-1β IL-2 IL-4 IL-5 IL-6 IL-10 IL-12 IL-13 TNFα IFNγ MCP-1 MIP-1α 
Pitman - - - - + - - + - - + + 
Kondo (447)   - - +   +   + + 
Ali (450) +    +   - +    
Ho (445)   -  +   +     
Moulin (443) + + - - + - -  + - +  
Table 3.1 – Mediators released by IL-33 treated mast cells: comparison with published data 
A comparison of the mediators produced by murine BMMCs stimulated with IL-33 organised by 
investigator. Assay of the supernatant of IL-33 stimulated BMMCs revealed the presence (+) or 
absence (-) of the corresponding protein. In some cases the particular protein was not measured 
(grey boxes). 
 
Investigators have also looked for the possibility that IL-33 could induce mast 
cells degranulation. Several papers have reported that human CBMCs(446,448) or 
murine BMMCs (443,445) show no evidence of degranulation in response to IL-33 
treatment, even if pre-incubated with IgE. However building on the work 
presented here others within the laboratory have found that murine peritoneal 
mast cells and human CBMCs do degraulate in response to IL-33 provided that 
they are preincubated with IgE for a sufficiently long period(449). 
Other studies attempted to confirm that the effect was IL-33 specific by using 
blocking antibodies against ST2(443) or IL-1RAcP, the other subunit of the IL-33 
receptor(450). However these antibodies were required at µg concentrations, up 
to 10,000 times the concentration of IL-33 used, and inhibition was not always 
Chapter 3:  110 
complete. I have presented data here from ST2-/- BMMCs demonstrating that in 
the absence of ST2 there is a complete abrogation of IL-33 induced cytokine and 
chemokine production, confirming that IL-33 acts on mast cells in a completely 
ST2 dependent manner.  
The mast cell product of IL-33 stimulation most consistently detected is IL-6 
(Table 3.1). Having originally been identified as a B-cell differentiation factor IL-
6 is traditionally considered to be primarily involved in the proliferation and 
differentiation of both B- and T-lymphocytes(451). However IL-6 has also been 
shown to promote mast cell survival(452), drive helper T cells towards a Th2 
phenotype(453) and to be an important co-factor in IL-4 induced IgE 
synthesis(454). In addition IL-6 has been implicated in the transition from acute 
to chronic inflammation and the associated resolution of neutrophilic 
inflammation and initiation of macrophage recruitment(455), partly acting via 
the induction of MCP-1 release(456). As a consequence IL-6 is thought to play an 
important role in auto-immune diseases such as rheumatoid arthritis and 
inflammatory bowel disease(457). 
While less frequently measured, the chemokines MIP-1α and MCP-1 are both 
consistently produced by IL-33 stimulated mast cells (Table 3.1). MCP-1 is a 
potent monocyte chemoattractant(458,459) and MIP-1α was originally identified 
as a neutrophil chemoattractant released by LPS treated macrophages(460), 
although both can be produced by a number of cell types and are capable of 
recruiting other inflammatory cells(461-464). In addition they play a role in the 
Th1-Th2 balance. MCP-1 drives T cells towards a Th2 phenotype(465-467) and 
MCP-1-/- mice have a marked defect in Th2 responses(468), while MIP-1α induces 
Th1 differentiation(466,467). 
With this in mind it is not difficult to see how IL-33 induced release of IL-6, MIP-
1α and MCP-1 by mast cells could play an important role in the initiation of 
inflammation. Given the data suggesting a role of ST2 in allergic inflammation 
and the strong eosinophilic response IL-33 promotes in vivo it is seems 
reasonable to consider the role that IL-33 induced release of IL-6, MIP-1α and 
MCP-1 by mast cells might play in asthma.  
Not only have elevated levels of IL-6 and the IL-6 receptor been detected in 
asthma(469-472), but IL-6 can induce subepithelial fibrosis(473) and lymphocyte 
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infiltration(474) in the airway. Mast cells can also be an important source of IL-6 
in allergic inflammation with mast cells accounting for over 90% of IL-6 positive 
cells in biopsies of allergic rhinitis(475). MCP-1 and MIP-1α are elevated in 
clinical asthma(258,476,477), and also play a role in experimental asthma. MCP-
1 is associated with lymphocyte and macrophage accumulation, mast cell 
degranulation and AHR(179,478,479) and MIP-1α with eosinophil 
recruitment(41,478,480). The other mediator commonly released by mast cells 
upon IL-33 stimulation is IL-13 (Table 3.1) which has a well established role in 
asthma as previously discussed. 
Having demonstrated a role for ST2 on mast cells, in the next two chapters I 
sought to examine the role of ST2 in airways inflammation by studying the 
impact of ST2 gene knock-out in a model of asthma (Chapter 4), and the effect 
of ST2 activation by IL-33 in the airways (Chapter 5). 
  
 
 
 
 
 
Chapter 4  
 
The role of ST2 in  
murine models of asthma 
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In this chapter I will establish, modify and validate a murine model of asthma 
before using this to study the requirement for ST2 in allergic airways 
inflammation. 
4.1 Introduction 
There is much to suggest that ST2 may play an important role in asthma. ST2 
expression is most widely recognised on Th2 cells and mast cells, and in the 
previous chapter mast cells were shown to release pro-inflammatory mediators 
upon stimulation via ST2. Both Th2 cells and mast cells are though of as 
important elements of human and murine asthma. Activation of ST2 in vivo, by 
the systemic administration of IL-33, results in local eosinophilia and elevated 
levels of IgE, IL-5 and IL-13(323), phenomena which are characteristic of asthma. 
There is also evidence that the absence of ST2 can result in dramatically 
impaired Th2 responses in vivo(382). ST2 is detected at increased levels in both 
experimental(360,372,395) and clinical asthma(398) giving further support to the 
notion that ST2 may be important in allergic airways inflammation. 
However, at the outset of this work the literature regarding the role of ST2 in 
murine models of asthma was far from clear. Studies utilising neutralising 
antibodies against ST2 that modified disease in a number of different models all 
supported a role for ST2 in experimental asthma(298,372,396). Conversely ST2 
gene-deleted mice demonstrated no difference in airway inflammation(381). 
This last study used an OVA and alum driven 35 day model of asthma with mice 
on a C57Bl/6 background. The main experimental endpoints including airways 
eosinophilia and raised total IgE titres occurred equally in wild type and ST2-/- 
mice, although AHR was not measured. BALB/c mice are generally considered 
more prone to Th2 inflammation than C57Bl/6 mice. As discussed in Chapter 1 
there can be significant differences in experimental outcome depending on the 
strain of mouse used, for example IL-5 gene deletion generally results in the loss 
of AHR in C57Bl/6 but not BALB/c mice(94,100). In addition the study of ST2-/- 
mice by Hoshino et al(381) utilised an intensive challenge protocol with mice 
receiving 15 OVA challenges in total, which resulted in high BAL eosinophil 
counts of greater than 50 x105 cells/ml. 
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In these examples there is incomplete evidence to conclude that ST2 has a role 
in airway inflammation. The effects of ST2 gene-deletion might be obscured by 
redundant mechanisms and it is conceivable that any contribution that ST2 
might make to airways inflammation was masked by strong stimuli involving 
multiple challenges and powerful adjuvants. 
In an attempt further examine the role of ST2 in experimental asthma I sought 
to study the effect of ST2 gene knock-out on AHR as well as eosinophilic 
inflammation in an antigen based model using mice from a BALB/c background. 
 
4.2 Developing a murine model of asthma 
The most well studied murine models of asthma employ systemic sensitisation 
with OVA, combined with alum as a Th2 adjuvant, followed by airways challenge 
with OVA alone. There are many published variations of this model, with changes 
in the dose, timing and number of administrations of OVA during sensitisation 
and challenge, and differing methods of delivery to the airways. There was 
considerable previous experience within our laboratory using a 28 day model of 
asthma(429-431), adapted from a previously published model(432). Therefore I 
set out to reproduce this model before making any modifications to the 
protocol. 
4.2.1 Induction of allergic airways inflammation in a 28 day model  
Mice immunised and challenged with OVA using the 28 day protocol developed 
significant airways eosinophilia (Figure 4.1). While there was a corresponding 
decrease in the proportion of macrophages there was nonetheless a significant 
rise in the absolute number of BAL macrophages. Neutrophils and lymphocytes 
were found at very low frequency. OVA-specific immunoglobulins, including high 
titres of IgE, were significantly elevated in the serum (Figure 4.2). In order to 
confirm the induction of a robust Th2 response the draining lymph nodes were 
studied. Single cell suspensions from the lymph nodes were restimulated with 
OVA in vitro (Figure 4.3). Cell proliferation was induced which was almost four-
fold greater from mice treated with OVA than those treated with PBS. OVA 
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treated mice also produced high concentrations of the Th2 cytokines IL-4 and IL-
5, in addition to the Th1 cytokine IFNγ. PBS treated mice produced higher levels 
of IFNγ with no IL-4 or IL-5. Cells from either group treated with medium alone 
did not proliferate or produce cytokines (data not shown). These results are all 
in keeping with the expected findings in this model of asthma. 
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Figure 4.1 – A 28 day model of asthma induces pulmonary eosinophilia 
BALB/c mice were immunised with OVA (100 µg) in 1% alum on days 0 and 14 and were 
challenged with intranasal OVA (30 µg) on days 14, 25, 26 and 27 (■). Control mice received PBS 
alone (□). BAL was collected on day 28. Total and differential cell counts were performed. Data 
are shown as the mean +/- SEM. n=9. * p<0.05, ** p<0.01 compared with PBS. 
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Figure 4.2 – A 28 day model of asthma induces antigen specific immunoglobulins 
Mice were immunised and challenged with OVA (●) or PBS (○) as is Figure 4.1. Serum was 
collected the day after the final challenge. OVA specific IgE, IgG1 and IgG2a were measured in 
the serum at the indicated dilutions. Results are shown as the mean of each group of mice +/- 
SEM. n=9 mice. * p<0.05, ** p<0.01 compared with PBS. 
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Figure 4.3 - A 28 day model of asthma induces antigen specific Th2 lymphocytes 
Mice were immunised and challenged with OVA (■) or PBS (□) as is Figure 4.1 and lymph nodes 
harvested the day after the final challenge. Single cell suspensions were stimulated with OVA (1 
mg/ml). (A) After 72 hours proliferation was measured by 3H thymidine uptake. (B) After 96 
hours supernatants were collected and IL-4, IL-5 and IFNγ measured by ELISA. Results are shown 
as pooled samples from groups of 9 mice. 
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4.2.2 Intranasal versus intratracheal dosing 
The most common methods of delivering antigen to the murine airway are either 
by placing conscious animals in a chamber containing nebulised antigen or by 
directly instilling the antigen into the airways of anaesthetised mice. There is no 
evidence that either method is superior to the other, therefore I chose direct 
instillation due to our established local experience with intranasal delivery. 
One concern with intranasal delivery is that not all of the instilled solution is 
guaranteed to reach the lungs, with the possibility that some is retained in the 
nasopharynx, or aspirated into the stomach. Although less common than 
intranasal administration, some investigators have reported using intratracheal 
delivery (282). By direct cannulation of the trachea it should be possible to 
deliver the entire solution into the lungs. 
Both delivery methods were compared using the 28 day model of asthma. 
Although total BAL eosinophil numbers appeared lower in the intratracheal 
group, there was no significant difference in BAL eosinophil percentage or 
absolute number (Figure 4.4), with no associated reduction in intra- or inter-
experiment variability. Given that intratracheal administration was more 
technichally demanding, more time consuming and more likely to lead to 
trauma, the decision was made to use intranasal administration in all subsequent 
experiments. 
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Figure 4.4 – Intratracheal OVA administration is not superior to intranasal administration 
BALB/c mice were immunised with OVA and alum on days 0 and 14 and were challenged with 
OVA on days 14, 25, 26 and 27 via the intranasal (■) or intratracheal (□) route. BAL was collected 
the day after the final challenge and eosinophil percentage (A) and absolute numbers (B) 
counted. Data are shown as the mean +/- SEM. n=6. 
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4.2.3 Validation of BAL differential cell counts 
One of the key endpoints in asthma models is the measurement of BAL 
eosinophilia. While FACS analysis can be used to analyse the cellular composition 
of BAL the gold standard remains microscope counting of stained cytospin 
preparations. Although internal bias is prevented by rigorous blinding any 
cytological system may be at risk of subjective error. In order to confirm inter-
observer consistency I undertook a blind comparison of results with another 
experienced investigator in the laboratory. Asthma was induced and BAL 
cytospins prepared. Each individual then performed differential counts on all the 
samples from the experimental group. Samples were unblinded independently 
and results compared. 
As shown in Figure 4.5 there was good inter-observer correlation. 
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Figure 4.5 – BAL differential cell counts are reproducible 
Mice were immunised and challenged with OVA and BAL cells collected as is Figure 4.1. 
Differential cell counts were performed by Investigator 1 (■) and investigator 2 (□). Data are 
shown as the mean +/- SEM. n=4 
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4.2.4 Pooled versus individual LN culture 
While the primary endpoints in the murine asthma models are generally lung 
eosinophil infiltration, IgE antibody and AHR; additional important information 
can come from the measurement of other variables. When antigen is delivered 
to the lung it can act directly on local cells, but is also taken up by dendritic 
cells which then migrate to the draining lymph nodes to become professional 
antigen presenting cells where they activate antigen specific lymphocytes(292). 
By antigen stimulation of the cells within the lymph nodes that drain the lung it 
is possible obtain information on the profile of the cytokines these cells are 
producing. 
Historically this had been carried out by pooling all the draining lymph nodes 
from the mice in each group and restimulating a fixed number with OVA. There 
are frequently variations in the extent of BAL eosinophilia within any treatment 
group, which can include quite extreme outliers. I was concerned that the cells 
from such over- or under-responsive mice could skew the data from pooled 
lymph node samples. In addition when lymph nodes are pooled there is no 
information on the variance within any given group making statistical analysis 
difficult. Consequently I set out to determine whether it would be feasible to 
culture the draining lymph nodes from individual mice separately, and to study 
the data obtained in this way. 
Although the total numbers of cells retrieved from the draining lymph nodes of a 
single animal is small, I established that with optimisation of culture conditions 
it was almost always possible to carry out individual lymph node cultures. 
Interestingly, despite similar cell counts in both groups (Figure 4.6A), the mean 
levels of proliferation (Figure 4.6B) and cytokine production (Figure 4.6C) were 
lower in the individual lymph node cultures than in pooled lymph nodes. This 
raises the possibility that when lymph nodes are pooled the response can be 
dominated by a small proportion of highly reactive cells from one or two mice. 
Individual lymph node culture provides addition data, allows for statistical 
analysis and may prevent skewing of the data by a small subset of mice. 
Consequently all subsequent lymph node culture was performed by isolating 
individual lymph nodes from each animal.  
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Figure 4.6 – Individual lymph node culture provides additional information 
BALB/c mice were immunised with OVA and alum before being challenged with intranasal OVA as 
in Figure 4.4. (A) Total eosinophils within the BAL were counted. Data are shown as the mean +/- 
SEM. Draining lymph nodes were either pooled from all mice (■,●) or separated by individual 
mice (□,○). A total of 2x106 lymph node cells were cultured with complete medium alone (■ and 
□) or with OVA at 1 mg/ml (● and ○). (B) Proliferation was measured by thymidine uptake. (C) 
Supernatant IL-4 and IL-5 were assayed by ELISA. The result from each culture well is plotted, in 
the case of individual node cultures the mean is represented by a bar. n=6. 
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4.2.5 Establishing a method to measure airways 
hyperresponsiveness 
One of the hallmarks of clinical asthma is AHR and this is generally reproduced in 
murine models of asthma. In both the clinical setting and animal models this is 
measured by establishing the degree of airflow resistance in subjects before and 
after inhalation of a bronchoconstricting agent such as histamine or 
methacholine. In humans, airflow resistance is measured by quantifying air flow 
during forced expiratory manoeuvres. Such techniques are effort-dependent and 
require co-operation and are therefore not possible in animals. The gold 
standard method of measuring AHR in animals requires anaesthesia and 
intubation. As discussed in Chapter 2, it is also possible to measure AHR in 
conscious, unrestrained animals using whole body plethysmography, where mice 
are placed in a chamber within which the pressure differences occurring are 
recorded and from these changes the parameter of enhanced Pause (Penh) is 
derived(29). 
Before utilising this method to answer experimental questions it was important 
that I validated the technique. As a positive control I used BALB/c mice in which 
allergic airways inflammation was induced using a 28 model of asthma which is 
well recognised to induce AHR(21). As a negative control naïve mice were 
challenged with intranasal PBS alone. As expected there is a significant rise in 
Penh, the measure of AHR, with increasing broncho-provocation with 
methacholine in both the control and the treated group (Figure 4.7). 
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Figure 4.7 - Airways hyperresponsiveness can be measured by Penh 
BALB/c mice were immunised with OVA and alum before being challenged with intranasal OVA as 
in Figure 4.4. Unimmunised control mice were challenged with PBS alone. The day after the final 
airways challenge Penh was measured with increasing doses of nebulised methacholine. Results 
are shown as the mean of each group of mice +/- SEM. n=4. Two-way ANOVA p<0.01 PBS vs OVA. 
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4.3 Establishing a twelve day model of asthma 
When S. mansoni eggs are used to drive pulmonary eosinophilic inflammation 
ST2 is only essential in mice that have not already been immunised(382), 
highlighting the fact that differences in sensitisation can affect the contribution 
of ST2. Speculating that the use of multiple systemic immunisations and an 
extended period of repeated challenges may obscure any requirement for ST2, a 
12 day model which had been described was attractive(49). This model utilised a 
single immunisation, followed by three airways challenges. Furthermore the 
move from a 28 day to a 12 day model not only allows for increased productivity 
in a shorter time frame, but also has economic implications. While the 12 day 
protocol had been shown to induce AHR, airways inflammation and 
immunoglobulin generation were not assessed. Therefore I set out to validate 
and optimise a novel 12 day model of asthma, base on that published by Stock et 
al(49). 
4.3.1 Features of asthma can be induced using a twelve day 
model 
The published protocol was for an immunisation using OVA (100 µg) with alum 
adjuvant followed by daily intranasal challenges of OVA (50 µg) on days 9 to 11 
in BALB/c mice (Figure 4.8). Initially I set out to repeat the protocol exactly as 
described and to look for the presence of eosinophilic inflammation in the 
airways. 
This protocol induced a robust inflammatory response in the airways as 
represented by total eosinophilia (Figure 4.9). The level of eosinophilia is 
towards the upper limit of what we would expect to see for the 28 day model 
and this was even more marked in subsequent repeats (data not shown). 
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Figure 4.8 - The twelve day model of asthma 
Mice are immunised with OVA and alum by the intraperitoneal route on day 1 before being 
challenged with intranasal OVA once on each of days 9, 10 and 11. On day 12 AHR is measured 
and/or mice are culled. 
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Figure 4.9 – BAL eosinophilia is induced by a twelve day asthma protocol 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (50 µg) on days 9, 10 and 11 (■). Control mice received PBS alone (□).BAL was collected the 
day after the final challenge and (A) total cell count, (B) differential percentages and (C) 
absolute cell numbers counted. Data are shown as the mean +/- SEM. n=5. * p<0.05, ** p<0.01 
compared with PBS.   
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4.3.2 Dose response to ovalbumin challenge in the twelve day 
model  
Having established that a significant BAL eosinophilia can be generated using a 
12 day model of asthma it was important to optimise this model. Following the 
observation that this model generated a more extensive eosinophilia than 
normally seen with the 28 day model, I anticipated that the effect of 
therapeutic intervention might be less readily detected with an inflammatory 
response of this magnitude. Therefore I adjusted the dose of OVA used at 
challenge in the 12 day model and performed a dose titration in order to 
establish a protocol which might be more susceptible to reasonable intervention. 
Given that a dose of 50 µg per mouse generated a marked eosinophilia I chose 
this as a starting point and studied this dose and below. 
Reducing the dose of OVA given at challenge resulted in a dose related decrease 
in BAL eosinophil numbers (Figure 4.10). While there was also a reduction in the 
percentage of eosinophils with lower doses of OVA challenge, even at 2.5 µg 
eosinophils still comprised 39% of BAL cells. Given that a dose of 10 µg appears 
to represent the mid-point of the dose response curve it likely that this protocol 
will be susceptible to interventions which either exacerbate or attenuate 
eosinophilic inflammation. Consequently a dose of 10 µg was used in subsequent 
experiments. 
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Figure 4.10 - BAL cell content related to OVA challenge dose 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (0 to 50 µg) on days 9, 10 and 11. BAL was collected on day 12 and (A) total and (B,C) 
differential cell counts performed. Data are shown as the mean +/- SEM. n=6 mice. 
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4.3.3 Validation of a twelve day model 
Thus far I have focused on BAL eosinophils as the primary end point when 
assessing the 12 day model of asthma, but there are other features one would 
expect to find in such a model. Before using this protocol I set out to confirm 
that these features of clinical asthma were reproduced. Most importantly BAL 
eosinophilia should be accompanied by eosinophilic inflammation in the lung 
tissue, OVA specific IgE in the serum and the generation of AHR. 
There is good evidence to suggest that eosinophilic inflammation and AHR can be 
dissociated, for example some models generate eosinophilia but not AHR in 
C57Bl/6 mice(50) whereas IL-5 gene deletion results in loss of eosinophilia with 
preserved AHR in BALB/c mice(100,103). Therefore one cannot assume that 
because the 12 day protocol generates a robust BAL eosinophilia that AHR will 
also be generated. Therefore I confirmed that the 12 day protocol selected did 
indeed induce significant AHR as measured by Penh (Figure 4.11). 
It is unresolved whether BAL eosinophilia is always associated with lung tissue 
eosinophil infiltration, therefore it is important to confirm if these features are 
present in the 12 day model. When the 28 day and 12 day models were 
compared directly there was no significant difference in BAL eosinophilia (Figure 
4.12) with a similar degree of inflammation also seen on histology (Figure 4.13). 
In models of atopic asthma antigen-specific IgE should also be generated. In both 
the 28 day and 12 day models OVA specific IgE was detected in the serum at 
comparable levels at a titre of 1/20 (Figure 4.12C), although at a titre of 1/180 
IgE was significantly lower in the 12 day model. OVA specific IgG1 and IgG2a 
were also generated and serum concentrations were once again significantly 
lower in the 12 day model than the 28 day model (Figure 4.14). 
The generation of antigen-specific antibodies provided evidence of effective 
immunisation. I choose to further examine T-lymphocyte immunisation by 
observing cells in culture from the draining lymph nodes in this model, to see 
whether they served as a readout of the antigen recall response. 
Cells from the draining lymph nodes of mice immunised and challenged with the 
12 day protocol were restimulated with OVA. These cells showed evidence of 
Chapter 4:  133 
activation as measured by proliferation (Figure 4.15A). It was also possible to 
measure the cytokines produced by these cells upon antigen restimulation 
(Figure 4.15B). As expected the recall response demonstrated Th2 polarisation 
with production of high concentrations of the Th2 cytokines IL-4 and IL-5 in 
much greater relative concentrations than that of the Th1 cytokine IFNγ. 
These data demonstrate that the selected 12 day protocol produces all the acute 
features of clinical asthma expected of a murine model, namely AHR, 
eosinophilic inflammation, IgE production and a Th2 cytokine response. 
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Figure 4.11 – The twelve day model of asthma induces airways hyperresponsiveness  
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (10 µg) on days 9, 10 and 11. Unimmunised control mice were challenged with PBS alone. 
The day after the final airways challenge Penh was measured. Results are shown as the mean of 
each group of mice +/- SEM. n=4 mice. * p<0.05, ** p<0.01 compared with PBS. Two-way ANOVA 
p<0.001 PBS vs OVA. 
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Figure 4.12 - The twelve day model of asthma induces lung eosinophilia  
BALB/c mice were immunised and challenged using the 28 day protocol (OVA 100 µg IP days 1 
and 14, OVA 10 µg IN days 25, 26 and 27) or the 12 day protocol (OVA 100 µg IP on day 1, 10 µg 
days 9, 10 and 11). Control mice received PBS challenge alone. The day after the final challenge 
BAL was collected. Differential counts were performed on BAL samples. Results are shown as the 
mean of each group of mice +/- SEM. n=4 mice. 
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Figure 4.13 - The twelve day model of asthma induces lung eosinophilia  
BALB/c mice were immunised and challenged as in Figure 4.12. The day after the final challenge 
lungs were collected and fixed in formalin. Sections were prepared and stained with H&E. Panels 
shown are representative sections. 
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Figure 4.14 - The twelve day model of asthma induces antigen specific immunoglobulins 
Mice were immunised and challenged as is Figure 4.12. Serum was collected the day after the 
final challenge. OVA specific IgE was measured in the serum at dilutions of 1/20 and 1/80. OVA 
specific IgG1 and IgG2a were measured at dilutions of 1/500 and 1/20 respectively. Results are 
shown as the mean of each group of mice +/- SEM. n=4 mice. * p<0.05 compared with 12d 
protocol. 
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Figure 4.15 - The twelve day model of asthma induces antigen specific Th2 lymphocytes 
Mice were immunised and challenged as is in Figure 4.8 and lymph nodes harvested the day after 
the final challenge. Single cell suspensions were stimulated with PBS or OVA (1 mg/ml). (A) After 
72 hours proliferation was measured by 3H thymidine uptake. (B) After 96 hours supernatants 
were collected and IL-4, IL-5 and IFNγ measured by ELISA. Results are shown as pooled samples 
from groups of 4 mice. 
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4.4 Cytokines and chemokines in the twelve day model 
Before studying any potential role for ST2 in the 12 day model of asthma I sought 
to characterise the model further. Having shown that IL-33, acting via ST2, could 
be a potent inducer of chemokine production I was interested in the relationship 
between cytokines, chemokines and the inflammatory response in the airways. 
There have been a number of studies examining the expression of and 
requirement for chemokines in asthma. As discussed in Chapter 1 there is 
evidence that chemokines, such as the eotaxins, as well as cytokines, 
particularly IL-5, play an important role in eosinophil recruitment to the 
airways. However there is less information on the temporal expression of 
chemokines following antigen challenge in allergic airways inflammation. While 
some data are available in many cases they are at the RNA level only(179,481) or 
use unconventional models or limited time points(41,179). Therefore I set out to 
measure cytokine and chemokine levels in the BAL and serum at multiple time 
points throughout airways challenge. 
4.4.1 Kinetics of airways inflammation following multiple 
challenges 
Having chosen to investigate the challenge phase of the 12 day model I designed 
an experiment where groups of mice were sacrificed at different intervals 
throughout the challenge period. This would make it possible to study the 
relationship between cytokines, chemokines and eosinophil accumulation. My 
hypothesis was that each intranasal challenge would stimulate cytokine and 
chemokine release and that eosinophil numbers would rise with each challenge, 
perhaps falling again between challenges. As shown in Figure 4.16 all mice were 
immunised according to the standard 12 day protocol. The first group were then 
culled immediately prior to the first intranasal challenge (0h), the next group 3 
hours after the first challenge (3h), the next immediately prior to the second 
challenge (24h), the next 3 hours after the second challenge (27h) and so on. A 
final group was culled at what would be the standard cull day in the 12 day 
model (72h). 
Throughout the challenge period the total number of cells recovered from the 
airways increased and was highest at 72 hours after the first challenge (Figure 
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4.17A); a time point analogous to the standard final day cull in the 12 day 
model. This rise in total cell numbers was mirrored by an increase in the 
percentage of eosinophils within the BAL to a peak of 72% at 72 hours (Figure 
4.17B). While the absolute number of macrophages increased slowly throughout 
the challenge period this is eclipsed by the rise in eosinophils by 72 hours (Figure 
4.17C). 
When the local cytokine and chemokine levels within the BAL were assayed, the 
Th2 cytokine levels all peaked at 24h after the initial challenge and decreased to 
almost undetectable levels at 72 hours (Figure 4.18). IL-4, IL-5 and IL-13 
increased to concentrations of 1810 pg/ml, 101 pg/ml and 459 pg/ml at 24 hours 
respectively before falling to 59 pg/ml, 7 pg/ml and 19 pg/ml. The pro-
inflammatory cytokine IL-6 followed a similar pattern with a peak concentration 
of 74 pg/ml at 24 hours (data not shown). Concentrations of IL-1, IL-2, IL-10, IL-
12, IL-17, IFNγ and TNFα were below 50 pg/ml. 
Given that eosinophilic inflammation within the airways progresses despite a fall 
in local Th2 cytokine levels I hypothesised that local chemokine production could 
be responsible for ongoing eosinophil recruitment and activation. Although MIP-
1α reached a peak of 217 pg/ml at the later time point of 48h, levels had fallen 
to only 76 pg/ml by 72h (Figure 4.18). Eotaxin-2 and TARC however did rise 
progressively throughout the challenge period (Figure 4.18). The changes in 
eotaxin-2 concentrations correlated particularly well with eosinophil numbers as 
shown in Figure 4.19. Concentrations of GM-CSF, KC, IP-10, MCP-1, MIG, eotaxin-
1 and TCA3 in the BAL were below 50 pg/ml. 
Although local cytokine and chemokine concentrations are likely to play an 
important role in the recruitment of cells to the site of inflammation, cytokines 
and chemokines released systemically can drive selective haematopoiesis and 
the mobilisation of cells from the bone marrow. Serum cytokine levels followed 
a similar pattern to that seen in the BAL with IL-5 and IL-13 peaking at 227 
pg/ml and 256 pg/ml at 24 to 27 hours before falling to 0 pg/ml and 40 pg/ml at 
72 hours (Figure 4.20A). IL-10 followed a similar pattern, peaking at 116 pg/ml 
at 24h (data not shown). Concentrations of IL-1, IL-2, IL-4, IL-6, IL-12, IL-17, 
IFNγ and TNFα in the serum were below 50 pg/ml.  
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The chemokines eotaxin-1 and KC did show a trend towards rising 3h after each 
challenge before falling again at 24h, whereas the converse was true of MIG 
(Figure 4.20B). Concentrations of GM-CSF, IP-10, MCP-1, MIP-1α, eotaxin-2, TCA3 
and TARC in the serum were below 50 pg/ml.  
Antigen specific IgE is generated in response to immunisation with OVA and 
there was no evidence that titres were affected by intranasal antigen challenge 
at dilutions of between 1/10 (Figure 4.21) and 1/1280. 
To obtain information on the local specific immune response cells from the 
lymph nodes draining the lungs were cultured with OVA and the cytokines and 
chemokines produced assayed (Figure 4.22). The cytokines produced by lymph 
node cells at the highest concentrations were IL-5 and IL-13, which increased 24 
hours after the first challenge and remained elevated thereafter. The other Th2 
cytokine IL-4 was produced in increasing amounts from lymph nodes as the 
challenge period progressed. The pro-inflammatory cytokines IL-17 and IFNγ 
were also detected at high concentrations, but there was no obvious relationship 
with the timing of intranasal challenges. A similar pattern, although at lower 
concentrations, was seen for IL-6 and MCP-1. The chemokines eotaxin-2 and 
TARC were released at relatively low concentrations, but lymph node cells from 
later in the challenge period produced these chemokines at higher 
concentrations than those from the beginning of the challenge period. IL-10, 
TNFα, GM-CSF, KC, MIP-1α, TCA3 and eotaxin-1 were produced at concentrations 
of between 100 to 300 pg/ml prior to antigen challenge and did not change 
significantly throughout the time course (data not shown). IL-1, IL-2, IL-12, IP-10 
and MIG were not detected in draining lymph node supernatants. 
These data demonstrate that in the 12 day model eosinophil numbers in the 
airways rise steadily during the challenge period, despite the fact that Th2 
cytokine concentrations, both locally in the BAL and systemically in the serum, 
peak prior to the second challenge before falling to very low concentrations by 
day 12. Chemokines may be responsible for the accumulation of eosinophils 
within the airways given that BAL eotaxin-2 concentrations correlate with 
eosinophil numbers and intranasal antigen challenges appear to result in 
transient increases in eotaxin-1 and KC within the serum. 
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Figure 4.16 – A time course study of the twelve day asthma model 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (10 µg) on days 9, 10 and 11. BAL, serum and draining lymph nodes were collected from 
groups of mice immediately prior to each challenge (0, 24 and 48 hours) or at 3 hours after each 
challenge (3, 27, 51 hours). Samples were collected from a final group at the standard day 12 
end point for the model (72 hours). 
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Figure 4.17 - Eosinophil numbers increase with time during challenge 
Mice were immunised and challenged as in Figure 4.16. (A) Total BAL counts were performed. 
(B,C) Differential counts were performed and macrophage (○) and eosinophil (●) proportions 
calculated. Arrows indicated intranasal challenges (0h, 24h and 48h). Results are shown as the 
mean of each group of mice +/- SEM. n=8 mice. 
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Figure 4.18 – BAL cytokine and chemokine concentrations change throughout the challenge 
period 
Mice were immunised and challenged as in Figure 4.16. BAL was collected from groups at each 
time point and cytokines and chemokines measured by ELISA or multiplexed immunoassay. Eo2 = 
eotaxin-2. Results are shown as the mean of each group of mice +/- SEM. n=8 mice. 
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Figure 4.19 - Airways eosinophilia correlates with local eotaxin-2 concentrations 
Mean total eosinophil numbers (Figure 4.17C) were plotted against BAL eotaxin-2 concentration 
(Figure 4.18D) for mice treated as in Figure 4.16. 
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Figure 4.20 – Serum cytokine and chemokine concentrations change throughout the 
challenge period 
Mice were immunised and challenged as in Figure 4.16. Serum was collected from groups at each 
time point and cytokines and chemokines measured by ELISA or multiplexed immunoassay. 
Results are shown as the mean of each group of mice +/- SEM. n=8 mice 
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Figure 4.21 - Serum IgE titres are unaffected by intranasal antigen challenge 
Mice were immunised and challenged as in Figure 4.16. Serum was collected from groups at each 
time point and OVA-specific IgE measured by ELISA at a dilution of 1/10. Results are shown as 
the mean of each group of mice +/- SEM. n=8 mice 
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Figure 4.22 – Th2 cytokines and eotaxins are produced by draining lymph node cells 
Mice were immunised and challenged as in Figure 4.16. Draining lymph nodes were collected 
from groups at each time point and single cell suspensions from individual mice restimulated 
with OVA 1 mg/ml. Supernatants were collected after 96 hours and cytokines and chemokines 
measured by ELISA or multiplexed immunoassay. Eo1 = eotaxin-1, Eo2 = eotaxin-2. Results are 
shown as the mean of each group of mice +/- SEM. n=8 mice 
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4.4.2 Kinetics of airways inflammation following a single 
challenge 
During the three day challenge period of the 12 day model, BAL Th2 cytokine 
concentrations decreased early while chemokine concentrations continued to 
rise. My hypothesis was that the stimulus for the increasing chemokine 
concentrations was the repeated antigen challenges. To test this hypothesis I 
chose to study the changes occurring after a single antigen challenge. I 
predicted that, as in the three challenge protocol, Th2 cytokines would increase 
transiently and then fall rapidly after a single challenge, but that chemokine 
concentrations would also fall in the absence of further challenges, and that this 
would result in a fall in eosinophil numbers. 
Mice were immunised with OVA and alum as previously. In order to make 
comparisons I choose to study the same time period as that used with three 
challenges, from days 9 to 12 (0 to 72 hours). Therefore the challenge given on 
day 9 would be identical in both experiments, but in the single challenge 
protocol there would not be the usual second and third challenge on days 10 and 
11. Groups of mice were culled at 24 hour intervals following the challenge and 
BAL and serum collected (Figure 4.23). 
Following a single intranasal OVA challenge the percentage of eosinophils in the 
BAL increased steadily throughout the following 72 hour period and reached a 
maximum of 27% at 72 hours post challenge (Figure 4.24A). This was associated 
with a rise in total eosinophil numbers over time to a maximum of 0.5 x 105 
cells/ml at 72 hours (Figure 4.24B).  
In the BAL IL-4 peaked 24 hours after challenge before falling rapidly (Figure 
4.24C). A similar pattern was seen with serum IL-5 (Figure 4.24D). BAL IL-5, 
serum IL-4 and BAL and serum IL-13 were undetectable. BAL eotaxin-2 
concentrations increased more slowly to a peak at between 48 and 72 hours. 
These data demonstrated that, as in the three challenge model, BAL and serum 
Th2 cytokine concentrations peak at 24 hours after challenge before rapidly 
falling again. Surprisingly BAL eosinophils continued to rise in the absence of 
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further challenges with the highest number recorded at the final 72 hours time 
point. This was associated with a continued rise in eotaxin-2 concentration. 
On day 12 of the single challenge protocol eosinophils are still in the minority at 
27% of total BAL cells, and absolute numbers are low at 0.5 x 105 cells/ml. This 
is in contrast to an eosinophilia of 59% or 4.6 x 105 cells/ml on day 12 in the 
three challenge model. Taking this into account I chose to continue to work with 
the three challenge 12 day model in which I had demonstrated the generation of 
AHR and histological changes earlier. 
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Figure 4.23 – A time course study of the twelve day asthma model 
BALB/c mice were immunised with OVA (100 µg) and alum on day 1 and were challenged with 
OVA (10 µg) on day 9. BAL, serum and draining lymph nodes were collected from groups of mice 
immediately prior to the challenge (0h) and then every 24 hours thereafter up to 72 hours. 
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Figure 4.24 – A single airways challenge induces eosinophilia and Th2 cytokines 
Mice were immunised and challenged as in Figure 4.23. BAL and serum samples were collected 
immediately prior to challenge (0h) or at the noted interval after challenge. (A,B) BAL 
differential counts were performed. (C,D,E) Cytokine and chemokine concentrations in BAL and 
serum were determined by ELISA. Results are shown as the mean of each group of mice +/- SEM. 
n=5 mice. 
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4.5 The role of ST2 in murine asthma models 
As discussed earlier the importance of ST2 in experimental asthma remains 
unclear. Neutralising antibodies against ST2 have attenuated eosinophilic 
inflammation(298,372,396). Whereas, at the outset of this work, the only study 
of asthma in ST2-/- mice found no difference in inflammation when a 35 day OVA 
based model of asthma utilising 15 airways challenges was used in C57Bl/6 mice. 
Given the conflicting data utilising antibodies, the intensive challenge protocol 
used in the ST2-/- study and the possibility that the strain could contribute 
significantly to the outcome; as in IL-5-/- studies where AHR is lost in C57Bl/6 but 
not BALB/c mice(94,100), I chose to study the effect on ST2 gene deletion on a 
BALB/c background in the 12 day model of asthma. 
4.5.1 The effect of ST2 gene knock-out in the twelve day model 
Using the 12 day asthma model validated above, we observed that in ST2 
deficient mice airways inflammation was significantly reduced compared with 
similarly challenged wild type (WT) mice. There was a reduction in the total 
number of inflammatory cells within the airways (Figure 4.25A). This was 
predominantly due to a reduction in the percentage and absolute number of 
eosinophils (Figure 4.25B,C), although there was also a reduction in macrophage 
numbers(Figure 4.25C). 
Cytokines and chemokines were generally only detected at low concentrations in 
the BAL in both groups and although there appeared to be a trend towards a 
reduction in BAL IL-4, eotaxin-2 and TARC in ST2-/- mice the changes were not 
statistically significant (Figure 4.26A). Concentrations of IL-1, IL-2, IL-5, IL-10, 
IL-12, IL-13, IL-17, IFNγ, TNFα, GM-CSF, FGF, IP-10, MCP-1, KC, TCA3 and 
eotaxin-1 in the BAL were below 50 pg/ml. 
With the exception of eotaxin-1, cytokines and chemokines were detected at 
low concentrations in the serum (Figure 4.26B). There was a significant 
reduction in serum IL-13 in ST2-/- mice, although the concentration in WT mice 
was only 40 pg/ml. Concentrations of IL-1, IL-2, IL-4, IL-5, IL-6, IL-12, IL-17, 
IFNγ, TNFα, GM-CSF, IP-10, MCP-1, MIP-1α, TARC and TCA3 in the serum were 
below 50 pg/ml. 
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When draining lymph node cells were restimulated with OVA IL-5 and IL-13 were 
produced at ng/ml concentrations with other cytokines and chemokines 
produced at lower concentrations (Figure 4.27). The only statistically significant 
difference between WT and ST2-/- mice was a reduction in the concentration of 
TNFα in ST2-/- mice. 
These data demonstrate that the absence of ST2 significantly attenuates allergic 
airways inflammation, but do not offer any insights into the mechanism behind 
this. 
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Figure 4.25 - ST2 gene knockout attenuates airways inflammation 
BALB/c WT and ST2-/- mice were immunised with OVA and alum prior to being challenged with 
OVA utilising the 12 day protocol (Figure 4.8). The day after the final challenge BAL was 
performed. (A) Total cell numbers were counted. (B,C) Differential counts were performed. 
Results are shown as the mean of each group of mice +/- SEM. n=7 mice. * p<0.05, ** p<0.01. 
Results are representative of three separate experiments.  
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Figure 4.26 –ST2 gene knockout does not affect BAL and serum cytokine and chemokines 
BAL was obtained from immunised and challenged WT and ST2-/- mice as in Figure 4.25. Cytokine 
and chemokine concentrations were measured by ELISA and multiplexed immunoassay in (A) BAL 
and (B) serum. Eo1 = eotaxin-1, Eo2 = eotaxin-2. Results are shown as the mean of each group of 
mice +/- SEM. n=7 mice. * p<0.05. 
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Figure 4.27 - ST2 gene knockout does not affect draining lymph node responses 
WT and ST2-/- mice were immunised and challenged as in Figure 4.25. Draining lymph nodes were 
collected on day 12 and single cell suspensions from individual mice restimulated with OVA 1 
mg/ml. Supernatants were collected after 96 hours and cytokines and chemokines measured by 
ELISA or multiplexed immunoassay. Eo2 = eotaxin-2. Results are shown as the mean of each 
group of mice +/- SEM. n=7 mice. * p<0.05. 
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4.5.2 Establishing an alum-free model of asthma 
Having demonstrated that ST2 is important in a 12 day model of asthma in 
BALB/c mice I sought to explore the mechanism for this. In addition to the 
previously cited paper(381), during the course of this work further data came to 
light published by Mangan et al(383). Both these studies are summarised in Table 
4.1. Using a 30 day OVA and alum based model in BALB/c mice Mangan et al 
found that, while histological inflammation and AHR were unaffected by ST2 
gene deletion, BAL eosinophils were elevated. The fact that I found a reduction 
in airways eosinophilia and Hoshino et al did not could be attributed to 
differences in mouse strain as well as model. However the fact that Mangan et al 
and I reached opposite conclusions using the same strain of ST2-/- BALB/c mice 
suggests that the model used may be crucial. I have used a 12 day model in 
which mice were immunised with OVA 100 µg in alum before being challenged on 
days 9 to 11 with 10 µg of intranasal OVA. Mangan at al immunised with 2 µg of 
OVA in alum on days 1 and 14 before challenging with nebulised OVA on days 28 
to 30. 
Investigator Mice Sensitisation Challenges Length EØ 
Hoshino(381) C57Bl/6 
OVA + Alum 
d0 + d12 
15 32 days NC 
Mangan(383) BALB/c 
OVA + Alum 
d1 + d14 
3 31 days  
Pitman BALB/c 
OVA + Alum 
d1 
3 12 days  
Table 4.1 – The effect of ST2 gene deletion in experimental asthma 
Key –  Sensitisation: antigen and adjuvant administered on indicated days. Challenges: number 
of airways challenges given. Length: Total duration of model. EØ: effect on lung 
eosinophil numbers. 
 
It is possible that the requirement for ST2 in experimental asthma is upon mast 
cells. The data I presented in Chapter 3 suggests that ST2 can be an important 
receptor on mast cells. As discussed previously conventional models of asthma 
featuring immunisation with OVA and alum are mast cell independent(157,162). 
The 12 day model used here has not been extensively studied, the difference 
between it and more conventional models, and the importance of mast cells in 
this model are unknown. One of the only models utilising alum in which mast cell 
deficiency resulted in reduced eosinophilia was very similar. Mice were 
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immunised with OVA and alum on days 1 and 5 before being challenged with OVA 
twice on day 12(159). 
I hypothesised that ST2 was required in models of asthma which were mast cell 
dependent. The omission of alum has been shown to induce mast cell 
dependency in models which otherwise do not require mast cells. Therefore I 
chose to study the role of ST2 in one of these published models. 
I tested two alum-free models based on published protocols. The first paper to 
highlight the role of mast cells in alum-free models used seven sensitisations of 
OVA (10 µg) alone over 14 days followed by three intranasal challenges of OVA 
(200 µg) on days 40, 43 and 46(162). A more recent paper demonstrated that the 
omission of alum from a shorter more conventional model resulted in mast cell 
dependence. Mice were sensitised with OVA (20 µg) alone on days 0 and 14 
before being challenged with nebulised OVA on days 28, 29 and 30(163). 
Both protocols were adapted slightly in line with our own laboratory experience, 
specifically they were both shortened from 47 and 31 days to 28 days, and in the 
later model intranasal delivery was used in place of nebulised delivery. Figure 
4.28 details the two models, Protocol A and Protocol B. I set out to confirm that 
with these minor changes these models generated airways and tissue 
inflammation, AHR and antigen specific IgE. 
Although BAL total cell counts were increased in both models this was only 
statistically significant in Protocol A (Figure 4.29A). The proportion of 
eosinophils within the BAL was significantly elevated in both protocols but was 
again more marked in Protocol A (Figure 4.29B). This translated to a rise in total 
BAL eosinophils which was greater and more statistically significant in Protocol A 
than Protocol B (Figure 4.29C). IL-4, IL-5 and IL-13 were not detected in the 
BAL. 
Significant AHR was generated in both models (Figure 4.30). Antigen specific IgE 
was also generated using both protocols, although levels were only significantly 
higher than PBS with Protocol B (Figure 4.31). 
The reason for the generally more pronounced inflammatory response, but 
reduced IgE titres in Protocol A is unclear. The only difference between the two 
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protocols was in the immunisation, with Protocol A using a total of 40 µg of OVA 
administered at two immunisations and Protocol B using a total 70 µg 
administered at seven immunisations. 
Protocol A was selected for further study. Not only was BAL eosinophilia more 
marked, but the reduced number of immunisations was preferable in terms of 
animal welfare. Histological sections confirmed that Protocol A also induced 
tissue eosinophilia (Figure 4.32). 
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Figure 4.28 – Two alum-free models of asthma 
(Protocol A) Mice were immunised with OVA (20 µg) alone on days 0 and 14 before being 
challenged with intranasal OVA (200 µg) on days 25, 26 and 27. AHR was measured on day 28 and 
mice culled on day 29. (Protocol B) Mice were immunised with OVA (10 µg) alone on days 0, 2, 4, 
6, 8, 10 and 12 before being challenged with intranasal OVA (200 µg) on days 25, 26 and 27. AHR 
was measured on day 28 and mice culled on day 29. 
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Figure 4.29 – BAL eosinophilia is generated in the absence of alum 
Mice were immunised, challenged and culled according to Protocol A (IP x 2) or Protocol B (IP x 
7) as detailed in Figure 4.28. Control mice (PBS) were sensitised with OVA (20 µg) on days 0 and 
14 before being challenged with PBS alone on days 25, 26 and 27. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=6 mice. * p<0.05, ** p<0.01. 
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Figure 4.30 – Airways hyperresponsiveness is generated in the absence of alum 
Mice were immunised and challenged as in Figure 4.29 with Penh being measured on day 28. 
Results are shown as the mean of each group of mice +/- SEM. n=6 mice. Two-way ANOVA 
p<0.001 IP x 2 compared with PBS, p<0.001 IP x 7 compared with PBS. 
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Figure 4.31 – Antigen specific IgE is generated in the absence of alum 
Mice were immunised, challenged and culled as in Figure 4.29. OVA specific IgE was measured in 
serum by ELISA at dilutions from 1/20 to 1/540. Results are shown as the mean of each group of 
mice +/- SEM. n=6 mice. Two-way ANOVA p<0.05 IP x 2 compared with PBS, p<0.001 IP x 7 
compared with PBS. 
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Figure 4.32 - Histological inflammation is induced in the absence of alum 
Mice were immunised, challenged and culled as in Figure 4.29. Lungs were fixed in formalin and 
stained with H&E. Panels shown are representative sections. 
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4.5.3 The role of ST2 in an alum-free model of asthma 
In order to determine whether or not there was an alum dependent requirement 
for ST2 in murine asthma I induced asthma in WT and ST2-/- mice with and 
without alum. Mice were immunised and challenged with OVA alone (Figure 
4.28A) or using an identical protocol with the addition of 1% alum to both the 
day 0 and day 14 immunisation. 
When immunised and challenged with OVA alone (OVA group) BAL total cell 
counts, eosinophil percentage and total eosinophil numbers were all significantly 
reduced in ST2-/- mice as compared with WT mice. Conversely, in the group 
immunised with OVA and alum (OVA-Alum group) BAL total cell counts and 
eosinophilia were no different between WT and ST2-/- mice (Figure 4.33). There 
was also evidence of attenuated eosinophilic inflammation on histology (Figure 
4.34). 
Despite ST2 gene deletion attenuating airway inflammation, the increased AHR 
in both asthma models was maintained. As expected AHR was generated in both 
the OVA alone model and the OVA-Alum model in WT mice. In both models AHR 
was unaffected by ST2 gene deletion (Figure 4.35). 
BAL cytokines and chemokines provided no clear explanation for the significant 
reduction in eosinophils in ST2-/- mice immunised with OVA alone. IL-1, IL-2, IL-
4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFNγ, TNFα, GM-CSF, KC, FGF, IP-10, MIG, 
MCP-1, MIP-1α and RANTES were undetectable or present at concentrations of 
less than 50 pg/ml, and did not differ significantly between protocols or strains. 
Eotaxin 1 and 2 were detected at slightly higher concentrations, and there was a 
non-significant trend for lower concentrations of eotaxin-2 in ST2-/- mice in both 
the OVA and the OVA-Alum protocols (Figure 4.36). 
As with the BAL, cytokine and chemokine concentrations in the serum were 
generally low, those detected at the highest concentrations are shown in Figure 
4.37. The mean concentration of IL-10 in WT mice immunised with PBS alone 
was high, although there was marked variance within this group. Concentrations 
of IL-10 were also relatively high in OVA-Alum mice immunised with OVA and 
Alum, but were undetectable in the serum of OVA mice. IL-12 was detected in 
the serum of all mice and was significantly reduced in ST2-/- mice relative to WT 
Chapter 4:  166 
mice in the OVA protocol. KC was present only in the serum of OVA or OVA-Alum 
WT mice, but despite the absence of KC in ST2-/- mice the difference was not 
significant due to the high variance. MIG was present in the serum of all OVA and 
OVA-Alum mice with the exception of ST2-/- mice immunised with OVA alone, but 
this difference was also not significant. Eotaxin-1 was detected at high 
concentrations and eotaxin-2 at lower concentrations. Both were detected at 
similar concentrations in the serum of all mice. Concentrations of IL-1, IL-2, IL-
4, IL-5, IL-6, IL-13, IL-17, IFNγ, TNFα, GM-CSF, FGF, IP-10, MCP-1, MIP-1α and 
RANTES in the serum were below 50 pg/ml. 
Antigen specific IgE is a critical component of any model of atopic asthma. While 
OVA specific IgE was unaffected by ST2 gene deletion in the OVA-Alum model, 
there was a significant reduction in IgE production in the OVA alone model 
(Figure 4.38A). The other Th2 associated antibody, IgG1 was unaffected by ST2 
gene deletion in either model (Figure 4.38B). OVA specific IgG2a was also not 
significantly different between WT and ST2-/- mice (Figure 4.38C). 
Given that isotype switching is likely to occur in the local draining lymph nodes 
under the influence of IL-4 or IL-13(120) I went on to examine the production of 
Th2 cytokines by draining lymph node cells when restimulated with OVA. When 
draining lymph node cells from mice immunised with OVA and alum were 
restimulated with OVA there was no difference in IL-4, IL-5 and IL-13 
concentrations between WT and ST2-/- mice (Figure 4.39). In contrast when mice 
were immunised with OVA alone there was a significant reduction in IL-5 and IL-
13 in lymph node cultures from ST2-/- mice, and a trend towards reduced IL-4 (p= 
0.06). There was no significant cytokine production when lymph node cells were 
cultured with medium alone (data not shown). 
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Figure 4.33 - BAL eosinophils are reduced in ST2-/- mice in the absence of alum 
WT (■) and ST2-/- (□) mice were immunised with OVA (10µg) and 1% alum (OVA Alum), OVA (10 
µg) alone (OVA) or PBS (PBS) on days 0 and 14. All mice were challenge with intranasal OVA (200 
µg) on days 25, 26 and 27. Mice were culled on day 29. (A) Total cell counts were performed 
upon BAL. (B,C) BAL differential counts were performed. Results are shown as the mean of each 
group of mice +/- SEM. n=8 mice. ** p<0.01 compared with WT. 
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Figure 4.34 – Tissue eosinophilia is reduced in ST2-/- mice in the absence of alum 
WT and ST2-/- mice were immunised and challenged and culled as in Figure 4.33. Lungs were 
fixed in formalin and stained with H&E. Panels shown are representative sections. 
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Figure 4.35 - Airways hyperresponsiveness is preserved in ST2-/- mice 
WT (■) and ST2-/- (□) mice were immunised and challenged as in Figure 4.33. Penh was measured 
on day 28. Results are shown as the mean of each group of mice +/- SEM. n=8 mice. 
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Figure 4.36 – BAL cytokines and chemokines are not significantly altered in ST2-/- mice 
WT (■) and ST2-/- (□) mice were immunised and challenged as in Figure 4.33. BAL was collected 
and cytokine and chemokine concentrations measured by ELISA and multiplexed immunoassay. 
Results are shown as the mean of each group of mice +/- SEM. n=8 mice. 
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Figure 4.37 – Serum cytokines and chemokines are not significantly altered in ST2-/- mice 
WT (■) and ST2-/- (□) mice were immunised and challenged as in Figure 4.33. Serum was 
collected and cytokine and chemokine concentrations measured by ELISA and multiplexed 
immunoassay. Results are shown as the mean of each group of mice +/- SEM. n=8 mice. ** p<0.01 
compared with WT 
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Figure 4.38 – Antigen specific IgE is reduced in ST2-/- mice in the absence of alum 
WT (■) and ST2-/- (□) mice were immunised and challenged as in Figure 4.33 Serum was collected 
and OVA specific immunoglobulins measured by ELISA. Results are shown as the mean of each 
group of mice +/- SEM. n=8 mice. ** p<0.01 compared with WT  
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Figure 4.39 – Lymph node Th2 cytokines are reduced in ST2-/- mice in the absence of alum 
WT (■) and ST2-/- (□) mice were immunised and challenged as in Figure 4.33. Single cell 
suspensions from draining lymph nodes were stimulated with OVA 1 mg/ml. Supernatants were 
collected after 96 hours and cytokines and chemokines measured by ELISA. Results are shown as 
the mean of each group of mice +/- SEM. n=8 mice. * p<0.05, ** p<0.01 compared with WT. 
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4.6 Conclusions 
The experiments in this chapter initially served to develop a murine model of 
allergic airways inflammation for later use in the study of the role of ST2 in 
experimental asthma. There were several stages in the development and 
validation of this model. A crucial step in the induction of airways inflammation 
is the introduction of antigen to the lungs. Ideally the dose delivered should be 
repeatable and equally distributed throughout the bronchial tree. One solution is 
to allow conscious animals to inhale a nebulised solution of antigen. While, with 
careful engineering(482), the concentration of particles within the chamber can 
be uniform, the dose delivered will be affected by the ventilatory pattern of 
each animal. Distribution throughout the airways may also be uneven with 
particle deposition in the upper airways(483) and significant variation in the 
dose delivered to different parts of the lung(484). An alternative method is to 
use intranasal administration, which can ensure that the same total dose is 
delivered on each occasion. However there is concern as to how the delivered 
antigen is distributed, with evidence that a significant proportion of delivered 
agent is localised to the upper GI tract and upper respiratory tract(485). By 
instilling antigen directly into the lungs via cannulation of the trachea these 
problems may be overcome. I found that there was no difference in the 
magnitude of the inflammatory response or intra-group variance between 
intranasal and intratracheal dosing. In addition when Evan‟s blue was instilled 
via the intratracheal route under terminal anaesthesia a significant quantity of 
dye was found within the upper respiratory tract and stomach (data not shown). 
It is likely that all routes of administration result in delivery of antigen to the 
upper respiratory tract, but given that this alone can result in pulmonary 
inflammation and AHR(486) the model is unlikely to be adversely affected. While 
in theory ingestion of antigen may result in oral tolerance(487), in practice all of 
the described delivery methods result in a robust recall immune response. 
Information on the nature of the T cell response upon antigen challenge can be 
obtained by culturing cells from the draining lymph nodes. I have found that the 
culture of lymph nodes from each mouse individually, as opposed to pooled from 
all mice, is practical and not prohibitively time consuming. This technique also 
allows for variance to be calculated and statistical comparisons to be made 
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between groups. The data also suggest that there may be a problem of high 
responders skewing the response in pooled cultures. 
I also set out to establish a method to measure AHR. While invasive 
measurement of airways resistance and compliance remains the gold standard it 
was out with the scope of this project to establish this technique within 
laboratory. Considerable technical skill is required to perform cut-down and 
tracheal intubation in live anaesthetised mice and such expertise was not 
available locally. A significant investment in equipment is also required. Within 
the group there was already the equipment and experience to measure Penh. 
The principles of this investigation have been discussed in Chapter 2. There are 
however concerns regarding the use of the dimensionless parameter Penh. These 
are in part due to the fact that although Penh measurements generally correlate 
well with direct measures of airways resistance, it is not clear exactly what Penh 
is a measure of(488,489). Although Penh is acknowledged to be affected by 
changes in airways resistance there is concern over the contribution of other 
factors such as nasal resistance, ambient temperature and humidity within the 
chamber and tidal volume(488,490). I found that, provided sufficiently large 
groups were used, all three models of asthma utilised in this chapter generated 
reproducible methacholine-induced changes in Penh which were significantly 
greater than in control mice. Furthermore Penh continues to be utilised by 
leading investigators in the field of experimental asthma(31-34). 
Having optimised and validated a short model of asthma I was able to study the 
kinetics of the immune response to antigen challenge. This led to two key 
observations. Firstly, it would appear that antigen challenge induces an 
inflammatory response within the airways which continues to develop in the 
absence of ongoing antigen dosing. One might predict that during the challenge 
period eosinophil numbers rise following each successive challenge, but the 
changes following a single antigen challenge were more unexpected. While it is 
recognised that by 7 to 14 days after challenge eosinophil numbers have fallen 
significantly(491-493), there is little data on earlier time points. In a 31 day 
model of asthma in which mice were sensitised twice with OVA and alum before 
being challenged with OVA on three consecutive days, eosinophil numbers 
peaked 48 hours after the final challenge, and began to fall by 72 hours(493). It 
was therefore surprising that in mice which had been sensitised once, a single 
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antigen challenge resulted in an inflammatory response which continued to 
develop for up to 72 hours. 
In light of this ongoing inflammation it was also unexpected that Th2 cytokines 
were produced only transiently. It is well established that IL-4, IL-5 and IL-13 are 
detected within the BAL and serum in murine models of asthma, usually 
measured 24 hours after the final challenge, and often at relatively low 
concentrations. BAL IL-4 was detected at high (ng/ml) concentrations 24 hours 
after a single antigen challenge, with IL-5 and IL-13 at lower concentrations. In 
the serum IL-5 and IL-13 were also elevated 24 hours after challenge. 
Surprisingly even when further challenges were given Th2 cytokine 
concentrations decreased and were at much lower or undetectable 
concentrations 24 hours after the third challenge. While there is some data 
available for the kinetics of BAL Th2 cytokine concentrations after the final 
challenge(493) I could find no data regarding changes during the challenge 
period. 
While Th2 cytokine concentrations in the BAL and serum decreased after the 
first challenge, eosinophil numbers in the airways continued to rise. The 
sustained chemokine release seen may account for this, with eotaxin-2 
concentrations rising regardless of whether or not further challenges were given. 
In fact BAL eotaxin-2 concentrations correlated closely with eosinophil numbers. 
In asthmatic patients eotaxin-1 and eotaxin-2 expression rises after a single 
antigen challenge(494,495) and eotaxin-2 also correlates closely with eosinophil 
numbers in bronchial biopsies(495). The close relationship between eosinophilic 
inflammation and eotaxin-2 is in keeping with the key role of the CCR3-eotaxin 
pathway in eosinophil recruitment during experimental asthma(268-270). 
These data suggest that initial exposure to allergen results in a Th2 cytokine 
response, which then appears to be down-regulated despite ongoing allergen 
exposure. This is followed by local eotaxin-2 production which drives eosinophil 
recruitment. Even though Th2 cytokine expression is fairly transient, IL-4, IL-5 
and IL-13 are required for eosinophilic inflammation in experimental asthma, as 
discussed in Chapter 1. It may be that inflammation is initiated by Th2 cytokine 
release but then perpetuated by ongoing eotaxin-2 production. IL-5 can induce 
eosinophils to mobilise from the bone marrow and express CCR3(496,497) 
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whereas IL-4 can induce eotaxin-2 production by macrophages(498), which are 
the most abundant cells within the airways. 
The other key finding was regarding the requirement for ST2 in allergic airways 
inflammation. In the 12 day model of asthma airways inflammation was 
significantly reduced in ST2 deficient mice. This is in contrast to published data 
from different asthma models. While the study by Hoshino et al found no effect 
of ST2 gene deletion on airways inflammation, they utilised a protocol in which 
C57Bl/6 mice were used rather than BALB/c mice, and 15 challenges were 
administered(381). However the study by Mangan et al, which also found no 
requirement for ST2 in the generation of eosinophilic inflammation, not only 
used BALB/c mice, but also a more conventional 30 day model in which mice 
were challenged three times(383). 
The reason for the dramatic difference between the 12 day and 30 day models is 
unclear. Subtle differences in models, such as the route of sensitisation, can 
have significant impact on the pathways required. For example when 
sensitisation is carried out by the epicutaneous rather than the intraperitoneal 
route, the requirement for IL-4 is bypassed(213). As there have been few studies 
using the short model little is know about how it differs functionally from other 
models. However a very similar model, in which mice were sensitised with OVA 
and alum on days 1 and 5 before being challenged twice on day 12, was unusual 
in showing a requirement for mast cells in the generation of eosinophilic 
inflammation(159).  
In light of these data and the role of ST2 on mast cells demonstrated in Chapter 
3, I went on to show that ST2 was required in an alum-free, mast cell dependent 
model of asthma. Eosinophilic inflammation was dramatically reduced in ST2-/- 
mice in the alum-free model while AHR was preserved. This was associated with 
a marked reduction in antigen specific IgE and reduced Th2 cytokine production 
by antigen stimulated lymph node cells. However when alum was used as an 
adjuvant during sensitisation ST2 gene deletion had no effect on airways 
inflammation or AHR. 
While the results from the 28 day alum model are in keeping with the published 
literature(381,383), the results from the alum-free model are novel. My 
hypothesis prior to performing the experiment was that mast cell ST2 is 
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necessary for allergic airways inflammation provided that the models of asthma 
used has a requirement for mast cells. Given that the use of alum confers mast 
cell independence and the omission of alum mast cell dependence(162), the 
data would support this hypothesis, ST2 was only required in the mast cell 
dependent model of asthma. This is of course not the only possible 
interpretation of the data. While the alum-free model of asthma is a mast cell 
dependent model, this may not be the sole effect of omitting alum. To 
appreciate other possible explanations it is important to consider the 
mechanisms by which alum functions as an adjuvant. 
In 1926 Glenny et al discovered that precipitating antigen onto insoluble 
aluminium potassium sulphate improved antibody responses(45). It was initially 
thought that alum worked simply by effecting a slow release of antigen over 
time. This theory persisted for many years but more recent data suggests that 
alum works by other methods. 
Following intraperitoneal administration of OVA alone antigen appears to travel 
passively to the draining lymph nodes where it is taken up and presented by 
resident DCs(499). When OVA is administered with alum it induces an influx of 
peritoneal monocytes that take up the OVA before maturing to become DCs and 
migrating to lymph nodes where they activate T cells. This process is dependent 
on urate production, and results in more effective activation of CD4 T cells than 
with OVA alone. One of the reasons why alum is able to recruit DCs in this 
manner appears to be by activation of the inflammasome. 
The innate immune system has a collection of receptors to recognise conserved 
molecules associated with pathogens or pathogen-associated molecular patterns 
(PAMPs). The best characterised of the PAMP receptors are the predominantly 
surface expressed TLRs, but there also the intracellular nucleotide binding and 
oligmerization domain (NOD)-like receptors (NLRs). They function in association 
with other proteins including pro-caspases, to form a complex referred to as the 
inflammasome(500). The NLRP3 containing inflammasome is associated with pro-
caspase-1 which is converted to active caspase-1 upon triggering and in turn 
cleaves IL-1β and IL-18 to their active forms(501). 
It has recently been demonstrated that alum synergises with LPS in vitro to 
induce IL-1β and IL-18 release from macrophages via the NLRP3 
Chapter 4:  179 
inflammasome(502-505). While IL-18 is expressed constitutively, LPS may be 
required in vitro to induce pro-IL-1β which is then cleaved by alum-mediated 
activation of the inflammasome(506,507). The NLRP3 inflammasome is also 
required for the adjuvant effect of alum administered with OVA in vivo, 
including antigen uptake and maturation of peritoneal DCs, IgG1 and IgE 
production and eosinophilic inflammation in experimental asthma(502,503,505). 
Despite these findings it is in alum-free models of asthma that IL-1 is 
indispensable(508,509). 
These data demonstrate that the use of alum results in alternative antigen 
transport and processing, activation of the NLRP3 inflammasome and generation 
IL-1β and IL-18. In an alum-free model of asthma there is a requirement for 
TNFα producing mast cells(33,162,163), IgE(125) and IL-1. I have demonstrated 
that in alum-free models there is also a requirement for ST2. 
The question remains as to whether or not ST2 is required at the time of 
sensitisation, perhaps as part of the pathway which is activated in the absence 
of alum, or whether in the absence of alum a pathway is utilised which then 
requires ST2, perhaps on mast cells, at the time of antigen challenge. 
In the following chapter I set out establish whether the activation of ST2 in the 
lungs with IL-33 induces the features of experimental asthma. 
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In this chapter I will study the effect of activating ST2 in the airways by the 
administration of IL-33. 
5.1 Introduction 
In Chapter 3 I demonstrated that IL-33 activated mast cells via the receptor ST2 
to release pro-inflammatory cytokines and chemokines in vitro. In particular IL-
6, IL-13, MIP-1α and MCP-1; all of which have the potential to play a pathological 
role in clinical and experimental asthma.  
In Chapter 4, I found that ST2 contributes to airways inflammation and IgE 
generation, but not AHR, in an alum-free model of asthma. A key difference 
between models of asthma which utilise alum and those that do not is that the 
use of alum appears to eliminate the requirement for mast cells in the 
development of airways inflammation and AHR(162).  
Taken together these data support the possibility that activating ST2 on mast 
cells plays an important role in experimental asthma. 
Schmitz et al(323) found that the systemic activation of ST2 by the 
administration of IL-33 induced blood eosinophilia, the generation of serum IgE 
and IgA, Th2 cytokine production and some perivascular and epithelial changes 
in the lungs. 
I hypothesised that the activation of ST2 on mast cells within the airways by IL-
33 would induce the features of experimental asthma. 
5.2 The effect of IL-33 on airways inflammation 
In the first instance I set out to establish whether or not the intranasal 
administration of IL-33 would induce inflammation within the lungs. Schmitz et 
al administered 0.4 or 4 µg of recombinant human IL-33 intraperitoneally to 
C57BL/6 mice daily for seven days and culled the animals the following 
day(323). I based the protocol for intranasal administration upon these methods. 
Others within the lab had found in studies of murine T cells in vitro that human 
recombinant IL-33 has approximately half the bioactivity of recombinant murine 
IL-33 (M. Kurowska-Stolarska, personal communication). Consequently I selected 
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a dose of 2 µg of murine IL-33 for initial studies. C57BL/6 mice were chosen 
given the proven efficacy of systemic IL-33 administration in this strain. In 
addition this would allow for future investigation of the contribution of mast 
cells to any effect observed, as mast cell deficient mice are available on the 
C57Bl/6 background. 
5.2.1 The effect of intranasal IL-33 
Recombinant murine IL-33 (2 µg) was administered via the intranasal route to 
C57Bl/6 mice each day for seven days. The day after the final dose mice were 
culled and BAL fluid and lungs collected. 
IL-33 administration resulted in a dramatic rise in cell numbers within the BAL, 
with a mean total cell count of 54 x105 cells/ml (Figure 5.1A). This compares 
with counts in the region of 2 – 5 x105 cells/ml in the models of asthma 
presented previously. There was an associated dramatic rise in the proportion of 
eosinophils in the BAL from 0% to 79% (Figure 5.1B). Consequently there was a 
marked rise in absolute eosinophil numbers from 0 to 43 x105 cells/ml (Figure 
5.1C). While the proportion of macrophages fell from 93% to 16% there was still 
a significant rise in absolute numbers from 1 to 8 x105 cells/ml. The proportion 
of neutrophils was low in both groups at 6% in the PBS group and 5% in the IL-33 
group, this did however translate to a rise in absolute neutrophil numbers from 
0.2 to 2.5 x105 cells/ml in the IL-33 group. 
Histological examination of the lungs revealed extensive eosinophilic 
inflammation throughout (Figure 5.2). The degree of inflammation was much 
more pronounced than that seen with the murine models of asthma in Chapter 4. 
Concentrations of the Th2 cytokines IL-4 and IL-13 were slightly elevated in the 
BAL at 34 pg/ml and 29 pg/ml respectively (Figure 5.3). The eosinophil 
chemoattractants eotaxin 1 and 2 were induced at relatively high concentrations 
by IL-33, 116 pg/ml and 397 pg/ml respectively. 
These data confirm that the intranasal administration of IL-33 induces 
inflammatory changes in the lungs similar to those seen in experimental asthma, 
the most striking of which is a profound eosinophilia. 
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Figure 5.1 – Intranasal IL-33 induces BAL eosinophilia 
C57BL/6 mice received PBS or 2 µg of recombinant murine IL-33 via the intranasal route on days 
1 to 7 before being culled on day 8 at which point BAL was collected. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=7 mice. ** p<0.01 compared with PBS 
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Figure 5.2 – Intranasal IL-33 induces inflammation within the lung 
PBS or IL-33 was administered to mice as in Figure 5.1. Lungs were fixed in formalin and stained 
with H&E. Panels shown are representative sections. 
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Figure 5.3 – Intranasal IL-33 induces BAL cytokines and chemokines 
PBS or IL-33 was administered to mice as in Figure 5.1. BAL was collected and cytokines assayed 
by ELISA. Results are shown as the mean of each group of mice +/- SEM. n=7 mice. * p<0.05, ** 
p<0.01 compared with PBS 
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5.2.2 Kinetics during serial IL-33 administration 
To better understand the changes that lead to the development of airways 
inflammation in mice administered repeated doses of IL-33, particularly the 
cytokines and chemokines which may be responsible for the recruitment of 
eosinophils, I undertook a study of the dynamic response to IL-33. I designed a 
protocol to study the kinetics of cytokines, chemokines and cell numbers within 
the lungs over the course of the eight day treatment period. As detailed in 
Figure 5.4, mice received up to 7 daily doses of intranasal IL-33 and groups of 
mice were culled at 24 hour intervals throughout this period. 
Total cell counts began to rise on day three, 24 hours after the third dose. 
Numbers continued to rise with time and repeated dosing to a maximum of 50 
x105 after the seventh dose (Figure 5.5A). Differential cell changes are shown in 
Figure 5.5B. Macrophage numbers rose gradually over the time course from 1.4 
x105 in untreated mice to 9.5 x105 after seven doses. Neutrophils were first 
detected on day 3 and rose thereafter to 8.4 x105 after seven doses. As 
predicted the most striking change was in eosinophils, which first appeared in 
the BAL at low numbers (0.5 x105) 24 hours after the third dose. Numbers rose 
sharply thereafter reaching 31.5 x105 on day seven, at which point they 
comprised 59% of the BAL cell population. 
Locally within the BAL IL-13 was the cytokine detected at the highest 
concentration (Figure 5.6). It was first detectable on day four, peaked at 770 
pg/ml on day five and fell thereafter. IL-5 followed a similar pattern but at a 
much lower concentration, peaking at 175 pg/ml. The other Th2 cytokine IL-4 
was never detected at a concentration greater than 82 pg/ml. Eotaxin-1 and 
eotaxin-2 were first detected on day three, earlier than IL-5 and IL-13. Eotaxin-1 
remained at a similar concentration over time while eotaxin-2 then fell slightly. 
IL-12 and IP-10 also rose modestly to peak on day four and three respectively. 
Concentrations of IL-1, IL-2, IL-6, IL-10, IL-17, IFNγ, TNFα, GM-CSF, KC, FGF, 
MCP-1, MIP-1α, RANTES and MIG were below 50 pg/ml.  
Within the serum the most marked change was a rise in IL-13 over time to a peak 
concentration of 614 pg/ml on day seven (Figure 5.7). The other Th2 cytokines 
IL-4 and IL-5 were detected at much lower concentrations, with IL-4 never rising 
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above 50 pg/ml and IL-5 peaking at 157 pg/ml after 3 doses. IP-10 and FGF were 
the only chemokines which changed significantly over time, rising and falling 
respectively from day zero to day seven. Concentrations of IFNγ, IL-6, GM-CSF, 
IL-17, MCP-1, MIP-1α, RANTES and MIG within the BAL were below 50 pg/ml. IL-
1, IL-2, IL-12 and TNFα were detected but did not change significantly over the 
time course. 
These data demonstrate that with repeated consecutive administrations of IL-33 
to the airways an eosinophilia is generated after four days which rises thereafter 
and is associated with elevated Th2 cytokine and eotaxin concentrations. 
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Figure 5.4 – Protocol for studying the kinetics of the response to IL-33 
2 µg of recombinant murine IL-33 was administered via the intranasal route once daily on days 1 
to 7. Groups of mice were culled 24 hours after each dose. For example Group 0 was culled prior 
to the first administration, Group 1 culled 24 hours after the first dose and Group 7 culled 24 
hours after the seventh and final dose. 
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Figure 5.5 - Eosinophils rise with successive IL-33 doses 
IL-33 was administered to mice as in Figure 5.4. (A) Total cell counts were performed upon BAL. 
(B) BAL differential counts were performed. Results are shown as the mean of each group of 
mice +/- SEM. n=4-5 mice. One-way ANOVA for the effect of IL-33 dose on macrophages p<0.001, 
eosinophils p<0.001, neutrophils p<0.001. 
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Figure 5.6 - Change in BAL cytokines and chemokines with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.4. BAL was collected and cytokines and chemokines 
assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of each group of 
mice +/- SEM. n=4-5 mice. One-way ANOVA for the effect of IL-33 dose on IL-13 p=0.005, 
Eotaxin-1 p<0.001, Eotaxin-2 p<0.001. 
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Figure 5.7 - Change in serum cytokines and chemokines with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.4. Serum was collected and cytokines and 
chemokines assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of 
each group of mice +/- SEM. n=4-5 mice. One-way ANOVA for the effect of IL-33 dose on IL-4 
n.s., IL-5 p<0.05, IL-13 p<0.001, FGF n.s., IP-10 p<0.05. 
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5.2.3 Kinetics following IL-33 administration 
Having shown that in the context of repeated IL-33 administration BAL eosinophil 
counts rise continuously I was interested to establish whether or not an 
inflammatory process had been initiated which would be perpetuated in the 
absence of ongoing ST2 stimulation. We had previously found that a single dose 
of IL-33 is insufficient to generate an appreciable airways eosinophilia at any 
point up to seven days after administration (P. Kewin et al unpublished), and so 
would need a protocol with multiple doses. 
Additionally, as I was interested in studying the contribution of mast cells to the 
response to IL-33 I wanted to establish an endpoint at which the response was 
not so great as to mask any contribution by individual cells and pathways. With 
seven doses of IL-33 inducing a profound eosinophilia I chose a point in the 
middle of the IL-33 dose response curve shown in Figure 5.5. Having shown that 
24 hours after 4 doses of IL-33 a moderate eosinophilia of 1.6x105/ml is 
generated I chose to study the changes within the BAL and serum for up to eight 
days after 4 consecutive IL-33 administrations (Figure 5.8). 
Following four intranasal doses of IL-33 total cell numbers continued to rise 
steadily, reaching a peak four days after dosing, before falling again (Figure 
5.9). Eosinophil numbers followed an identical pattern peaking at 24x105/ml four 
days after dosing, at which point they comprised 68% of BAL cells. Macrophages 
similarly rose to a peak at the earlier time point of three days post dosing, 
although the relative change was less dramatic with a maximum of 12x105/ml 
and a minimum of 5.3x105/ml. Neutrophils were also induced, peaking at 
4.2x105/ml on day two. While numbers had fallen significantly by day eight, with 
virtually no detectable neutrophils, there were still a significant number of 
macrophages and eosinophils present at this late time point. Macrophages are 
the default cell found on BAL, where generally they make up 100% of the total 
cell count. While numbers are higher than those seen in naïve mice, at 
5.3x105/ml this is perhaps less striking than the persistence of eosinophils seen 
over a week after IL-33 administration. At day eight the eosinophil count was 
still 6x105/ml, making up 50% of all BAL cells, levels which are often not even 
achieved in standard asthma models immediately after antigen challenge. 
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Perhaps unsurprisingly Th2 cytokine levels within the BAL fell with the cessation 
of IL-33 dosing (Figure 5.10). IL-13 was present at high concentrations the day 
after final dosing, but fell rapidly thereafter. IL-4 and IL-5 began at more 
modest levels and also fell rapidly. Eotaxin-1 and eotaxin-2 followed a similar 
pattern, although with a more gradual decline, not beginning until day three in 
the case of eotaxin-2. IFNγ and IL-10 followed a different pattern, rising from 
zero to peak briefly two days after the last IL-33 administration. IL-12 was 
initially detected at low levels then also fell rapidly (data not shown). 
Concentrations of IL-1, IL-2, IL-6, TNFα, GM-CSF, KC, FGF, MCP-1, MIP-1α, 
RANTES, IP-10 and MIG were below 50 pg/ml. 
Serum cytokine concentrations were all very low. IL-4 and IL-5 concentrations 
remained below 100 pg/ml, where IL-13 fell gradually from 160 pg/ml at day one 
to below the limit of detection at day eight (Figure 5.11). Concentrations of IL-
1, IL-2, IL-6, IL-10, IL-12, IL-17, IFNγ, TNFα, eotaxin-1, eotaxin-2, GM-CSF, KC, 
FGF, MCP-1, MIP-1α, RANTES, IP-10 and MIG were below 50 pg/ml. 
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Figure 5.8 – Protocol for studying the kinetics following four doses of IL-33 
2 µg of recombinant murine IL-33 was administered via the intranasal route once daily on days 1 
to 4. Groups of mice were culled 1, 2, 3, 4, 5 and 8 days after the final dose. 
 
 
Total Cell Count
0
10
20
30
40
0 1 2 3 4 5 6 7 8
day
c
e
ll
s
 (
X
1
0
5
/m
l)
 
Differential Cell Counts
0
5
10
15
20
25
30
0 1 2 3 4 5 6 7 8
day
c
e
ll
s
 (
X
1
0
5
/m
l)
macrophages
eosinophils
neutrophils
 
Figure 5.9 – Change in BAL cell numbers with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.8.Total and differential cell counts were 
performed upon BAL. Results are shown as the mean of each group of mice +/- SEM. n=5 mice. 
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Figure 5.10 - Change in BAL cytokines and chemokines with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.8. BAL was collected and cytokines and chemokines 
assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of each group of 
mice +/- SEM. n=5 mice. 
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Figure 5.11 - Change in serum cytokines and chemokines with repeated IL-33 dosing 
IL-33 was administered to mice as in Figure 5.8. Serum was collected and cytokines and 
chemokines assayed by multiplexed immunoassay or ELISA. Results are shown as the mean of 
each group of mice +/- SEM. n=5 mice. 
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5.2.4 A three dose protocol for the study of IL-33 in C57Bl/6 mice 
Using the data from the previous dose response and time course experiments we 
designed a model to utilise for subsequent experiments. In Figure 5.9 the 
midpoint of the eosinophil response occurred three days after the last intranasal 
IL-33 dose. Given that eosinophil numbers continue to rise after dosing is 
completed we reduced the number of doses from four to three. This also had 
advantages in terms of reducing both the demands upon the limited supply of IL-
33 and the number of procedures mice were subjected to, improving animal 
welfare. The final protocol of three doses followed by a cull three days later is 
shown in Figure 5.12. 
Figure 5.13 demonstrated that this protocol did induce a moderate eosinophilia 
of 10x105/ml or 60% (Figure 5.13). The magnitude of this is not dramatically 
greater than that seen in the asthma models in Chapter 4, but is significantly 
less than that seen with seven doses of IL-33 (Figure 5.1). Lung eosinophilia was 
also evident on histology (Figure 5.14). This protocol was then used for 
subsequent studies. 
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Figure 5.12 – Final protocol for intranasal IL-33 administration 
2 µg of recombinant murine IL-33 was administered via the intranasal route once daily on days 1 
to 3. Mice were culled on day 6. 
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Figure 5.13 – BAL eosinophilia is induced by the modified IL-33 administration protocol 
C57BL/6 mice received recombinant murine IL-33 as in Figure 5.12. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=5 mice. 
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Figure 5.14 –Lung Inflammation is induced by the modified IL-33 administration protocol 
PBS or IL-33 was administered to mice as in Figure 5.12. Lungs were fixed in formalin and stained 
with H&E. Panels shown are representative sections. 
Chapter 5:  199 
5.2.5 The effect of IL-33 in BALB/c mice 
As discussed in Chapter 1 there can often be significant differences between 
different strains of mice. I initially chose to study the effect of IL-33 on the 
airways of C57Bl/6 mice for two reasons. This was the strain proven to respond 
to intraperitoneal IL-33, and mast cell deficient mice are available on this 
background. 
Before proceeding further it was important to determine the specificity of the 
observed effects of IL-33 for ST2. In Chapter 3 I demonstrated that the effect of 
IL-33 on mast cells in vitro was completely ST2 dependent. To confirm that the 
in vivo effects are mediated via ST2 I planned to utilise ST2-/- mice. The ST2-/- 
mice I had access to were on the BALB/c background. Therefore I needed to test 
the effect of IL-33 on mice from this background. 
The administration of IL-33 into the lungs of BALB/c mice resulted in a rise in 
total cell numbers within the BAL (Figure 5.15A), as well as eosinophil numbers 
(Figure 5.15B). The other cell types detected in the BAL were predominantly 
macrophages, with a very small proportion of neutrophils (Figure 5.15C). 
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Figure 5.15 – IL-33 induces airways eosinophilia in BALB/c mice 
IL-33 (■) or PBS (□) was administered to mice as in Figure 5.12. (A) Total cell counts were 
performed upon BAL. (B,C) BAL differential counts were performed. Results are shown as the 
mean of each group of mice +/- SEM. n=5 mice. * p<0.05, ** p<0.01 compared with PBS  
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5.2.6 The role of ST2 in IL-33 induced inflammation 
In order to confirm the specificity of IL-33 for ST2 in vivo I employed ST2-/- mice 
on a BALB/c background. 
IL-33 was administered to wild type (WT) and ST2-/- mice. As expected a robust 
eosinophilia was generated in the BAL of WT mice (Figure 5.17). In ST2-/- mice 
the total cell count was similar to that in PBS treated mice, and there was a 
complete absence of eosinophils. The same was true of lung histology, with 
eosinophilic inflammation induced in WT but not ST2-/- mice (Figure 5.17). 
This confirms that IL-33 is acting exclusively through the ST2 receptor to 
mediate the inflammatory effects seen in the lungs in vivo. It also serves to 
verify that the phenomena observed are not due to contamination by other bio-
active material of the IL-33, which is produced within our laboratory. 
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Figure 5.16 – IL-33 induced BAL eosinophilia is ST2 specific 
IL-33 or PBS was administered to wild type (WT) or ST2-/- mice as in Figure 5.12. Total and 
differential cell counts were performed upon BAL. Results are shown as the mean of each group 
of mice +/- SEM. n=5 mice. * p<0.05, ** p<0.01 compared with PBS. 
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Figure 5.17 – IL-33 induced lung inflammation is ST2 specific 
IL-33 or PBS was administered to wild type (WT) or ST2-/- mice as in Figure 5.12. Lungs were 
fixed in formalin and stained with H&E. Panels shown are representative sections.  
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5.3 The effect of IL-33 on airways hyperresponsiveness 
The data here demonstrate that IL-33 can induce eosinophilic airways 
inflammation similar in nature to that seen in models of asthma, although of a 
greater magnitude than is generally seen in such models. One of the other key 
features of experimental asthma is the development of AHR. As discussed in 
Chapter 1 eosinophilia and AHR do not always accompany each other and are 
regulated by different mechanisms. I therefore wanted to establish if IL-33 could 
induce airways eosinophilia alone, or both eosinophilia and AHR. 
5.3.1 Airways hyperresponsiveness following three doses of IL-33 
Given that I planned to assess the contribution of mast cells play to the effects 
of IL-33 in vivo I began by testing the attenuated three dose protocol I had 
developed for use in C57Bl/6 mice (Figure 5.12). 
As shown in Figure 5.18A there was a complete failure of IL-33 to generate AHR. 
While it is certainly possible to induce AHR in C57Bl/6 mice with a number of 
asthma protocols, it is well know that they have a tendency to display reduced 
spontaneous(50,53) and induced AHR(21,50,54). Consequently I went on to 
examine the effect of IL-33 on AHR in BALB/c mice. 
While IL-33 did appear to enhance AHR in BALB/c mice this result was not 
statistically significant (Figure 5.18B). ST2-/- mice were also used to confirm the 
specificity of any observed effect. The dose response curve to methacholine for 
ST2-/- mice mirrored that seen with PBS in wild type mice, supporting the 
hypothesis that the effects of IL-33 are once again ST2 dependent. 
The failure to demonstrate statistical significance in the wild type BALB/c mice 
treated with IL-33 may be in part due to the small group size used. It is also 
possible that the magnitude of the response is attenuated by the fact that the 
protocol involves a delay of three days from the last intranasal IL-33 
administration. While I have demonstrated that eosinophilia persists for many 
days after treatment this may not be true of AHR.  
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Figure 5.18 – IL-33 induces a trend towards AHR in BALB/c but not C57Bl/6 mice 
(A) IL-33 or PBS was administered to wild type C57Bl/6 mice as in Figure 5.12. AHR was 
measured by Penh on day 6 (B) Wildtype or ST2-/- BALB/c mice were similarly treated. Results 
are shown as the mean of each group of mice +/- SEM. n=4-5 mice. 
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5.3.2 Airways hyperresponsiveness following seven doses of    
IL-33 
Given the failure to generate statistically significant AHR in either strain of mice 
using the attenuated protocol I investigated whether seven consecutive 
administrations of IL-33, which induces a profound BAL eosinophilia (see Figure 
5.1A), would be capable of inducing AHR, measured the day after the final dose. 
I chose to study both C57Bl/6 mice, due to the background of the mast cell 
deficient strain, and BALB/c mice, due to the encouraging results in the three 
dose protocol. Based on the data from the three day protocol a power 
calculation with a power of 0.95 for a result with a significance of 0.05 
recommended a group size of 11 and group sizes were increased accordingly. 
Once again AHR in C57Bl/6 mice was unchanged between the PBS group and the 
treatment group despite the increased IL-33 dose, reduced time from dosing to 
AHR measurement, and increased group size (Figure 5.19A). 
In BALB/c mice AHR was induced by treatment with IL-33, and this became 
statistically significant at all does of methacholine (Figure 5.19B). Also shown in 
the graph is the response curve for mice in which experimental asthma had been 
induced using the 12 day protocol (Figure 4.8) which I had previously found to 
generate AHR as effectively as the more traditional 28 day protocol (Figure 
4.11). This serves to demonstrate that the degree of AHR generated by IL-33 is 
very similar to that seen in allergic airways disease. 
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Figure 5.19 – IL-33 induces significant AHR in BALB/c but not C57Bl/6 mice 
(A) IL-33 or PBS was administered to wild type C57Bl/6 mice as in Figure 5.1. AHR was measured 
by Penh on day 6 (B) Wild type BALB/c mice were similarly treated. Asthma was also induced in 
wild type BALB/c mice as in Figure 4.8. Results are shown as the mean of each group of mice +/- 
SEM. n=8-12 mice. Two-way ANOVA p<0.001 BALB/c PBS vs IL-33. 
 
 
Chapter 5:  208 
5.3.3 Study of the seven day protocol in BALB/c and C57Bl/6 mice 
Although eosinophilia and AHR are not always associated, as discussed in Chapter 
1, it seemed possible that the magnitude of the response to IL-33 in BALB/c 
mice, which are predisposed towards Th2 responses(510,511), might be greater 
in terms of both eosinophilic inflammation and AHR. Given that the difference in 
AHR between the two strains was most marked following seven doses of IL-33 I 
performed a direct comparison between BALB/c and C57Bl/6 mice using this 
protocol. 
Figure 5.20 shows that the magnitude and nature of the inflammatory response 
generated in the BAL is identical in BALB/c and C57Bl/6 mice. Therefore there is 
a marked dissociation between AHR and eosinophilia.  
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Figure 5.20 – IL-33 induced inflammation is equal in BALB/c and C57Bl/6 mice 
IL-33 (■) or PBS (□) was administered to BALB/c and C57Bl/6 mice mice as in Figure 5.1. Total 
and differential cell counts were performed upon BAL. Results are shown as the mean of each 
group of mice +/- SEM. n=8 mice. 
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5.4 The role of mast cells in the response to IL-33 
It is unclear why IL-33 failed to generate AHR in C57Bl/6 mice, despite a robust 
eosinophil response identical to that seen in the BALB/c mice, in which AHR is 
generated. While the failure may be due to the intrinsically reduced AHR seen in 
C57Bl/6 mice rather than a specific difference in the response to IL-33, it is 
generally possible to induce AHR in these mice with the appropriate protocols. 
Therefore I hypothesised that there may be a difference in the response to IL-33 
at a cellular level. Given the response of BALB/c mast cells to IL-33 
demonstrated in Chapter 3 I asked whether this response was affected by mouse 
strain. There is already evidence of functional differences in mast cells between 
these strains, including a deficiency in mast cell protease 7 in C57Bl/6 mice(56) 
and differences in mediator release upon FcεR cross-linking(512).  
5.4.1 Strain differences in bone marrow mast cell development 
Bone marrow mast cells were cultured in parallel from wild type C57Bl/6 and 
BALB/c mice for 7 weeks with SCF and IL-3 as detailed previously. Before 
studying the effect of IL-33 I looked for phenotypical differences between 
BALB/c and C57Bl/6 BMMCs. Due to the prolonged culture time I was unable to 
make robust comparisons of growth rates, but there was a suggestion that the 
C57Bl/6 population grew more slowly (data not shown). 
C57Bl/6 mast cells appeared to mature more rapidly than BALB/c mast cells. At 
5 weeks, 93% of C57Bl/6 cells were double positive for both c-kit and FcεRIα, 
compared with 83% of BALB/c cells at the same time point (Figure 5.21). The 
level of c-kit expression was similar at 98% and 99% respectively. ST2 expression 
was also similar for both strains. By 8 weeks of culture BMMCs from both strains 
were at least 95% c-kit+ and 90% FcεRIα+. 
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Figure 5.21 – C57Bl/6 BMMCs mature more rapidly than those from BALB/c mice 
The surface expression of c-kit, FcεRIα and ST2 on 5 week old BALB/c and C57Bl/6 BMMCs was 
analysed by FACS. 
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5.4.2 Strain differences in the effect of IL-33 on mast cells 
To assess whether mature BMMCs from these two strains of mice responded 
similarly to IL-33 C57Bl/6 and BALB/c BMMCs were simultaneously stimulated 
and the following cytokines and chemokines measured. MIP-1α was measured as I 
had consistently detected it at the highest concentrations from IL-33 stimulated 
BALB/c BMMCs. IL-13 was selected as it was also released by BALB/c BMMCs, was 
detected at the highest concentrations in the BAL of IL-33 treated mice, and 
plays a key role in the generation of AHR in asthma, as discussed in Chapter 1. 
Despite the previous lack of induction from BALB/c BMMCs eotaxin-1 and 
eotaxin-2 were also measured as they are potently induced by intranasal IL-33, 
and are important chemokines in eosinophil migration. 
IL-13 was induced at low levels from BALB/c BMMCs stimulated with IL-33, but at 
higher levels from C57Bl/6 BMMCs, particularly when IL-33 was used at a 
concentration of 100 ng/ml (Figure 5.22). MIP-1 was more potently induced 
from both strains of mast cells, but was again released at markedly higher 
concentrations from C57Bl/6 than BALB/c BMMCs. Eotaxin-1 and eotaxin-2 were 
undetectable in supernatants of IL-33 stimulated BMMCs of either strain (data 
not shown). Given the failure to demonstrate a difference in the cytokines or 
chemokines produced which might account for the enhanced AHR in BALB/c mice 
a small number of samples were screened by multiplexed immunoassay. IL-6 and 
GM-CSF were detected at high concentrations, but as with IL-13 and MIP-1, 
were higher from C57Bl/6 than BALB/c BMMCs. None of the cytokines or 
chemokines assayed were released at higher concentrations from BALB/c than 
C57Bl/6 BMMCs (data not shown). 
These data do not support a strain difference in mast cell chemokine or cytokine 
release as the explanation for the enhanced AHR in BALB/c mice. 
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Figure 5.22 – C57Bl/6 BMMCs are more responsive to IL-33 than those from BALB/c mice 
Mature WT BMMCs from C57Bl/6 and BALB/c mice at a concentration of 1x106/ml were cultured 
in duplicate with mIL-33 at between 10 and 100 ng/ml and aliquots of the supernatant were 
harvested at 24 hours. MIP-1α and IL-13 were measured by ELISA. Results are shown as the mean 
of duplicate culture wells +/- SEM. Two-way ANOVA for the effect of strain on IL-13 p<0.001, on 
MIP-1α p<0.001. 
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5.4.3 The role of mast cells in the response to intranasal IL-33 
I have demonstrated that IL-33 has potent activity within the lung, generating a 
marked eosinophilia in addition to AHR in BALB/c mice, two key features of 
asthma. While I could find no evidence of a mast cell basis for the difference in 
AHR between strains of mouse, mast cells are still a strong candidate as the first 
line cells responding to IL-33 administered to the lungs. They are the most 
strongly ST2 positive of all cells studied thus far. I have shown they produce pro-
inflammatory cytokines and chemokines in response to IL-33, including the Th2 
cytokine linked to AHR, IL-13. They are essential for AHR and eosinophilia in 
adjuvant free models of asthma(162) where I have found that ST2 is also 
essential. 
This led me to the hypothesis that in asthma IL-33 is released locally and acts on 
mast cells which in turn release mediators to induce AHR and eosinophil 
recruitment. 
Having demonstrated that IL-33 can induce the features of experimental asthma 
when delivered to the lungs the question remained as to whether these effects 
are mediated by ST2 on mast cells. In order to answer this question I 
administered IL-33 to the lungs of mast cell deficient, W-Sh mice. As discussed in 
Chapter 2 these mice are profoundly mast cell deficient with no mast cells 
detectable in the lungs(426,427). Having developed an attenuated dosing 
schedule to improve the chances of detecting any contribution by mast cells to 
the inflammatory response to IL-33, I used this three dose protocol in C57Bl/6 
wild type and W-Sh mice. 
When IL-33 was administered intranasally mast cell deficiency had no impact on 
the total cell count or the extent of eosinophilia generated in the BAL (Figure 
5.23). The accumulation of other cell types was similarly unaffected. 
Since I had only been able generate AHR in BALB/c mice, a background on which 
there are no mast cell deficient strains, it was not possible to assess the 
importance of masts cells in IL-33 induced AHR. 
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Figure 5.23 – IL-33 induced inflammation is unaffected by mast cell deficiency. 
IL-33 was administered to C57Bl/6 mice wild type (■) or W-sh (□) mice as in Figure 5.12. Total 
and differential cell counts were performed upon BAL. Results are shown as the mean of each 
group of mice +/- SEM. n=5 mice. 
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5.5 Conclusion 
The data in this chapter demonstrate that IL-33 has a profound effect when 
administered directly into the airways, inducing the key features of 
experimental asthma. Based on the initial dosing regime utilised by Schmitz et al 
for intraperitoneal administration(323) I demonstrated that following seven 
doses of intranasal IL-33 a marked eosinophilia is generated within the BAL and 
lung parenchyma. 
In order to better understand the events which led to pulmonary eosinophil 
accumulation time course experiments were carried out. When repeated doses 
of IL-33 were administered eosinophils were not detected in the BAL until three 
days after the initial dose, but increased steadily to a very high cell count after 
seven days. In models of asthma, eosinophils accumulate within 24 hours of 
initial challenge, as demonstrated in Chapter 4. Although it is possible that 
antigen sensitisation in these models somehow primes or mobilises eosinophils, 
in studies administering recombinant cytokines such as IL-5 and eotaxin-1 to 
naïve animals, eosinophils also begin to appear in the BAL within 24 
hours(513,514). The three day delay I observed in accumulation within the lungs 
suggests that the effect of IL-33 on eosinophils is indirect. In the time course 
experiments eotaxin-1 and eotaxin-2 are also undetectable until after the third 
dose. The correlation between eotaxin detection and initial eosinophil 
accumulation suggests that this release of eotaxin-1 and eotaxin-2 may be 
responsible for recruiting the eosinophils to the lungs. The eotaxins certainly 
have the potential to recruit eosinophils, and play an important part in the 
eosinophilia that is seen is experimental asthma(179,260,266-268,514). Given 
that eosinophils themselves can produce eotaxin(515) one other possibility would 
be that the eosinophils are recruited by another mechanism and then they are 
responsible for the release of the eotaxins detected. The Th2 cytokines IL-5 and 
IL-13 were not present within the BAL until 24 hours after eosinophils and 
eotaxins were detected suggesting that Th2 cytokine production is not the 
initiating factor responsible for eosinophil recruitment. It is possible that the 
converse is true and that eosinophil recruitment is required for Th2 cytokine 
production,  and there is evidence from eosinophil deficient mice that this is the 
case in asthma models(116). 
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When four doses of IL-33 were given there were still a high number of 
eosinophils within the BAL eight days after the final administration. In models of 
asthma eosinophil numbers are generally very low by seven days after cessation 
of antigen challenge(492,493). While one must be cautious in interpreting the 
limited time course data available they raise the possibility that an initial 
release of IL-33 may be sufficient to initiate an inflammatory process which 
becomes self-sustaining. To test the hypothesis that a limited number of 
administrations of IL-33 induces persistent inflammation, and perhaps airway 
remodelling, it would be necessary to obtain BAL and histological samples at 
time points many days after initial IL-33 treatment.  
After initially studying C57Bl/6 mice I went on to demonstrate that airways 
eosinophilia was also generated in BALB/c mice, and that the extent of 
inflammation was unaffected in by strain, despite the preponderance for Th2 
responses generally seen in BALB/c mice(510,511). By using BALB/c mice it was 
also possible to confirm that IL-33 had no effect in ST2-/- mice. This 
demonstrated for the first time that the effects of IL-33 in vivo are mediated via 
ST2 alone. It also served to confirm that all the phenomena observed were due 
to a specific effect of IL-33 rather than any possible contaminant. 
Using BALB/c mice I have demonstrated that the administration of IL-33 to the 
lungs induces AHR. When studied initially in a protocol where 3 doses of IL-33 
where followed by a delay of 3 days AHR appeared to be induced, but the effect 
did not reach statistical significance. This failure to reach significance may be 
due to the delay between the final administration and measurement of AHR, 
although in models of asthma in BALB/c mice AHR can persist for up to seven 
days after antigen challenge(492). Alternatively this failure may have been due 
to the small group size, with only four to five mice in each group. When AHR was 
studied in BALB/c mice 24 hours after a seventh dose of IL-33, using eight to 
twelve mice per group, there was a statistically significant increase with 
methacholine doses as low as 12.5 mg/ml. The magnitude of AHR generated was 
similar to that seen in a model of asthma. 
In C57Bl/6 mice there was no evidence of IL-33 induced AHR regardless of the 
protocol used. Given that the extent of eosinophilia induced is the same in both 
strains it seems unlikely to be due to a fundamental inability of C57Bl/6 mice to 
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respond to IL-33. The dissociation of eosinophilia and AHR is not unprecedented 
as AHR occurs alone in some IL-5 knock-out asthma studies and eosinophilia 
alone in some IL-13 knock-out studies(100,225,228). 
I could find no evidence that the strain difference in the response to IL-33 was 
due to different responses of mast cells to IL-33. However as mentioned 
previously there are reported functional differences in mast cells between these 
strains (56,512). Having been unable to induce BALB/c mast cell degranulation 
with IL-33 I did not study this in C57Bl/6 mice, although building on the data in 
Chapter 3 others within our research group have gone on to demonstrate that IL-
33 can induce the degranulation of IgE primed mast cells in vitro(449). 
Another possible reason for the failure to generate AHR in C57Bl/6 mice might 
relate to the use of Penh. It has been demonstrated that the correlation 
between Penh and other invasive measures of AHR is not as strong in C57Bl/6 
mice as it is in BALB/c mice(516,517). There is now one published report in 
which IL-33 appeared to generate AHR in C57Bl/6 mice as measured by Penh, 
however the was no measure of variance reported and no attempt at statistical 
analysis(447). There has since been data presented at the recent American 
Thoracic Society conference in 2009 showing that IL-33 can induce AHR in 
C57Bl/6 mice(518). IL-33 was used at a higher dose than I used (5 µg) and AHR 
was measured invasively. 
My hypothesis was that the activation of mast cells via ST2 would be responsible 
for the effects if IL-33 in the lungs in vivo. Using mast cell deficient W-sh mice I 
have demonstrated that there is no requirement for mast cells in IL-33 induced 
pulmonary eosinophilia. Due to the failure to generate AHR in C57Bl/6 mice I 
was unable to utilise W-sh mice to assess the contribution of mast cells. 
However in the recent abstract mentioned above not only did IL-33 treatment 
result in increased concentrations of mast cell protease within the BAL, but AHR 
was induced in wild type but not mast cell deficient mice(518). 
In summary I have demonstrated that IL-33 acts in an ST2-dependent manner to 
induce two of the key features of asthma; pulmonary eosinophilia and AHR. This 
provides further evidence that the ST2-IL-33 axis may play an important role in 
clinical asthma.  
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General Discussion 
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While the contribution of Th2 inflammation in asthma is accepted, the function 
of different cells and cytokines at different stages of disease development and 
resolution remains unclear. Key questions include the role of mast cells, the 
relationship between structural cells and inflammatory cells and the factors 
involved in the initiation of asthma. In the context of the emerging role of ST2 in 
allergic inflammation and the discovery of IL-33, the ligand for ST2 and an 
inducer of Th2 inflammation, at the outset of this thesis I set out the hypothesis 
that „the activation of ST2 on mast cells by IL-33 plays an important role in 
allergic airways inflammation‟. 
My aims were to test this hypothesis by meeting three objectives; to assess the 
effect of IL-33 on mast cells in vitro, to study the requirement for ST2 in a 
murine model of asthma, and to examine the effect of IL-33 administration to 
the airways. A summary of my findings and their interpretation is below. 
6.1 Summary of results 
I addressed the first of these aims in Chapter 3, where I demonstrated that ST2 
was expressed at high levels from a very early stage of mast cell development in 
vitro and correlated closely with expression of the early mast cell marker c-kit. 
Despite this, the absence of ST2 did not alter the growth or maturation of mast 
cells from the bone marrow of ST2 gene-deleted mice in vitro, implying that IL-
33 does not play an essential role in mast cell development. Mast cells 
stimulated with IL-33 released a number of pro-inflammatory mediators, 
specifically the pro-inflammatory cytokine IL-6, the Th2 cytokine IL-13 and the 
chemokines MIP-1α and MCP-1, and at times the growth factors GM-CSF and 
VEGF. I was also able to utilise ST2-/- mast cells to confirm the ST2 specificity of 
this effect. 
Having demonstrated the pro-inflammatory effect of IL-33 in vitro I went on to 
study the role if ST2 in experimental asthma in Chapter 4. I began by optimising 
and validating a short model of asthma in mice and used this to demonstrate for 
the first time that ST2 gene deficiency could attenuate allergic inflammation. To 
try and understand the discrepancy between this finding and those published 
using other models of asthma(381,383) I went on to compare the requirement 
for ST2 between a mast cell dependent and a mast cell independent model of 
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asthma. As others had reported(381,383), I demonstrated that ST2 gene 
deficiency did not attenuate AHR or inflammation in a mast cell independent 
model of asthma in which mice were immunised with OVA and alum. However 
when mice were immunised with OVA alone, a protocol which has been shown to 
confer mast cell dependence(162,163), ST2 deficiency had no impact on AHR but 
resulted in a significant reduction in eosinophilic inflammation. This was 
associated with a specific reduction in IgE and reduced Th2 cytokine production 
by draining lymph node cells. 
In Chapter 5, I went on to study the effect of ST2 activation in the airways by 
the direct administration of IL-33. Intranasal IL-33 induced a dramatic and long 
lasting airways eosinophilia as well as generating AHR, two of the key features of 
murine models of asthma. Using ST2-/- mice it was possible to demonstrate that 
these effects were specific for ST2. Based on the effect of IL-33 on mast cells 
demonstrated in Chapter 3 and the requirement for ST2 in a mast cell dependent 
model of asthma reported in Chapter 4 I formulated the hypothesis that the 
effect of IL-33 administration to the airways was mediated by the activation of 
ST2 on mast cells. However when I tested this hypothesis using mast cell 
deficient mice, there was no impact on eosinophil recruitment, demonstrating 
that this component of inflammation was induced by IL-33 in a mast cell 
independent manner. Due to the fact that AHR was only generated in BALB/c 
mice it was not possible to assess the contribution of mast cells to this 
phenomenon. 
In order to interpret these findings in the context of asthma it is necessary to 
consider the potential source of biologically active IL-33 and the effects it is 
likely to have at a cellular level. 
6.2 The cellular source of IL-33 
While Schmitz et al published data on the expression of IL-33 RNA in a number of 
cells and tissues in their initial report(323), any data on the detection of IL-33 
protein was limited until very recently. This is due in part to the lack of 
available reagents but primarily to the apparent scarcity of extracellular IL-33 
protein.  
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The first studies to detect IL-33 protein did so by immunohistochemistry, with 
the earliest report identifying nuclear localisation within epithelial cells of 
tonsillar HEVs(417), specialized blood vessels which mediate lymphocyte 
recruitment into lymphoid organs. The investigators referred to the protein as 
nuclear factor from HEV (NF-HEV) as this report predated the formal 
characterisation of the protein as IL-33 by two years. This finding has since been 
confirmed by others(418,519) and IL-33 has been identified by 
immunohistochemistry in other vascular endothelial cells(520-523) as well as 
fibroblasts(407,521,523) and epithelial cells(521).  
Despite these findings doubt remained as to whether IL-33 was ever released 
from cells. IL-33 contains a DNA-binding domain and both naturally occurring and 
transfected IL-33 localises to the nucleus (417,418,519,521). Also, even though a 
commercial IL-33 ELISA eventually became available we and others struggled to 
detect IL-33 in a number of in vivo and in vitro settings. It was originally 
proposed that as IL-33 was an IL-1 family member it would be processed for 
secretion in a similar manner to IL-1β(323), which is activated by the cleavage of 
pro-IL-β by caspase-1(524). However, as discussed in Chapter 1, while Schmitz et 
al showed that IL-33 could be cleaved by caspase-1 in vitro it does not have a 
classical caspase-1 cleavage site. 
Four papers published within the last few months have greatly enhanced our 
understanding of IL-33 processing. While three of these studies confirmed that 
IL-33 could be cleaved by caspase-1, cleavage was shown to be inefficient as 
compared with the cleavage of IL-1β, and very limited when physiological 
concentrations of caspase-1 were used(525-527). Furthermore in a stringently 
controlled setting where all other proteases were eliminated caspase-1 failed to 
cleave IL-33(526), suggesting that any cleavage by caspase-1 may be due to the 
ability of caspase-1 to activate other proteases(528). However IL-33 did appear 
to be cleaved more effectively by caspase-7 and to a lesser extent caspase-
3(525,527). A separate study using inhibitors suggested that LPS induced IL-33 
cleavage was mediated by calpain rather than caspase-1(529). The other novel 
finding was that the cleavage site for these caspases was within the IL-1 like 
domain, therefore neither of the cleavage products corresponded to so called 
“mature IL-33” and both were biologically inactive(525,527). This cleavage of IL-
33 by proteases occurs during apoptosis(525,527) and is presumably a mechanism 
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to avoid the release of potentially bio-active IL-33 during programmed cell 
death. 
These data do not support the theory that active IL-33 is released upon the 
cleavage of “pro-IL-33” to “mature IL-33” by caspase-1 and therefore led 
investigators to study the properties of full length “pro-IL-33”. It has now been 
convincingly demonstrated that full length IL-33 is biologically active in vitro 
(525-527). These recent findings have led to a revision of the theory regarding 
IL-33 processing and release. 
Two other molecules with similarities to IL-33 are High Mobility Group Box 1 
(HMGB1) and IL-1α. HMGB1 is generally found within the nucleus and affects 
transcriptional regulation. HMGB1 can also act via pattern recognition receptors 
such as RAGE(530) and TLRs(531) to mediate a number of pro-inflammatory 
effects on macrophages, neutrophils, T cells and endothelial cells including 
cytokine secretion and upregulation of surface receptors(532). Like IL-33, 
HMGB1 is inactivated during apoptosis(533). While HMGB1 can be secreted by 
non-classical pathways similarly to IL-1β(534,535), it is well recognised for being 
released by necrotic cells(536). 
IL-1α is synthesised as a precursor, pro-IL-1α which is targeted to the nucleus by 
nuclear localisation sequence within the pro-domain(537), although the function 
of nuclear IL-1α remains unknown. While there is also uncertainty regarding the 
active secretion of IL-1α(538,539), it is clear that IL-1α is released by cell 
necrosis(540,541). IL-1α and IL-1β both act via the IL-1 receptor with identical 
biological effects and are collectively referred to as IL-1. IL-1 is a classical pro-
inflammatory cytokine with wide ranging effects including the induction of nitric 
oxide and eicosanoid synthesis, triggering of the acute phase response, the 
release of a wide number of other cytokines and chemokines and the 
upregulation of adhesion molecules(542,543). 
The concept that the specific immune response can be activated by the 
presence of „danger signals‟ was formalised with the discovery of receptors for 
exogenous pathogen-associated molecular patterns (PAMPs), such as the TLRs 
and NOD-like receptors (NLRs). More recently it has been suggested the 
endogenous „danger signals‟ released in response to tissue injury and necrosis be 
referred to as „alarmins‟, with PAMPs and alarmins collectively forming a family 
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of damage-associated molecular patterns, or DAMPs(544,545). Both HMGB1 and 
IL-1α have been classed as alarmins due to the fact that they are released by 
necrotic but not apoptotic cells and act to recruit and activate immune 
cells(544,545). 
It now appears that IL-33 is also a member of this family. In addition to the 
other characteristics shared with HMGB1 and IL-1α, several investigators have 
been able to detect IL-33 protein release from damaged or necrosed 
cells(525,527,529). Similarly to HMGB1, there is also data to show that 
proinflammatory signals such as TLR agonists or cytokine cocktails can induce 
the release of full length IL-33(503,526,546,547), although the possible 
contribution of cell necrosis was not assessed in these experiments.  The 
potential role of IL-33 as an alarmin released upon tissue damage may explain 
why the main sites of IL-33 protein detection have been within structural cells 
such as endothelial cells, fibroblasts and epithelial cells. This may also account 
for the recent detection of IL-33 protein in the damaged tissues from diseases 
such as rheumatoid arthritis(523,548) and dermatitis(449). 
6.3 Cellular targets of IL-33 
At the outset of this research a number of cells were known to express ST2 on 
their surface but there was almost no data on the functional effect of IL-33 upon 
cells in vitro. Schmitz et al had demonstrated that IL-33 enhanced IL-5 and IL-13 
production by Th2 cells and activated signalling pathways in mast cells(323). 
Since then IL-33 has been shown to have effects on a wide range of different 
cells. 
In Chapter 3 I demonstrated that IL-33 could activate mast cells to release pro-
inflammatory cytokines from murine mast cells. This has since been published by 
us(449) and confirmed by other investigators in both human and murine mast 
cells(443,445,447,450). Basophils are closely related to mast cells and are also 
targets of IL-33. Upon IL-33 stimulation basophils produce a number of cytokines 
and chemokines, particularly IL-4, IL-6 and IL-13, although this is generally at 
low levels unless pretreated or co-cultured with IL-3, which is required to induce 
ST2 expression(447,549-551). IL-33 also enhances basophil adhesion, integrin 
expression, chemotaxis, degranulation and survival(549,551). 
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While others have confirmed the finding that IL-33 enhances IL-5 and IL-13 
production by Th2 cells(550,552), our group have published data showing that IL-
33 can polarise naïve T cells to produce IL-5 and IL-13, and that this occurs 
independently of IL-4, which is usually required for Th2 polarisation(553). In 
addition data from our laboratory has shown that IL-33 can be chemotactic for 
Th2 cells(419). IL-33 has a less restricted effect on NK and iNKT cells, enhancing 
the release of Th2 cytokines, including IL-4, as well as Th1 cytokines(552,554). 
Both the original data published by Schmitz et al(323) and the data presented 
here show that IL-33 is a potent inducer of eosinophilia in vivo. Eosinophils do 
not appear to express surface ST2, although it can be induced by GM-
CSF(550,555,556). However IL-33 is active on eosinophils, inducing IL-8 and 
superoxide production, upregulating adhesion molecules, enhancing adhesion 
and prolonging survival(550,555,556). It does not appear to induce 
chemotaxis(556) and there was conflicting data regarding the ability of IL-33 to 
induce degranulation(555,556). The only granulocyte upon which IL-33 does not 
appear to have any effect is the neutrophil(550,555). 
There is also data now to demonstrate that IL-33 has effects upon cells of the 
monocytes lineage. It enhances the production of TNFα by LPS and LTA treated 
macrophages, probably by increasing receptor, co-receptor and adapter protein 
expression(557). Dendritic cells also have no detectable ST2 upon their surface 
but respond to IL-33 by upregulating surface HMC-II and costimulatory 
CD86(558). IL-33 can induce the release of IL-6 from pure DCs, and of IL-5 and 
IL-13 when co-cultured with CD4 T cells(558), possibly due to the ability of DC 
derived IL-6 to induce Th2 polarisation(453). The lack of detectable ST2 
expression on cells responding to IL-33 is likely to represent a limitation of flow 
cytometry in detecting low level expression on a small subset of cells, as there 
have been no reports of IL-33 acting in an ST2 independent manner. 
In light of all this new information on the effects of IL-33 at a cellular level, and 
the data presented in this thesis, we can postulate how IL-33 may be involved in 
allergic airways inflammation. 
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6.4 The role of IL-33 in airways inflammation 
In Chapter 5 I demonstrated that in an alum free model of asthma eosinophilia 
but not AHR was markedly reduced in the absence of ST2. This may be due to a 
requirement for ST2 at sensitisation, at challenge, or both. 
6.4.1 IL-33 at sensitisation 
In support of a role for IL-33 at sensitisation was the finding that antigen specific 
IgE was dramatically reduced in ST2-/- mice in the alum free model, suggesting a 
primary failure of allergic sensitisation. As discussed in Chapter 4 the use of 
alum fundamentally changes the way antigen is taken up, transported and 
presented(499). The action of alum is also dependent on the activation of the 
NLRP3 inflammasome(502-505). It is therefore possible that in the absence of 
alum a pathway is required which is dependent on IL-33 and ST2 for effective 
antigen presentation and T cell activation. 
In the absence of alum, antigen is taken up and presented by resident DCs in the 
local draining lymph nodes and there may be a requirement for ST2 at this point. 
IL-33 can activate DCs to upregulate costimulatory molecules(558) and drive CD4 
cell Th2 polarisation as well as enhancing Th2 recruitment and activation 
(323,419,553). 
Given the high level of ST2 expression on mast cells and the requirement for 
mast cells in this model, IL-33 induced activation of mast cells may be required 
at sensitisation. There is accumulating evidence that mast cells can play an 
important role during antigen presentation. They play a significant role in lymph 
node hypertrophy during infection(559) and mast cell activation can enhanced 
DC recruitment and migration to draining lymph nodes resulting in the 
generation of antibodies against otherwise innocuous antigens(560). Both these 
effects were dependent on mast cell derived TNFα. Mast cells are a crucial early 
source of TNFα, being the only cells capable of releasing pre-stored TNFα(438) 
and mast cell derived TNFα is essential in alum free models of asthma(33,163). 
One could hypothesise that there are two separate pathways for the generation 
of a Th2 memory response to antigen, as represented in Figure 6.1. These 
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represent activation of the adaptive immune response due to the effect of two 
different types of DAMP acting initially on the innate immune system. Pathway A 
represents the effect of antigen presented with a PAMP, in this case the 
activation of the inflammasome by alum acting as an NLR agonist. In pathway B 
Th2 development is driven by the effect of activation by the „alarmin‟ IL-33. 
This may act directly on DCs and Th2 cells or indirectly via the release of TNFα 
and other mediators from mast cells. Although I found that IL-33 induced TNFα 
release from mast cells in vitro was variable, it has been reported by 
others(443,450).  
Interestingly activation of the NLRP3 inflammasome by LPS and alum resulted in 
the release of IL-33 protein from monocytic cell lines(503). The mechanism for 
this is unclear given that the majority of IL-33 detected was full length “pro-IL-
33”. This may represent some form of crosstalk between the two pathways. 
 
 
 
Figure 6.1 – Two pathways of pathogen-associated molecular pattern (PAMP) activation 
Pathway A – Alum acts as an NLR agonist to activate the NLRP3 inflammasome which in turn 
leads to the activation of T cells by dendritic cells (DC). 
Pathway B – Tissue damage during the intraperitoneal administration of OVA results in the 
release of IL-33 which can activate DCs, Th2 cells or mast cells (MCs) directly. IL-3 induced TNFα 
from mast cells can also activate DCs. 
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In support of the role of „alarmins‟ in models utilising OVA alone is the finding 
that when mice were injected with intraperitoneal OVA alone on the right side 
of the abdomen T cell proliferation occurred in the draining lymph node at that 
side only, but when mice also received a sterile needle puncture on the other 
side then T cell proliferation also occurred in the draining lymph at that 
side(499). While the antigen could be readily available it may be that the local 
needle puncture is required to induce the co-stimulatory „alarmin‟ signal. Work 
from our laboratory has demonstrated that the injection of intraperitoneal IL-33 
at the time of sensitisation enhances the inflammatory response in an OVA/alum 
model of asthma(553). 
6.4.2 IL-33 at challenge 
Alternatively ST2 and IL-33 may be required at the time of antigen challenge. 
The fact that AHR is preserved even though eosinophilic inflammation is 
dramatically reduced suggests that a memory response to OVA has been 
generated. Studies using anti-ST2 antibodies suggest a requirement for ST2 at 
challenge. When asthma is induced by adoptive transfer of antigen specific T 
cells the administration of anti-ST2 at the time of antigen challenge results in a 
substantial reduction in BAL and lung eosinophilia and AHR(360,372). The data 
presented in Chapter 5 also demonstrates that the activation of IL-33 in the 
airways by ST2 can induce the features of experimental asthma. The question 
remains as to which cells are respond to IL-33 in the airways to elicit airways 
inflammation and AHR.  
Given that I and others have demonstrated that IL-33 can activate mast cell to 
generate pro-inflammatory cytokines and chemokines in vitro I speculated that 
IL-33 was acting via mast cells to induce eosinophilia and AHR in vivo. However I 
have demonstrated that airways eosinophilia is unaffected in W-sh mice. 
Although these mice may not be completely mast cell deficient there are no 
reports of mast cells being detected within the lungs and only one report of mast 
cells within the skin at 1% of normal levels(426,427). Unfortunately I was only 
able to generate significant AHR in BALB/c mice and not in C57Bl/6 mice, the 
background on which the W-sh mutation is present. This meant that it was not 
possible for me to asses any contribution of mast cells to IL-33 induced AHR. 
However others have been able to induce AHR, as measured invasively, with IL-
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33 in C57Bl/6 mice and found that this was IL-13 dependent and was lost in the 
absence of mast cells(518). 
Th2 cells release IL-5 and IL-13 in response to IL-33, and work from our 
laboratory has demonstrated that such IL-33 polarised cells can be used induce 
airways inflammation in an adoptive transfer model of asthma(553). However 
studies from our group and others have demonstrated that T cells are not 
required for the induction of eosinophilic inflammation and AHR by intranasal IL-
33(G. Murphy et al unpublished)(447,518). 
It is possible that IL-33 acts directly on eosinophils themselves. Although there 
are normally no eosinophils present in the lungs, as demonstrated by the 
absence of eosinophils in control mice in experiments presented here and 
published by others, it is possible that IL-33 acts to recruit eosinophils directly 
from the pulmonary circulation. However, as discussed above, IL-33 does not 
appear to be chemotactic for eosinophils(556). The delay in eosinophil 
recruitment demonstrated in Chapter 5, with eosinophils first detected three 
days after IL-33 dosing begins, suggests a less direct effect. The appearance of 
the eosinophil chemokines eotaxin-1 and eotaxin-2 at the same time suggests 
that these chemokines drive eosinophil recruitment. We have been able to 
demonstrate that blocking eotaxin-1 or eotaxin-2 results in a marked reduction 
in IL-33 induced airways eosinophilia(561). 
Macrophages are the most abundant inflammatory cell within the lung and have 
been shown to respond to respond to IL-33(557). On the basis of the data 
presented in Chapter 5, work within the laboratory has been carried to look at 
the possible role of macrophages in this response(562). IL-33 is able to synergise 
with IL-4 or IL-13 in vitro to induce macrophages to differentiate to the 
alternatively activated macrophage (AAM) phenotype and produce eotaxin-2. 
Furthermore intranasal IL-33 administration induces AAM development and 
macrophage depletion attenuates eosinophilic inflammation. 
As discussed earlier it appears that, like the other „alarmins‟ IL-1α and HMGB1, 
IL-33 is released upon cell breakdown in response to injury. In addition to the 
data regarding the expression of IL-33 in vascular endothelial cells, IL-33 protein 
has also been detected in epithelial cells(521) and we have reported the 
detection of IL-33 protein within the lung parenchyma(553). 
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Figure 6.2 is a schematic representation of how tissue injury within the lung 
could result in the release of IL-33 which induces eosinophilic inflammation and 
AHR by two distinct pathways. IL-33 triggers eotaxin release from alternatively 
activated macrophages which results in the recruitment of eosinophils, and mast 
cells are activated by IL-33 to induce AHR. 
 
 
 
Figure 6.2 – The release of IL-33 as an ‘alarmin’ inducing the features of asthma 
Local tissue injury in the lung results in the release of IL-33 which acts on macrophages (MO) to 
recruit eosinophils (EO) via eotaxin and on mast cells (MC) to induce airways hyperresponsiveness 
(AHR) via IL-13. 
 
6.5 IL-33 in clinical asthma 
The data presented in this thesis have been derived entirely from in vitro studies 
and in vivo animal models. The effect of IL-33 on mast cells described in Chapter 
3 has since been repeated within our group using human cord blood derived mast 
cells(449). However it is important to consider the role of the IL-33 – ST2 axis in 
the context of the intact organism in vivo. Given that it would not be practical 
or ethical to study the effect of blocking ST2 or administering IL-33 in humans, I 
have chosen to utilise mice. In Chapter 4 I demonstrated that the requirement 
for ST2 was dependent on the model of asthma used. One might criticise the 
validity of a model where such modifications can have such a dramatic impact 
on the outcome. However one of the limitations of gene-deletion studies is the 
degree of redundancy which occurs in many biological systems. It is interesting 
to note that in all studies using anti-ST2 antibodies in intact animals treatment 
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attenuated experimental asthma(298,360,372,396,492) with similar results in a 
recent study using anti-IL-33 antibody(563). It may be that the modification to 
the model is required to overcome such redundancy, perhaps by emphasising the 
contribution of mast cells. One could argue that the omission of adjuvant makes 
the model more akin to clinical asthma. 
In Chapter 5 I demonstrated that IL-33 is a potent inducer of eosinophilic 
inflammation and AHR, and this data in combination with the work of others 
suggests that this occurs via two separate pathways. This raises the possibility 
that IL-33 has a pivotal place in the cytokine hierarchy. If IL-33 is an alarmin 
which is released by structural cells in response to tissue damage then it could 
be a key upstream mediator of inflammation and bronchospasm in asthma. IL-33 
release could be induced by bioactive allergens such as those from house dust 
mite. Such allergens have been shown to induce cytokine release from epithelial 
cells(564) and there is a preliminary report of house dust mite extract inducing 
IL-33 release from cultured epithelial cells(547). Viral infections are the 
commonest cause of exacerbations in asthma(5) and can induce the release of 
the related alarmin IL-1α from epithelial cells(565-567). It is possible that viral 
infection in asthmatic induces the release of IL-33 from infected epithelial cells 
which goes on to trigger eosinophilic inflammation and AHR as represented in 
Figure 6.2. Once inflammation is established the epithelial damage which 
characterises asthma(57,69) may result in ongoing IL-33 release and the 
perpetuation of asthma. IL-33 has recently been detected at elevated 
concentrations from the lungs in an model of asthma seven days after the 
antigen challenge(492). 
6.6 Future work 
IL-33 biology is a fast moving area of research at present, both within our 
laboratory and internationally, but there are a number of specific lines of 
investigation which would advance the work presented here. 
- In order to definitively establish whether or not the requirement for ST2 
in the alum free model is upon mast cells adoptive transfer experiments 
could be undertaken. Mast cells can be restored in W–sh mice by the 
adoptive transfer of bone marrow derived mast cells(426). It would 
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therefore be possible to study the alum free model of asthma in W-sh 
mice reconstituted with wild type or ST2-/- mast cells. In such 
reconstituted mice only the mast cells would lack ST2. 
- Further work is required to establish the potential source and stimulus of 
IL-33 release in the context of both experimental and clinical asthma. 
Studies carried out in vitro on murine and human samples could establish 
whether triggers such as house dust mite and viral infection result in IL-33 
release from specific cells, particularly epithelial cells. Further animal 
studies could also establish whether these triggers resulted in the release 
of IL-33 in vivo. 
- To begin to establish a role for IL-33 in clinical asthma it is important to 
demonstrate that IL-33 is elevated in asthma. We have recently found 
that IL-33 expression is enhanced within the epithelial cells of asthmatic 
patients(568). An important next step would be to assay the extracellular 
IL-33 in clinical samples, particularly sputum or BAL. If IL-33 is released 
from epithelial cells in response to allergens or infections it would be 
useful to measure IL-33 in samples collected during asthma exacerbations. 
- Building on the data presented in Chapter 3 and some preliminary data 
not shown, others within the group have characterised the role of IL-33 
activation in other models of allergic inflammation(449). IL-33 could 
induce both passive cutaneous anaphylaxis and systemic anaphylaxis in IgE 
sensitised mice in the absence of antigen. This was mediated by 
degranulation of IgE sensitised mast cells. We have also demonstrated 
that the activation of mast cells by IL-33 can play a role in experimental 
arthritis(548). 
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6.7 Conclusions 
At the outset of this work there was only a single published report on IL-33 and 
very little information on the biological function of this novel cytokine. The data 
presented in this thesis is among the earliest work on IL-33. I have demonstrated 
that IL-33 administration induces pulmonary eosinophilia and AHR, that IL-33 is a 
potent activator of mast cells, and that ST2 is crucial in an adjuvant free mast 
cell dependent model of asthma, perhaps more akin to human asthma. These 
data position IL-33 as a central cytokine in allergic airways inflammation and 
hence a novel therapeutic target in clinical asthma. 
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